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Abstract 
 
Platelets are essential for the physiological process of haemostasis, but also drive 
pathological thrombosis. Platelet lifespan is a tightly controlled process through 
which platelets exist for approximately 10 days within the circulation of healthy 
individuals. However, in a number of disease states this process is dysregulated 
leading to an accelerated platelet turnover. Indeed, there are a number of reports 
suggesting that newly formed platelets are hyper-reactive and their presence has 
been associated with a higher risk of thrombosis. Whilst there are these indications 
of hyper-reactivity in young platelets, there are few systematic studies. Here I have 
used proteomics coupled with functional studies and immunofluorescence to show 
that there is a progressive decline in mitochondrial and cytoskeletal proteins as 
platelets age and an increase in apoptotic pathways. Given the apparent importance 
of mitochondria in supporting the predetermined platelet lifespan, it raised the 
question as to whether mitochondria are important for other platelet functional 
processes. Therefore, I sought to elucidate the impact of platelet activation on 
mitochondrial function and dynamics. Physiological stimulation causes an increase in 
mitochondrial respiration, consistent with an increase in energy demand. 
Interestingly, P2Y12 receptor inhibition causes a reduction in basal oxygen 
consumption, suggesting a dysregulation in mitochondrial function. Furthermore, 
this work highlights a role for mitochondria beyond energy production, with 
indications that stimulation causes platelets to package and release their 
mitochondria into microvesicles. Interestingly, these mitochondria-containing 
microvesicles have high P-selectin expression suggesting they may be more likely to 
interact with neutrophils than the rest of the microvesicle population. Indeed, 
incubation of neutrophils with mitochondria-positive microvesicles but not 
mitochondria-negative microvesicles causes alterations in the expression of surface 
markers; CD11b, CD66b and CXCR2, indicative of neutrophil activation potentially as 
a result of phagocytosis. This work highlights an important role of mitochondria in 
both platelet ageing and activation.  
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 Introduction 
 
 Haemostasis  
 
The cardiovascular system is composed of the heart and a network of branching 
arteries, veins and capillaries. Fundamental for delivering nutrients throughout the 
body, this closed system is vital to maintain the functionality of every organ. Under 
physiological conditions, the maintenance of blood flow is achieved by haemostasis, 
a process which prevents excessive blood loss, preserves vascular integrity and 
provides a barrier for infection.  
 
Haemostasis is a tightly regulated process intended to achieve a fine balance 
between excessive bleeding and thrombosis. Maintaining the haemostatic balance is 
a complex interplay between procoagulant and anticoagulant mechanisms and is 
achieved through four components; the vascular endothelium, platelets, the 
coagulation system and fibrinolysis.1 
 
The role of the vascular endothelium is primarily providing a physical barrier between 
blood components and pro-thrombotic factors within the subendothelial layer. 
Furthermore, under basal physiological conditions, endothelial cells exhibit a number 
of anti-thrombotic properties including the production and secretion of a range of 
vasoactive mediators, affecting vascular tone, inhibiting platelet aggregation and 
coagulation and promoting fibrinolysis.2 As a result of damage to the vasculature 
there is a reduction of nitric oxide and prostacyclin production by endothelial cells, 
which coupled with the exposure of the subendothelial extracellular matrix causes 
local, rapid platelet activation and aggregation. This initial phase of platelet 
activation is termed primary haemostasis.3 
 
Subsequently, secondary haemostasis includes the activation of the coagulation 
system, which acts to stabilise the clot through the production of a fibrin network. 
This process is initiated by the exposure of phosphatidylserine and tissue factor, on 
the surface of activated platelets and endothelial cells.4 The coagulation system is 
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separated into two pathways; the intrinsic pathway - a longer pathway - and the 
extrinsic pathway (Figure 1.1). Both pathways proceed in a step wise fashion through 
the activation of serine protease enzymes, which circulate as inactive zymogens, 
subsequently interacting with their substrates and cofactors.5 The intrinsic and 
extrinsic pathways converge into the Common Pathway, with the activation of Factor 
X to Factor Xa, finally leading to the production of thrombin and fibrin. The 
composition of the fibres within the fibrin network determines the clot strength, and 
ultimately affects the rates of clot break down, and retraction, also known as 
fibrinolysis.6 
 
As with the coagulation cascade, fibrinolysis is a tightly controlled process involving 
serine proteases, cofactors and inhibitors. This pathway proceeds with the cleavage 
of plasminogen into plasmin, by tissue-type plasminogen activator (tPA) or 
urokinase-type plasminogen activator (uPA) which are produced by endothelial cells 
and macrophages or monocytes respectively.7  The active plasmin, subsequently acts 
to degrade the fibrin network within the clot network. These fibrin degradation 
products are then removed from the circulation and further degraded in the liver.8 
 
Physiological haemostasis is a multifaceted process, with a number of steps that can 
become dysregulated causing pathological thrombosis or bleeding. In thrombotic 
scenarios, over-activation of platelets or the coagulation cascade can lead to 
occlusive thrombi, causing the onset of a stroke or myocardial infarction. On the 
other hand, impaired platelet aggregation or defective coagulation proteins may lead 
to uncontrollable bleeding.  
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Figure 1.1 Schematic representation of the coagulation cascade 
Schematic diagram of the coagulation cascade representing the intrinsic (blue) and extrinsic 
(yellow) pathways converging with the activation of factor X and the initiation of the 
common (red) pathway of coagulation in which there is thrombin generation and the 
conversion of fibrinogen to fibrin which is stabilised by cross-linking facilitated by factor XIII. 
The breakdown of the fibrin network proceeds through fibrinolysis (green) with the 
conversion of plasminogen to plasmin. Adapted from Loof et al, 2014.9 
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 Platelet production 
 
Platelets are small, anucleate cell fragments derived from megakaryocytes within the 
bone marrow. Platelet formation is a highly regulated, continuous process, in which 
1011 platelets are produced and destroyed every day. Platelet biogenesis is a multi-
step process during which megakaryocytes undergo maturation from 
haematopoietic stem cells.10  During the early 1990s, the hormone thrombopoietin 
(TPO) was identified as a key regulator of megakaryocyte differentiation and 
maturation and consequently platelet production.11 During the initial phases of 
biogenesis, haematopoietic stem cells exist in a hypoxic niche relying exclusively on 
anaerobic glycolysis for energy production. However, increases in TPO levels cause a 
metabolic switch in haematopoietic stem cells, with a rapid upregulation in 
mitochondrial activity which is accompanied by a preferential differentiation down 
the megakaryocyte lineage.12  
 
Following the initial cell lineage commitment phase, megakaryocytes undergo 
endomitosis, a process of several cycles of DNA replication without cell division, 
leading to their transformation into large polyploid cells.10 Endomitosis is important 
for priming megakaryocytes with sufficient protein and messenger ribonucleic acid 
(mRNA) to pass on to their platelet progeny, whilst not detracting from the 
maintenance of cellular functionality.10 Indeed, the synthesis of large quantities of 
protein and lipids facilitates the development of an extensive invaginated membrane 
system continuous with the plasma membrane. This complex membrane supported 
by cytoskeletal fibres and spectrin networks develops throughout the megakaryocyte 
cytoplasm, acting as a reservoir of membrane structure for the production of 
proplatelets.13 As megakaryocytes advance through ploidy cycles, the abundance of 
protein allows for the formation and packaging of granules for the subsequent 
trafficking into proplatelets.14 
 
The initiation of proplatelet production begins with the disassembly of centrosomes, 
and the movement of microtubules to the cell cortex.15 The formation of long 
pseudopodia originates from a single region of the megakaryocyte plasma 
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membrane, from which the proplatelet shaft elongates and narrows enabled by rapid 
microtubule polymerisation and sliding, forming linear bundles which loop back 
towards the proplatelet body at the free end.16 Microtubule dynamics facilitate the 
trafficking of organelles and cellular components towards tandem arrays of platelet 
sized swellings along the length of the proplatelet shaft, elongating into the 
sinusoidal blood vessels.17  The terminal phase of proplatelet production allows 
tandem swellings packaged with organelles, proteins and ribonucleic acids (RNA), 
connected by cytoplasmic bridges to bud off into the circulation as preplatelets. The 
process of cytoplasmic fragmentation and proplatelet formation continues, 
extending throughout the entire cell body, until the entire megakaryocyte is 
transformed into proplatelets, after which the nucleus is extruded and degraded. 
Unlike the proplatelets, preplatelets form a discoid shape with the characteristic 
platelet cortical microtubule band.18 The processes involved in the maturation of 
preplatelets into platelets are poor defined, however there is evidence that they the 
undergo fission events producing singular circulating cell fragments. 
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Figure 1.2 Pro-platelet model of platelet development 
Megakaryocytes become polyploid cells, undergoing rapid cytoplasmic expansion, allowing 
the accumulation of cytoplasmic and granule proteins and the formation of a demarcation 
membrane system. Cytoplasmic reorganization leads to the formation of protrusions, 
termed pro-platelets, which elongate and branch facilitated by thick linear arrays of 
microtubules. Once cytoplasmic reorganisation is fully completed, pro-platelets with bulbous 
ends are released into the vasculature where they mature into platelets. Adapted from Patel 
et al, 200516. 
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 Platelet turnover, lifespan and clearance 
 
 
 Platelet turnover 
 
Following release into the circulation, platelets in a healthy person circulate for 
approximately 10 days.19 Platelet turnover is a tightly regulated, continuous process 
maintained through a fine balance of platelet production and destruction.20 It has 
been reported that in a number of pathological states, such as diabetes mellitus, 
chronic kidney disease and coronary artery disease, the rate of platelet turnover is 
altered, with the average lifespan reducing to approximately 5-7 days.21 The triggers 
for the initiation of platelet clearance remain elusive. Early evidence suggested a 
‘multiple hits’ model, in which the accumulation of external damage causes 
engagement of internal cell death pathways.22,23 However, more recently there is 
data suggesting platelets have a predetermined lifespan, termed the ‘molecular 
clock’.24 Given that platelets are anucleate, without the capacity to produce large 
quantities of protein to repair themselves, it is probable that both models are 
contributors to the determination of platelet lifespan.  
 
 Platelet lifespan and clearance 
 
Since the initial documentation of platelet lifespan in the 1950s, significant research 
has been conducted to understand the mechanisms governing the predetermined 
lifespan.19  To date, a number of pathways of clearance have been proposed, 
however the mechanism of determining clearance under healthy, steady state 
conditions remains unclear.  
 
One of the proposed mechanisms of clearance is through the intrinsic (or 
mitochondrial) apoptosis pathway mediated by Bak and Bcl proteins. It has been 
established that platelets have the ability to undergo apoptosis, however the 
conditions triggering this response and the physiological relevance remain to be 
determined.25–27 Experiments, using both pharmacological inhibition as well as 
knockout murine models, have indicated that anti-apoptotic Bcl-XL and pro-apoptotic 
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Bak are the major components governing the control of platelet lifespan via intrinsic 
apoptosis.28 As platelets age, the progressive degradation of Bcl-XL causes the 
balance of anti- and pro-apoptotic signals to shift, triggering Bak mediated apoptosis 
and subsequent clearance (Figure 1.3). The importance of the intrinsic pathway in 
platelet clearance has been highlighted in clinical trials of navitoclax, an anti-cancer 
drug targeting the Bcl proteins, in which its administration causes acute 
thrombocytopenia, due to the inhibition of Bcl-XL.29,30 
 
Another potential mechanism of clearance is through time-dependent surface 
modifications such as desialylation. The platelet surface is covered in glycoproteins, 
of which sialic acid acts as the terminal monosaccharide of both N- and O-linked 
glycans. The loss of sialic acid residues from these surface glycans acts to expose β-
galactose, which is recognised by the Ashwell-Morell receptor (AMR); a lectin 
asialoglycoprotein receptor, and subsequently phagocytosed (Figure 1.3).31 Reports 
have indicated that this surface modification is important in the clearance of several 
blood components including erythrocytes, and as such may be additionally applicable 
to platelet clearance. Indeed, both pharmacological inhibition of sialidase activity 
and knockout of the lectin asialoglycoprotein receptor cause a 30-35% increase in 
platelet lifespan, highlighting the importance of this pathway in platelet clearance.32 
 
As there is convincing evidence that both the intrinsic apoptosis and desialyation 
pathways are important in the maintenance of platelet lifespan, it raises the question 
as to whether one pathway is basally active, maintaining the predetermined platelet 
‘internal clock’, whilst the other is engaged under pathological conditions.  Indeed, 
during platelet storage, the levels of sialic acid on the platelet surface decrease at a 
rate proportional to the storage length, facilitating an increase in phagocytosis by 
hepatic macrophages and subsequent increase in TPO levels.33,34 Furthermore, 
evidence has indicated that sepsis associated thrombocytopenia is linked to 
increased levels of desialylation.35 Given that platelet storage does not represent 
physiological conditions and research has highlighted increased desialylation in 
septic patients, I would speculate that intrinsic apoptosis is basally active, 
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maintaining physiological platelet turnover, whilst desialylation is engaged in 
pathological conditions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Proposed mechanisms of platelet clearance 
Platelet clearance may be initiated through two pathways; intrinsic apoptosis and 
desialylation. Intrinsic apoptosis is controlled by the fine balance between Bcl-XL and Bax, 
leading to the release of caspase 3 and subsequent phosphatidylserine exposure. Platelet 
ageing, causes the release of sialidase from lysosomes which acts to remove sialic acid from 
membrane glycoproteins, thereby exposing β-galactose which is subsequently recognised by 
the Ashwell-Morell receptor on hepatocytes. Adapted from McArthur et al, 2018 and Li et 
al, 2016.24,36  
 
 
 
 
 
 
 28 
 Alterations in platelet lifespan 
 
As detailed above, the lifespan of a platelet within a healthy individual is 
approximately 10 days, however there are reports of alterations in platelet lifespan 
associated with various pathologies.  
 
Accelerated platelet turnover has been demonstrated in patients with chronic kidney 
disease and diabetes mellitus, associated with an increased risk of thrombosis and 
coronary artery disease.37,38 Indeed, newly formed platelets have been widely 
reported as being hyper-reactive based on higher thrombotic risk in patients with a 
higher proportion of young platelets. Whilst this association provides clues into the 
nature of changes in platelet reactivity in disease, it is hard to unpick the cause of the 
increased reactivity. For example, there are reports that patients with diabetes 
mellitus have an increased risk of thrombosis due to hyper-reactive platelets, which 
may be due to accelerated platelet turnover, or endothelial dysfunction, causing 
inappropriate  platelet activation.39  
 
In contrast to the changes observed in platelet turnover secondary to the main 
complications of diabetes mellitus and chronic kidney disease, altered platelet 
lifespan is central to immune thrombocytopenia. This autoimmune disease is 
characterised by an abnormally low platelet count as a result of increased 
destruction of platelets or impairment in platelet production.40 It is caused by 
autoantibodies produced by autoreactive B cells, which target platelet and 
megakaryocyte glycoproteins, resulting in a shorter platelet lifespan.40 
 
To monitor platelet turnover in these pathologies, the immature platelet fraction is 
measured using a diagnostic platform such as a Sysmex analyser and taken as an 
indicator of newly formed platelets, which are often referred to as reticulated 
platelets. Commonly used within the clinic, this automated machine uses a nucleic 
acid dye to stain platelet RNA acting as a surrogate marker for platelet age.41  
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 Platelet structure and composition 
 
Platelets are smooth, anucleate discoid cell fragments comprising a unique 
intracellular structure that that supports the rapid response required to maintain 
haemostasis. 
 
 Platelet membranes 
 
The platelet plasma membrane is formed of a bilayer of asymmetric lipids maintained 
in balance by lipid transporters. Following physiological stimulation or the initiation 
of apoptosis this asymmetric distribution of anionic phospholipids is lost.42 Whilst 
ATP-dependent flippase enzymes act to retain the asymmetric distribution of anionic 
phospholipids within the plasma membrane, the redistribution of phospholipids is 
facilitated by the actions of scramblases causing negatively charged lipids to become 
exposed on the outer leaflet of the plasma membrane.43,44  
 
In addition to the plasma membrane, platelets have a vast, continuous and highly 
complex internal membrane formed from invaginations of the lipid bilayer called the 
open canalicular system (OCS).45 This extensive membrane structure has a similar 
lipid and surface glycoprotein composition to the plasma membrane, providing a 
reservoir of membrane for the expansion of platelet surface area. Indeed, the OCS 
allows for the formation of filopodia and lamellipodia in response to vessel damage, 
facilitating an increase in platelet surface area of up to 420%.46,47 Furthermore, the 
OCS is a complex structure of surface connected and interconnected channels, 
functioning to allow the rapid release of molecules during granule secretion, as well 
as the transport proteins and molecules from the plasma into the platelet cytosol 
where they are subsequently packaged into storage granules.48 
 
 Platelet cytoskeleton  
 
To establish and maintain their discoid shape, platelets have a highly consistent and 
organised internal cytoskeleton, including a tyrosinated microtubule marginal band 
formed below the plasma membrane.49 The circumferential marginal band, a unique 
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feature to platelets, is composed of a 7-12 filamentous microtubule rings encircling 
the periphery of the cytoplasm, which when in a quiescent state are heavily 
acetylated.49 
 
Whilst circulating in their inactive form, approximately 50% of a platelet’s actin is 
maintained in a filamentous form.50 Upon, activation and adhesion rapid 
reorganisation occurs, causing the actin to form bundles and net-like arrangements 
facilitating the formation of pseudopodia and lamellipodia.51 During adhesion, the 
assembly of these protrusions increases the platelet surface area which facilitates 
the prevention of blood loss at sites of injury. 
 
 Platelet organelles 
 
Despite lacking a nucleus, platelets contain an array of organelles including the dense 
tubular system, granules, mitochondria, lysosomes and peroxisomes.  
 
1.4.3.1 The dense tubular system 
 
Forming a closed tubular network, the dense tubular system (DTS) is a remnant of 
the megakaryocyte endoplasmic reticulum playing an essential role in platelet 
activation.52 The DTS is a structure discrete from the OCS, however in some 
circumstances these structures have been observed to be intertwined.53 
 
As a major calcium store within platelets, the DTS sequesters and releases calcium in 
response to various stimuli.52 In resting platelets, the DTS stem forms a long-
elongated structure, acting to maintain a cytoplasmic calcium concentration of 
approximately 100nmol/L.52 However, following the addition of a physiological 
stimulus such as thrombin, the DTS rapidly expels calcium through the inositol-1,4,5-
trisphosphate receptor (IP3R) increases cytoplasmic calcium levels.52 In addition to 
being an important calcium store, the DTS has been recognised as a site of 
prostaglandin endoperoxidase and thromboxane A2 synthesis, as well as a store of 
protein disulphide isomerases.54,55 
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1.4.3.2 Platelet granules 
 
Platelets contain a range of granules including α-granules, dense granules and 
lysosomes, which are packaged with a diverse repertoire of pro-inflammatory and 
pro-thrombotic molecules. The formation of platelet granules begins within the 
megakaryocyte, where granule proteins are synthesised within the endoplasmic 
reticulum before undergoing maturation in the Golgi apparatus. Following 
maturation, the granule cargo is packaged into small vesicular bodies and 
transported from the trans-Golgi network.56 The subsequent trafficking of granules 
into the terminal ends of proplatelets is mediated by microtubule bundles and motor 
proteins. Following the release of platelets into the circulation, granules continue to 
mature, with proteins being taken up from the circulation through endocytosis and 
packaged and stored within platelet granules.57  
 
Of the three types of granules, α-granules are the largest and most abundant; ranging 
from 200-500nm in size with approximately 50-80 per platelet.57 These granules are 
heterogeneous with differing cargoes, including soluble factors such as platelet 
factor 4 as well as membrane associated molecules such as P-selectin.58 The majority 
of the cargo within a-granules is trafficked through multivesicular bodies within the 
megakaryocyte, however a small proportion of factors are endocytosed from the 
circulation. Electron microscopy has revealed that a-granules have a unique 
structure, typically made up of four distinct morphological zones.  This includes the 
membrane, a dense nucleoid comprising of proteoglycans and chemokines, a less 
dense area containing fibrinogen, and a peripheral zone containing von Willebrand 
factor.56 Defects in α-granules are associated with a number of inherited bleeding 
disorders, including gray platelet syndrome and von Willebrand disease.59 
 
Dense granules are less numerous than a-granules, with approximately 3-8 per 
platelet.60 These acidic granules are rich in nucleotides and have a dark, dense 
appearance when viewed by electron microscopy. These storage granules, are 
packaged with pro-thrombotic small molecules including serotonin, adenosine 
diphosphate (ADP), adenosine triphosphate (ATP) and CD63.61 Furthermore, they are 
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also important calcium stores within platelets accounting for approximately 60-70% 
of the total calcium.61  
 
Further to the two secretory granules detailed above, platelets also contain 
approximately 1-3 lysosomes, comprising of molecules such as cathepsin, 
heparitinase and β-hexosaminidase. Generally, lysosomal contents are involved in 
degradation, however the function of lysosomes within platelets remains 
unclear.57,62 
 
Early reports demonstrated that activated platelets lose protein, without disruption 
of the integrity of the membrane, indicating they may be undergoing granule 
exocytosis.63 Originally termed the release reaction, recent work has indicated that 
this process is highly regulated with differential packaging and release of granular 
content in response to different stimuli.63 Indeed,  evidence suggests subsets of 
granules are released at different rates; small molecules packaged in dense granules 
are rapidly released, potentiating the activation signal, and facilitating the slower 
release of a-granule and lysosomal content.64–66 The release of granular content is 
reliant on fusion machinery located on both the granule itself and the target 
membrane, either the open canalicular system or the plasma membrane.67 During 
the release reaction, the granules proceed through two stages; docking of the 
granules and subsequent fusion.61 These processes are mediated by fusion 
machinery encompassing SNAREs (SNAp REceptor), vesicles SNAREs (vSNAREs) 
present on the granule membrane and target SNAREs (tSNAREs) resident on the 
target membrane.68 
 
1.4.3.3 Platelet peroxisomes 
 
In addition to the granules detailed above, platelets have a small number of 
peroxisomes, but their function is unknown.69 In other cell types they are involved in 
reactive oxygen species metabolism, fatty acid oxidation and lipid biosynthesis. As 
they are involved in oxidation reactions, they also produce harmful substances such 
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as hydrogen peroxide, and as such they are also a store for the enzyme catalase 
which is involved in the decomposition of these harmful substances.70  
 
1.4.3.4 Platelet mitochondria 
 
Despite lacking a nucleus, platelets contain a small number of fully functional 
mitochondria.71 Given that platelets are significantly smaller than nucleated cells, the 
mitochondria resident within a platelet are much smaller and do not form 
mitochondrial networks, but rather are discrete organelles. While mitochondria in 
nucleated cells are involved in a myriad of processes their full contribution to platelet 
functionality remains to be fully characterised.72 Further description of mitochondrial 
function in platelets is described in section 1.7.  
 
1.4.3.5 Platelet Ribonucleic Acid 
 
During biogenesis, platelets inherit a small amount of RNA from their parent 
megakaryocyte. As they are anucleate, this residual RNA is largely lost within the first 
few days following their release into the circulation.73 Emerging evidence has 
identified that platelets contain translational machinery, and therefore have a 
limited capacity to synthesise new protein from inherited mRNA.74  
 
In the last decade is has also become apparent that platelets contain an array of small 
non-coding RNAs, comprising approximately 500 microRNAs (miRNAs).75 Maturation 
of pre-miRNA into miRNA is facilitated by miRNA processing machinery including 
Dicer, Argonaute-2, and RISC-loading complex subunit TARBP2.76,77 These mature 
miRNAs exert their effects on protein-coding genes by interacting with mRNA, acting 
to regulate its translation.78  Indeed, these miRNAs have also been shown to play a 
role in intracellular communication, as they have been detected in platelet derived 
microvesicles. Using microarray screening, the most abundant miRNAs within 
platelets and platelet-derived microvesicles have been identified as miR-223, miR-
126, miR-196, miR-24 and miR-21.78 There is evidence that the miRNA profile is linked 
to platelet activation and aggregation; with platelets having the capacity to control 
the expression of P2Y12, therefore regulating their ability to aggregate.79 
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Interestingly, miRNA expression profiles have been linked with age, sex and disease 
states, and have been suggested as a potential biomarker for the progression of 
pathologies.75,80   
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 Platelet activation, adhesion and aggregation 
 
The main function of platelets is to maintain vascular integrity by preventing blood 
loss following vascular injury. In order to properly carry out their haemostatic 
function, platelets circulate within the bloodstream at the periphery of the blood 
vessel, in very close proximity to the endothelium. Platelet margination occurs as a 
result of the high concentration of circulating erythrocytes, which given their greater 
size push platelets towards the vessel wall.81 Under normal physiological conditions, 
platelets gently roll along the lumen wall, being maintained in a quiescent state by 
the influence of nitric oxide and prostacyclin released from the endothelium. The 
presence of nitric oxide and prostacyclin causes an increase in cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which inhibit 
platelet activation by the elevation of protein kinase A (PKA) and protein kinase G 
(PKG) levels.82  
 
The close proximity of platelets to the endothelium allows for the rapid detection of 
vascular damage. Following the detection of exposed extracellular matrix 
components such as collagen along with shear forces, platelets arrest at the site of 
damage.82 Initial tethering occurs in conjunction with von Willebrand factor (vWF) 
and the glycoprotein GPIb-V-IX complex, which allows for the subsequent activation 
of additional platelet receptors for collagen, glycoprotein VI (GPVI) and integrin a2β1, 
thereby stabilising the interaction.82–84 Initial platelet adhesion allows for sequential 
actions facilitating platelet activation and aggregation (Figure 1.4).85  
 
The activation of the collagen receptors facilitates a series of intracellular signalling 
cascades, mediated by phospholipase C (PLC), protein kinase C (PKC) and 
phosphatidylinositide-3-kinase (PI3K).86 The engagement of these pathways causes 
an elevation in intracellular calcium, facilitated by its release from the intracellular 
stores as well as entry through the plasma membrane. These processes are mediated 
by inositol-1,4,5-trisphosphate (IP3) and 1,2-diacyl-glycerol (DAG) produced through 
the hydrolysis of phosphoinositide-4,5-bisphosphate (PIP2) regulated by PLC.82,87 
Subsequently, IP3 binds to IP3 receptors on the intracellular stores, causing calcium 
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release into the cytoplasm. In parallel, DAG acts to facilitate calcium entry through 
the transient receptor potential channel 6 (TRPC6) within the plasma membrane. In 
addition, IP3 can stimulate the uptake of extracellular calcium by stimulating store 
operated calcium entry (SOCE). Following calcium release from intracellular stores, 
the calcium sensor stromal interaction molecule 1 (STIM1) is redistributed within the 
membrane of the dense tubular system, where it interacts with the store operated 
calcium channel, Orai1, facilitating its opening and influx of calcium.87 
 
The rapid increases in cytosolic calcium levels promotes the secretion of secondary 
mediators, and cytoskeletal rearrangement facilitating platelet shape changes.82,88 
The release of secondary mediators such as ADP and thromboxane A2 potentiates 
the haemostatic response by binding to, and activating receptors on additional 
circulating platelets.89  
 
Platelet activation causes a conformational change in the glycoprotein, GPIIb-IIIa 
receptor, which reveals the fibrinogen binding domain.90 The high plasma 
concentration of fibrinogen readily binds to the GPIIb-IIIa receptor, thereby 
crosslinking adjacent activated platelets, and forming a platelet aggregate.90 
Stabilisation of the platelet aggregate proceeds through the initiation of the 
coagulation cascade.  
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Figure 1.4 Schematic representation of platelet interactions with exposed extracellular matrix components in the vessel wall 
Interactions between platelets and collagen within the exposed extracellular matrix. The initial interaction is mediated by vWF and the GPIb-V-IX complex, 
which given its weak nature promotes rolling of the platelet along the vessel wall. Subsequently, a more stable interaction between GPVI and collagen is 
established, facilitating platelet arrest and activation. During platelet activation, the secretion of secondary mediators signal for the recruitment of additional 
platelets to the growing thrombus which interact and form an aggregate by binding fibrinogen through the activated GPIIb-IIIa receptor. Adapted from 
Gibbins, 2004.85
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 Platelet activators and inhibitors 
 
In order for platelets to undergo the adhesion, aggregation and activation pathways 
detailed above, platelets have a wide range of surface receptors which allow them 
to respond to a multitude of endogenously produced stimulatory and inhibitory 
mediators. The interaction between these surfaces receptors and their ligands 
initiates signalling cascades eliciting reactions with varying strengths and functions. 
These mediators, along with stable synthetic mimetics, are utilised in laboratory 
testing of platelet function (Figure 1.5). 
 
The majority of the classical platelet activation pathways signal through G protein 
coupled receptors (GPCRs). These transmembrane receptors are formed of a single 
polypeptide chain folded forming a looped shape spanning the membrane seven 
times with an exposed extracellular tail.91 Following ligand binding, GPCRs become 
activated undergoing a conformational change which alters their interaction with G 
proteins within the plasma membrane.92 These G proteins are heterotrimeric, 
formed of alpha, beta and gamma subunits, and in their inactive state bind to 
guanosine diphosphate (GDP). Following activation, guanosine triphosphate (GTP) 
replaces GDP on the G protein, and causes the dissociation of the subunits, creating 
an alpha subunit and a beta-gamma dimer. There are four G protein families; Gs, Gi, 
Gq, G12/13, which stimulate or inhibit different intracellular pathways, through second 
messenger signalling.93,94 
 
 Adenosine diphosphate 
 
As touched on above, platelets contain secretory granules packed with pro-
thrombotic molecules, such as ADP. Following the initial, primary wave of 
aggregation, platelets release ADP into the extracellular milieu, which activates 
additional platelets by binding to the P2Y12 and P2Y1 receptors.95 Binding of these 
receptors activates both Gi and Gq signalling. The engagement of the Gi pathway 
facilitates the downstream activation of PI3K, Rap1b, Akt and potassium channels, as 
well as inhibition of adenylyl cyclase. The Gq pathway elicits its effects by activating 
PKC and calcium mobilisation.96  
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 Arachidonic acid and thromboxane A2 
 
Following initial activation, increases in cytosolic calcium enable the activation of 
phospholipase A2 enzymes, which subsequently cleave fatty acids facilitating the 
liberation of arachidonic acid from the plasma membrane. Arachidonic acid (AA) is 
then converted into thromboxane A2 (TXA2) through a series of two intermediate 
prostaglandins; cyclic endoperoxide prostaglandin G2 and H2 (PGG2, PGH2) produced 
by cyclooxygenase-1, which are then converted into thromboxane A2 by 
thromboxane synthase.97–99 The release of thromboxane A2 acts as a positive 
feedback loop activating additional platelets by binding to the thromboxane 
prostanoid (TP) receptor which couples to Gq and G13 proteins.86 The activation of 
these G proteins causes the stimulation of PLC, increasing IP3 and DAG levels and  
therefore increases intracellular calcium levels and activation of PKC, facilitating 
platelet shape changes, potentiating platelet activation and aggregation.100 
 
 Collagen 
 
As touched upon above, vascular damage causes exposure of the subendothelial 
extracellular matrix components including collagen. The interaction between 
collagen and platelets can be either indirect via von Willebrand factor and the 
glycoprotein Ib-V-XI complex, or direct via GPVI or integrin α2β1.82 The activation of 
these collagen receptors, stimulates downstream signalling and platelet activation 
through PI3K and PLC.82  
 
 Epinephrine 
 
Epinephrine is a weak platelet activator, acting to potentiate the effects of other 
platelet agonists following its binding to α2A-adrenergic receptors.101 Activation of 
these receptors causes coupling to Gi and subsequent inhibition of adenylyl cyclase 
and a decrease in cAMP levels reducing the brake on other platelet activation 
pathways.89  
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 Thrombin 
 
Thrombin is a serine protease effector of the coagulation cascade produced locally 
at the site of vascular damage. Thrombin is the most potent platelet agonist causing 
strong activation through the proteolytic cleavage of the N-terminal tail of its GPCR, 
the protease-activated receptor (PAR), exposing the thrombin receptor activating-
peptide, which subsequently acts a ligand to the transmembrane receptor.89 In 
human platelets, thrombin is able to cleave PAR-1 and PAR-4, however these 
receptors have distinct activation differences. PAR-1 is a high-affinity thrombin 
receptor, responding to low concentrations of thrombin, eliciting a rapid and strong 
activation signal. On the other hand, PAR-4 is a low-affinity thrombin receptor, 
responding to high thrombin concentrations, with a slower and weaker activation 
signal.102 
 
 Fibrinogen and Fibrin 
Recent work has highlighted a role for fibrinogen and fibrin in binding and activation 
of GPVI.103,104 Unlike collagen activation of GPVI which requires receptor 
dimerization, there is conflicting reports on whether fibrin binding requires receptor 
clustering and dimerization.105 Following activation of GPVI, intracellular signalling 
cascade facilitate spiking in cytoplasmic calcium, and promotes a conformational 
change in GPIIb-IIIa from a low to a high affinity fibrinogen state. Binding of 
fibrinogen to GPIIb-IIIa causes outside-in signalling through activation of PLC and 
calcium mobilisation, and causes cross-linking between adjacent platelets.104 
 
 Apyrase (ATP diphosphohydrolase) 
 
Apyrase is an endogenous anti-haemostatic agent which hydrolyses ADP into 
adenosine monophosphate (AMP) thereby inhibiting the potentiation of aggregation 
following from binding of ADP to P2Y1 and P2Y12 receptors.106  
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 Prostacyclin 
 
Prostacyclin (PGI2) is released from the endothelium and acts to maintain platelets in 
a quiescent state.107 PGI2 binds to the IP receptor, activating Gs which binds and 
activates adenylyl cyclase stimulating the conversion of AMP into cAMP. Subsequent 
activation of PKA causes inhibition of both calcium mobilisation and granule 
secretion.82,107  
 
 Prostaglandin E1 
 
Prostaglandin E1 (PGE1), synthesised from dihomo-gamma-linolenic acid, has anti-
inflammatory and anti-platelet affects. This inhibitory mediator is longer lasting than 
PGI2, but also binds to the IP receptor causing activation of adenylyl cyclase and 
subsequent elevation in cAMP levels, PKA activation and inhibition of calcium 
release.108 
 
 Pharmacological inhibitors 
 
Cardiovascular disease is the leading cause of morbidity and mortality in the western 
world. As platelets are central to thrombotic disease, they are an attractive target for 
the prevention of thrombotic events. As platelets have a vast repertoire of surface 
receptors and activation mechanisms, there are numerous pharmacological agents 
targeted at different aspects of platelet activation.109 The most widely prescribed is 
acetylsalicylic acid, more commonly known as aspirin. This anti-platelet therapeutic 
works by irreversibly inhibiting cyclooxygenase-1 (COX-1), the enzyme involved in the 
metabolism of arachidonic acid into thromboxane A2.110 
 
In addition to aspirin, P2Y12 antagonists, such as prasugrel, ticagrelor and clopidogrel, 
have been shown to be efficacious in reducing the risk of thrombosis. This class of 
anti-platelet drug act by blocking the ADP receptors, therefore inhibiting the 
potentiation of platelet aggregation following release of ADP from granular stores.111 
In recent years, dual antiplatelet therapies using a combination of aspirin and P2Y12 
antagonists have become common place, and demonstrated to reduce thrombotic 
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events. Despite being effective at reducing thrombotic events there is an intrinsic risk 
of bleeding when using antiplatelet therapies, in particular within the 
gastrointestinal tract, and as such caution needs to be taken when prescribing.112  
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Figure 1.5 Schematic of platelet activation and inhibition pathways 
Endogenous platelet activation (blue) and inhibition (green) pathways. Synthetic platelet 
activation (purple) and pharmacological inhibition (red) pathways. Initial tethering and 
adhesion processes are mediated by vWF and collagen binding to the GPIb-V-IX complex. 
Stable adhesion proceeds with collagen binding to GPVI and integrin a2β1. Activation by 
extracellular mediators such as thrombin, epinephrine and fibrinogen/fibrin, binding to PAR-
1/PAR-4, α2A and GPVI receptors respectively facilitates the liberation of AA from the plasma 
membrane and subsequent conversion into TXA2. Additionally, ADP is released from the 
dense granules. These secondary mediators bind to the TP and P2Y12/P2Y1 receptors, 
respectively, amplifying the activation response. Platelet aggregation is mediated by the 
activation and binding of fibrinogen to the GPIIb-IIIa receptor. In addition, activation can 
follow from exposure to TRAP-6, a synthetic agonist of the PAR-1 receptor, and U46619, a 
stable synthetic analogue of prostaglandin H2 which binds to the TP receptor. PGI2 and PGE1 
inhibit platelet activation by binding to the IP receptor and causing increases in intracellular 
cAMP. Apyrase inhibits platelet function by facilitating the conversion of ADP into AMP. 
Pharmacological inhibition by aspirin irreversibly blocks the action of COX-1 and therefore 
the conversion of AA into TXA2. The P2Y12 receptor antagonists, prasugrel, ticagrelor and 
clopidogrel, inhibit the P2Y12 receptor and block ADP induced platelet activation. 
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 Platelet mitochondrial function 
 
 Energy production 
 
As touched upon previously, platelets have a small number of fully functional 
mitochondria. Most commonly described for their role in energy production, 
mitochondria produce ATP through oxidative phosphorylation (Figure 1.6).113 In this 
process, ATP is generated by the transfer of electrons from nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) to oxygen via a series 
of electron carrier proteins; complexes I-IV.113  
 
Platelets are highly metabolically active cells, requiring a significant amount of 
energy to maintain themselves in a quiescent state, as well as for the rapid responses 
essential to maintain haemostasis.114,115 Whilst every cell type has different energy 
requirements, with varying ratios of glycolysis to oxidative phosphorylation, it was 
originally proposed that under basal conditions, oxidative phosphorylation accounts 
for approximately 40% of energy production, whilst glycolysis is responsible for the 
remaining 60%.116 In recent years, however, the rate of glycolysis has been 
demonstrated to been much lower, with only around 13% of glucose being converted 
into lactate. Interestingly, a recent report has highlighted an extramitochondrial 
source of oxidative phosphorylation has been identified in platelets which is active 
under resting conditions and increases following physiological stimulation.117 This 
report highlights a high rate of NADH-fuelled oxygen consumption and ATP 
production, which is not affected by an inhibitor of the adenine nucleotide 
translocase, suggesting this process is happening at a site distinct from the 
mitochondria. 117 Indeed, the authors speculate the extramitochondrial oxidative 
phosphorylation machinery may be present within the dense tubular system as 
determined by colocalization of the endoplasmic reticulum marker calnexin and 
cytochrome c oxidase and ATP synthase.117,118 Although this data provides an 
interesting theory of energy metabolism in platelets, this is a singular report of the 
existence of an extramitochondrial oxidative phosphorylation machinery, so would 
need further investigation to confirm this data.  
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Figure 1.6 Schematic representation of oxidative phosphorylation 
Oxidative phosphorylation is a process implemented to produce ATP following from the 
shuttling of electrons through a series of four electron transport proteins, generating a 
proton motive force which is harnessed for the formation of ATP. Electrons can enter the 
oxidative phosphorylation pathway at two points; the first point of entry is at Complex I 
(NADH-coenzyme Q oxidoreductase) where NADH generated from the citric acid cycle is 
oxidised by the coenzyme ubiquinone (Q). The reduction of ubiquinone causes a 
conformational change in the transporter, facilitating the movement of four protons (H+) into 
the intermembrane space. The second point of entry is at Complex II (Succinate-Q 
oxidoreductase), where succinate from the citric acid cycle is oxidised to fumerate 
transferring electrons to ubiquinone. Subsequently, Complex III (cytochrome c 
oxidoreductase) oxidises ubiquinone to ubiquinol, enabling the movement of two protons 
into the intermembrane space, and the subsequent transfer of the electrons to cytochrome 
c. The final electron transport protein, Complex IV (cytochrome c oxidase) receives the 
electrons from cytochrome c, supplying them to oxygen (O2), which is subsequently 
converted into water (H2O) with four protons being transported into the intermembrane 
space. In the final step, ATP synthase uses the proton gradient to generate ATP from ADP.119 
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 Reactive oxygen species production and metabolism 
 
During oxidative phosphorylation, mitochondria generate a vast quantity of reactive 
oxygen species with effects on cellular health. As such, mitochondria possess a host 
of machinery that acts to minimise the detrimental effects, by metabolising the 
reactive oxygen species.120 Indeed, reports have identified that patients with type II 
diabetes, a disease associated with high oxidative stress, have higher levels of the 
mitochondrial anti-oxidant enzymes superoxide dismutase-2 and thioredoxin-
dependent peroxide reductase 3 compared to healthy controls.121  Furthermore, the 
production of mitochondrial reactive oxygen species has been tightly linked with 
alterations in mitochondrial membrane potential, and is associated with increased 
platelet activation.71 
 
 Calcium buffering  
 
Calcium is integral for platelet function, with higher cytoplasmic calcium levels 
associated with activation. As detailed previously, calcium flux can occur from the 
extracellular milieu or through release from intracellular calcium stores. In addition 
to the DTS and dense granules, mitochondria act as a calcium store and buffer by the 
passive flow of calcium from the cytoplasm across the ion impermeable inner 
membrane of the mitochondria as a result of the electrical and chemical gradient.122 
Interestingly, recent work has indicated that in a small subset of platelets, agonist 
stimulation causes an increase in mitochondrial calcium levels which facilitates the 
exposure of phosphatidylserine.122 
 
 Mitochondrial induced apoptosis 
 
As described in section 1.3.2, platelet mitochondria are involved in the intrinsic 
apoptosis pathway facilitating the exposure of phosphatidylserine on the platelet 
surface. The intrinsic apoptosis pathway is mediated by a fine balance of pro- and 
anti-apoptotic factors. Degradation of the anti-apoptotic Bcl-XL, allows activation of 
pro-apoptotic Bax thereby triggering mitochondrial damage and facilitating the 
release of cytochrome c.123 Subsequent caspase-3 activation cleaves hundreds of 
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intracellular substrates resulting in impairment of important cellular process. 
Coupled with caspase activation is the exposure of phosphatidylserine on the platelet 
membrane. Phosphatidylserine can be exposed following platelet activation and 
apoptosis; however recent work has indicated that the pathways governing these 
outcomes vary with the former supporting the coagulation cascade, and the latter 
acting as an eat-me signal.124 Phosphatidylserine exposure during apoptosis is not 
reliant on calcium flux, and may proceed through the caspase-3 cleavage of the 
scramblase Xkr8.24,125 
 
 Mitochondrial dynamics 
 
Mitochondria are dynamic organelles which can undergo fission and fusion. These 
processes have been widely characterised in other cell types as a mechanism to 
maintain mitochondrial health, but it is unclear if platelets have the same 
capabilities. These processes are mediated by the dynamin family of proteins; fission 
is mediated by dynamin-1-like protein (DNM1L), whilst fusion is mediated by 
mitofusin 1 and 2 (Mfn1, Mfn2).126 Proteomic analysis has revealed that platelets 
possess these proteins, but it remains unknown whether they are functional or are 
residual from the parent megakaryocyte.127  
 
In addition to the fission-fusion pathways, damaged mitochondria can be marked for 
degradation by the autophagosome during a process termed mitophagy. Two 
mitophagy pathways have been described in platelets; firstly, the PTEN-induced 
kinase 1 (PINK1)/PARKIN pathway and secondly, the FUN14 domain-containing 1 
(FUNDC1) pathway.128,129 
 
When mitochondria are healthy, PINK1 is internalised from the outer mitochondrial 
membrane and degraded within the mitochondrial matrix. However, following loss 
of mitochondrial membrane potential, during mitochondrial damage, PINK1 remains 
on the outer leaflet of the mitochondrial membrane.129 The presence of PINK1 on the 
outer membrane causes the recruitment of the translocase of the outer membrane 
(TOM) complex, and subsequent recruitment of PARKIN. Following translocation to 
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the mitochondrial membrane, PARKIN is phosphorylated and subsequently 
ubiquitylates membrane proteins, thereby recruiting cytoplasmic factors such as p62 
and microtubule-associated protein light-chain (LC3) to the mitochondria, marking it 
for degradation by autophagy.130  
 
The second mitophagy pathway identified in platelets is mediated by FUNDC1 and is 
initiated in response to hypoxia. This pathway proceeds with FUNDC1 becoming 
dephosphorylated, thereby increasing the interaction with LC3 via the LC3-
interacting region (LIR).128,131 Recent work by the same group has identified that Nix, 
a mitophagy receptor in erythrocytes, is also involved in platelet mitophagy, with 
knockout murine models showing an increased lifespan potentially as a result of 
higher Bcl-XL levels.132  
 
 Alterations in mitochondrial function in disease 
 
It is clear that mitochondria are important for platelet function as well as contributing 
to the control of lifespan, therefore mitochondrial dysfunction may cause 
impairments in platelet functional pathways. Given the ease of platelet isolation, 
platelet mitochondrial dysfunction has been described in a number of pathological 
states, including diabetes mellitus, sepsis, Alzheimer’s, Huntington’s and Parkinson’s 
disease (Figure 1.7). Notably, these conditions exhibit mitochondrial dysfunction as 
a result of distinct functional changes.133 
 
Reports have demonstrated that in Parkinson’s, Alzheimer’s and Huntington’s 
disease there is a reduced expression or activity of electron transport proteins; 
Complex I-II, Complex III and IV and Complex I respectively.134–137 Interestingly, the 
reduction in expression of complex I and II in Parkinson’s does not cause alterations 
in mitochondrial membrane potential.138 In addition to reductions in electron 
transport carrier proteins, platelets from Alzheimer’s patients have a lower basal 
oxygen consumption rate, with suggestions that this may be as a result of reduced 
availability of substrate to the complexes, as it is restored following platelet 
permeabilisation.135 Likewise, deficiencies in the activity of electron transport 
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proteins have also been described in patients with sepsis, most notably in complex I, 
III and IV.139 
 
A number of studies have demonstrated mitochondrial dysfunction in patients with 
diabetes mellitus. Fengming and colleagues have attributed these findings to higher 
levels of reactive oxygen species and lower mitochondrial membrane potential.140 
Confirmation of these findings in a murine model of diabetes mellitus, indicated that 
diabetes causes abnormal mitochondria structures and significantly lower 
mitochondrial ATP content.140 Additionally, the basal oxygen consumption rate is 
significantly lower in platelets from diabetic patients compared to healthy controls, 
showing a 40% reduction. Interestingly, these patients had significantly higher levels 
of mitochondrial antioxidant proteins, suggesting the reduction in mitochondrial 
function may be due to increased reactive oxygen species.121  
 
Interestingly, a number of pharmacological agents have been shown to effect 
mitochondrial function in platelets. Metformin, commonly prescribed to treat 
diabetes mellitus, has been shown to have adverse effects on platelet mitochondrial 
health at high levels. Metformin overdose is rare, but can develop in patients with 
renal complications. In these conditions, metformin has been shown to reduce 
mitochondrial membrane potential and oxygen consumption.141 Furthermore, 
statins used to reduce blood lipid levels have been shown to effect the function of 
Complex I of the electron transport chain.142 
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Figure 1.7 Alterations in platelet mitochondrial function in pathological states 
Mitochondrial dysfunction has been reported in a number of disease states with alterations in varying aspects of mitochondrial function ranging from the 
expression and activity of complexes of the electron transport chain, to changes in ATP content and DYm.121,133,135,137,138,143–148
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 Platelet microvesicles 
 
It has long been established that platelet activation causes the exocytosis of 
secondary mediators into the local site of injury to potentiate platelet recruitment 
and activation. However, in recent years it has become clear that during both 
physiological and pathological activation, platelets release small membrane-bound 
vesicles, termed microvesicles, into the circulation. Originally termed ‘platelet dust’ 
by Wolf in 1967, recent advances in technology have allowed for the identification 
and characterisation of these vesicles.149 With the advancement in techniques, 
interest has flourished in the field of extracellular vesicle research, which can be 
found in numerous bodily fluids including blood, saliva urine, and synovial fluid and 
are produced by a range of different cell types.150 The nomenclature within the 
vesicle field is varied, with the term extracellular vesicles encompassing a range of 
membrane bound vesicles varying in size and origin including exosomes (20nm-
100nm), microvesicles (100nm-500nm) and apoptotic bodies (500nm-1000nm).150  
 
 Platelet-derived microvesicle production 
 
Platelet-derived microvesicles can be formed and released into the circulation in 
response to a number of physiological stimuli including activation and apoptosis, in 
addition to physical stimuli such as shear stress.151 The process of vesicle formation 
is crucially dependent on calcium, which is intimately linked to both the inhibition 
and activation of a number of enzymes.151 Under resting physiological conditions, the 
platelet phospholipid membrane is maintained by flippases and floppases in a 
dynamic asymmetric configuration, in which phosphatidylserine and 
phosphatidylethanolamine are confined to the inner membrane, whereas 
phosphatidylcholine and sphingomyelin are restricted to the external membrane.152 
However, the presence of extracellular platelet activators causes outside-in 
signalling, leading to a rapid rise in intracellular calcium and cytoskeletal 
rearrangement. After the initial activation and engagement of membrane integrins 
and G-protein coupled receptors, platelets undergo a series of processes leading to 
the engagement of scramblase, a bi-directional lipid transporter which causes 
disruption of the phospholipid asymmetry.152 The disturbance of the membrane 
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asymmetry causes disruption to the anchorage between the plasma membrane and 
the cytoskeleton, subsequently allowing for blebbing of the plasma membrane, 
allowing the formation and release of microvesicles.151,153 In addition to budding 
from the plasma membrane, microvesicle formation can be initiated from the OCS, 
following release of granular and cytoplasmic contents.154 
 
 Platelet-derived microvesicle structure and composition  
 
Microvesicles are a heterogeneous population of particles containing a myriad of 
cargoes inherited from their parent platelets; including surface receptors, soluble 
mediators, microRNAs and organelles encapsulated within a phospholipid bilayer 
(Figure 1.8).155,156 As discussed previously, microvesicles can form in response to a 
number of stimuli and as a result can be formed into a number of different structures. 
These range from the most abundant structure consisting of a simple single 
membrane, to complex structures of multi-membrane vesicles.153 In addition, multi-
vesicular particles have been identified consisting of approximately 15 individual 
microvesicles. These structures can take two forms; the first is formed of multiple 
single membrane vesicles which are free to move within a restricted large 
membrane, the second lacks the restrictive membrane and the vesicles rather form 
tight contact sites with one another.153 Despite the identification of these different 
structures, the roles of each subpopulation of microvesicle remain unclear. 
Proteomic analysis of platelet-derived vesicles indicates that they contain 
approximately 600 proteins, suggesting that they may play important roles in a wide 
range of process from haemostasis to inflammation.157 Indeed, there is evidence to 
suggest platelet-derived vesicles may be selectively packaged with cargo consistent 
with the formation of distinct vesicle populations with varying functions.158 
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Figure 1.8 Formation and composition of platelet-derived microvesicles 
Platelet-derived microvesicles are produced during platelet activation facilitated by the 
exposure of phosphatidylserine on the outer leaflet of the plasma membrane, cytoskeletal 
rearrangement and subsequent membrane blebbing. With the advances in the technologies, 
research has established that platelet-derived microvesicles contain varying content 
including cytokines, chemokines, organelles, and miRNA.152,155 
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 Platelet-derived microvesicle function 
Since their earliest characterisations it has become clear that platelet microvesicles 
play an important role in blood coagulation because of the exposure of 
phosphatidylserine on the vesicle surface. The asymmetric flipping of 
phosphatidylserine onto the outer membrane provides ideal conditions for the 
initiation and assembly of the coagulation cascade, causing thrombin generation 
through the contact pathway.159 Indeed, reports suggest platelet vesicles have up to 
a 100-fold higher procoagulant activity than whole platelets.160 Aside from their 
contribution to coagulation, emerging evidence suggests vesicles may play an 
important role in immune modulation and inflammation through interactions with 
leukocytes and the endothelium.161,162 Despite the growing literature characterising 
microvesicles, their lifespan still remains unclear, with some groups reporting 
removal from the circulation within a few minutes, whilst others have been able to 
identify these particles circulating for up to four hours.163 
 
 Platelet-derived microvesicle in disease 
 
Microvesicles from varied cellular origins are basally present in the plasma of healthy 
individuals, however the most abundant are platelet-derived microvesicles. Given 
the presence of microvesicles in healthy individuals, it would suggest they play  a 
physiological role which remains to be identified.151 However, it well established that 
circulating levels of platelet-derived microvesicles are increased in a number of pro-
inflammatory and pro-thrombotic disease pathologies.  
 
Notably, recent studies have indicated that patients with cardiovascular disease, 
diabetes mellitus and rheumatoid arthritis exhibit higher levels of platelet-derived 
microvesicles.164–166 Indeed, these diseases are all associated with increased levels of 
platelet activation which is important for vesicle formation.167 Furthermore, 
increased levels of platelet microvesicles have been reported in patients with active 
Crohn’s disease. The associated microvesicle populations demonstrate significantly 
higher levels of angiogenic factors such as MMP9, MMP2 and PDGF⍺ which are 
functionally active in promoting tubule formation in both endothelial cells and 
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interstitial cells.168 Interestingly, platelet microvesicles appear to have a role in both 
chronic diseases, as detailed above, and acute injuries, such as traumatic injury. In 
this latter case, it has been reported that traumatic injury causes an increase in 
platelet-derived microvesicles and in platelet microvesicle-leukocyte interactions 
which correlate with injury severity score and prognosis.169  
 
Given the plethora of research indicating elevated microvesicle number in disease 
pathologies, interest in recent years has focussed on using vesicles as biomarkers of 
disease.170 The ease of isolation of vesicles from peripheral blood makes their use as 
a biomarker particularly appealing, as it is a far less invasive process than taking 
tissue biopsies. Although there are conflicting reports on microvesicle lifespan, 
following isolation and storage at -80˚C, microvesicles remain relatively stable and 
thus so may provide a potential novel disease biomarker.170 Vesicles could be utilised 
as biomarkers in two ways; detection of specific origin vesicles or the detection of a 
specific surface markers on the vesicles. Analysing vesicles’ cellular origin has been 
used in the investigation of experimental models such as myocardial infarction, 
which have identified an increase in cardiomyocyte extracellular vesicle number 
following reperfusion. Although an interesting observation, the use of cardiomyocyte 
extracellular vesicles as an acute biomarker of myocardial infarction is an unlikely 
avenue to pursue as it has been shown it takes 15 days for the levels to significantly 
rise.171 On the other hand, the use of vesicle surface marker expression has proved 
useful in identifying glypican-1 as a potential marker of pancreatic cancer, as it has 
been shown to be specific to exosomes derived from cancer cells.172  
 
Whilst microvesicles make an appealing non-invasive biomarker, there are a number 
of limitations using them in the diagnosis and prognosis of disease. Firstly, there are 
no standard procedures for the collection and analysis of microvesicles from blood 
samples, thus these would need to be established prior to the use of microvesicles 
as a biomarker.173 Furthermore, it remains to be established how long elevated levels 
of microvesicles can be detected in the circulation. Thus, the time frame in which 
microvesicles may be a useful diagnostic or prognostic tool remains unknown. In 
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addition, research has not demonstrated the effect of co-morbidities of microvesicle 
number or composition, which may provide misleading results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57 
 Platelet interactions 
 
In addition to platelets interacting with one another, they also readily interact with 
endothelial cells and leukocytes, causing activation of pro-thrombotic and pro-
thrombotic signalling pathways and subsequently altering the phenotype and 
modulating of the endothelium and leukocytes. While these interactions are 
detectable under physiological conditions, there are many reports of elevated levels 
under pathological conditions contributing to a potentiation of thrombotic and 
inflammatory responses.  
 
 Platelet-endothelial cell interactions 
 
Given the close proximity to endothelial cells in which platelets circulate it is 
unsurprising that there is extensive cross talk between them. Platelets can 
communicate and interact with endothelial cells in a paracrine manner; through the 
release of bioactive mediators such as platelet-derived growth factor (PDGF) and 
vascular endothelial growth factor (VEGF), through transient interactions, and 
through receptor mediated adhesion.  
 
Following platelet activation, CD40 ligand (CD40L) is translocated to the plasma 
membrane which subsequently promotes the interaction between platelets and 
endothelial cells by binding CD40.174 Moreover, platelet rolling along the activated 
endothelium is supported by GPIb-V-IX complex and vWF released from the 
endothelial cells, with the aid of P-selectin and P-selectin glycoprotein ligand-1 
(PSGL-1). The subsequent firm adhesion is mediated by the platelet integrin aIIbβ3 
and the endothelial integrin aVβ3 and intracellular adhesion molecule 1 (ICAM-1).175 
In addition, platelet-endothelial interactions act as a bridge for the capture and 
activation of circulating leukocytes.176 Sustained platelet-endothelial interactions are 
thought to contribute to low grade chronic inflammation, endothelial dysfunction 
and increased risk of cardiovascular diseases.177,178 
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 Platelet-leukocyte interactions 
As touched upon above, platelets interact with a range of white blood cells, including 
neutrophils, monocytes, T cells and macrophages.179 Indeed, platelet-neutrophil and 
platelet-monocyte aggregates are detectable within peripheral blood samples from 
healthy individuals, with reports suggesting they account for approximately 20% of 
the leukocyte population (Figure 1.9).180 These interactions are mediated by a 
number of platelet surface receptors and adhesion molecules including; P-selectin 
and PSGL-1, ICAM-1/2 and lymphocyte function-associated antigen 1 (LFA-1), and 
CD40 and CD40L for platelets and leukocytes respectively. 180,181  
 
The initial interaction between platelets and neutrophils is largely mediated by 
P-selectin and PSGL-1, which subsequently promotes a stable interaction between 
GPIb or fibrinogen bound to GPIIb-IIIa on platelets and the integrin aMβ2 on 
neutrophils.181 The firm adhesion can also be mediated by ICAM-2 on platelets and 
LFA-1 on neutrophils.181 Likewise, platelet-monocyte aggregates are mediated by the 
interaction between P-selectin and PSGL-1, and there is also evidence for a role of 
ICAM-1 binding to LFA-1 or to fibrinogen in facilitating this interaction.182,183 
 
Activated platelets at the site of vascular injury play a crucial role in the recruitment 
of leukocytes to the growing thrombus, where they are captured by endothelial cells 
and subsequently undergo rolling and arrest on the activated endothelium.184 
Consequently, the leukocytes are able transmigrate into the surrounding inflamed 
tissue, with emerging evidence suggesting leukocytes bound to platelets have an 
increased capacity to undergo transmigration into inflamed tissue. 184,185 
 
Elevated levels of circulating platelet-leukocytes complexes  have been reported in a 
number of disease states including coronary artery disease, liver inflammation, 
sepsis, diabetes mellitus and traumatic injury.169,186–188 Identification of increases in 
these complexes may act as an indicator of increased platelet reactivity and 
inflammation within the vasculature.  
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B 
 
Figure 1.9 Representative Image Stream pictures of platelet-leukocyte aggregates 
Interaction between platelets (CD61; green) and A. monocytes (CD14; red) and B. 
neutrophils (CD66b; purple) identified in lysed whole blood from a healthy individual.  
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 Platelets in disease 
 
As touched upon previously, under physiological conditions, circulating blood 
platelets are fundamental for maintaining haemostasis and vascular integrity, 
however under pathological conditions, platelets are key drivers of thrombosis. 
Additionally, in recent years it has been established that platelets are essential 
modulators of innate immunity and inflammatory responses, contributing to 
pathologies such as cancer, diabetes mellitus, autoimmune disorders, and allergic 
responses (Figure 1.10).189  
 
 Platelets and cardiovascular diseases 
Cardiovascular disease is the leading cause of mortality and morbidity within the 
western world, with the most common vascular events being strokes and myocardial 
infarction as a result of coronary artery disease. Reports have clearly demonstrated 
that platelets play an essential role in the pathogenesis of ischemic stroke, exhibiting 
significantly higher activation markers such as PAC-1 binding, P-selectin expression 
and calcium secretion, than the platelets of healthy controls.  Furthermore, 
proteomic analysis of platelets from patients with ischemic stroke show a marked 
alteration in protein expression, with a predicted contribution to inflammatory 
responses and haematological system.190–192 Likewise, recent work has shown that 
platelets isolated from patients who have recently experienced an acute myocardial 
infarction have marked morphological differences such as extended pseudopodia, 
suggesting they have been activated.193 In confirmation of this, platelets from 
patients with coronary artery disease express higher levels of P-selectin.194 
Furthermore, elevated levels of circulating platelet-leukocytes aggregates have been 
detected in patients with coronary artery disease and myocardial infarction.194  
 
 Platelets and cancer 
Whilst the role of platelets in cardiovascular disease has long been recognised, 
research is now focussing on the contribution of platelets to other pathologies. 
Indeed, reports have indicated platelets may play a role in the pathogenesis of 
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several cancers, with an  association between raised platelet counts and malignant 
tumours, with thrombosis being more common in a number of cancers.195,196  
 
Reports have implicated platelets in several aspects of cancer progression. The 
elevation in thrombosis risk may be influenced by the exposure of extracellular 
matrix during intravasation of tumour cells into the circulation. In addition, the 
release of tumour by-products has been shown to cause platelet activation and 
aggregation, subsequently causing initiation of the coagulation cascade.197 Further, 
tumour cell induced platelet activation has been identified to be involved in the 
promotion of angiogenesis by releasing bioactive mediators.198 Moreover, research 
has detailed that platelets protect tumour cells within the circulation from damage 
by sheer stress and from detection by natural killer cells. Indeed, following tumour 
cell migration into the circulation, platelets become activated and encapsulate the 
tumour cells within aggregates masking them from detection and damage.198 In 
addition, platelet aggregates interact with endothelial cells via surface receptors such 
as P-selectin, thereby promoting the arrest and extravasation of tumour cells out of 
the vasculature, facilitating their metastasis to secondary sites.199,200  
 
Emerging evidence also suggests that within the tumour microenvironment, where 
there is a leaky vasculature, platelet-derived microvesicles can readily infiltrate and 
transfer miRNA into tumour cells.201 Consistent with selective packing of microvesicle 
content detailed in section 1.8, evidence suggests miRNA transfer both supports and 
suppresses tumour progression dependent upon the miRNA present. For example, 
the transfer of miR-223 has been shown to increase the invasiveness of lung cancer 
cells, while miR-24 causes mitochondrial dysfunction and apoptosis and so 
suppresses tumour growth.201  
 
  Platelets and autoimmune diseases 
Recent work has detailed a role for platelets in the pathogenesis of autoimmune 
diseases, including rheumatoid arthritis and systemic lupus erythematosus.202,203 
Elevated circulating platelet-leukocyte complexes have been identified in 
rheumatoid arthritis, associated with an increase in platelet activation markers P-
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selectin and CD63.204,205 Furthermore, research has detected increased levels of 
platelet-derived microvesicles, which as well as being detectable in the circulation 
are present within synovial fluid where they contribute to joint inflammation by the 
transfer of pro-inflammatory cytokines.162,167  
 
 Hypothesis and Aims 
 
Until recently, the roles of mitochondria within platelets were largely overlooked, as 
their contribution was thought to be restricted to energy metabolism. However, 
given the ease of platelet isolation, the investigation of mitochondrial function in 
pathological conditions has flourished and with it our knowledge of platelet 
mitochondrial function in physiological conditions. Despite this advancement there 
are still a number of unanswered questions regarding mitochondrial biology in 
platelets.  
 
This thesis will explore the hypothesis that mitochondria and mitochondrial function 
may become altered during the inherent process of platelet ageing and play an 
important role during platelet reactivity and cross-talk with other cells. To this end, 
this thesis is split into three chapters focussed upon exploration of the following 
questions: 
 
1. How do different agonists and anti-platelet treatments affect classical platelet 
activation pathways and mitochondrial respiration? 
 
2. Does the structure, composition and function of a platelet change as it ages 
within the circulation of healthy individuals? 
 
3. How are mitochondrial dynamics affected by platelet activation, including 
microvesicle release and how does this affect other circulatory cells? 
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Figure 1.10 Overview of alterations in platelet function in different pathological states 
Platelet function is altered in a number of pathological conditions and can drive disease progression. This diagram indicates diseases associated with changes 
in platelet function (blue boxes), reported alterations in platelet function (pink boxes) and functions that platelets facilitate and so aid disease progression 
(green boxes).206,207
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 Materials 
 
 Reagents 
Product Company 
0.2µm filters VWR, UK 
24 well plate - Falcon™ Polystyrene Microplates Thermo Fisher Scientific, UK 
96-well flat-bottomed sterile plates  VWR, UK 
96-well half-area microtitre plate Thermo Fisher Scientific, UK 
96-well round-bottomed sterile plates  VWR, UK 
Acetylsalicylic acid Sigma-Aldrich, UK 
Annexin V APC Biolegend, UK 
Annexin V binding buffer Biolegend, UK 
Anti-human CD11b Brilliant Violet 421™  Biolegend, UK 
Anti-human CD192 Brilliant Violet 421™ Biolegend, UK 
Anti-human CD42b Brilliant Violet 421™  Biolegend, UK 
Anti-Human CD45 PerCP-Cyanine5.5 Life Technologies, UK 
Anti-Human CD61-APC Life Technologies, UK 
Anti-Human CD61-FITC Life Technologies, UK 
Anti-Human CD62-P APC Biolegend, UK 
Anti-human CD62L Brilliant Violet 421™ Biolegend, UK 
Anti-human CD66b Pacific Blue™  Biolegend, UK 
Anti-human CXCR2 Pacific Blue™  Biolegend, UK 
Anti-mouse Alexa Fluor 488 Invitrogen, UK 
Anti-mouse Alexa Fluor 555 Invitrogen, UK 
Anti-mouse Alexa Fluor 647 Invitrogen, UK 
Apyrase Sigma-Aldrich, UK 
AR-C 66096 tetrasodium salt BioTechne, UK 
Bovine serum albumin Sigma-Aldrich, UK 
Calbryte 630™ Stratech, UK 
Calcium chloride Sigma-Aldrich, UK 
CD45 XP® Rabbit mAb Abcam, UK 
Cell Trace™ Violet Cell proliferation Kit Life Technologies, UK 
cOmplete™ Mini Protease Inhibitor Cocktail Tablet Sigma-Aldrich, UK 
Corning® Cell-Tak™ Cell and Tissue Adhesive VWR, UK 
D-Glucose Sigma-Aldrich, UK 
Dextran VWR, UK 
Dimethyl sulfoxide (DMSO) VWR, UK 
Donkey serum Sigma-Aldrich, UK 
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Dulbecco’s Phosphate Buffered Saline Sigma-Aldrich, UK 
Eptifibatide acetate Sigma-Aldrich, UK 
Ethanol VWR, UK 
Fluo-4 AM Invitrogen, UK 
Formalin Sigma-Aldrich, UK 
Hanks Buffered Salt Solution  Sigma-Aldrich, UK 
Haemocytometer  VWR, UK 
HEPES Sigma-Aldrich, UK 
Histopaque 1077  Sigma-Aldrich, UK 
Horm Collagen  Takeda, Austria 
Hydrochloric acid  Sigma-Aldrich, UK 
Image-iT™ TMRM Reagent Thermo Fisher Scientific, UK 
Ionomycin Life Technologies, UK 
Isotonic glucose Takeda, Austria 
Magnesium chloride  Sigma-Aldrich, UK 
Methanol VWR, UK 
MitoProbe™ DiIC1(5) Invitrogen, UK 
MitoTracker Orange CMTMRos Life Technologies, UK 
Mouse anti-TOM20 Santa Cruz, USA 
Mouse anti-α-tubulin Sigma-Aldrich, UK 
Paraformaldehyde VWR, UK 
Phalloidin Alexa Fluor 488 Thermo Fisher Scientific, UK 
Phalloidin Alexa Fluor 647 Thermo Fisher Scientific, UK 
Phosphate buffered saline Sigma-Aldrich, UK 
Poly-l-lysine coverslips VWR, UK 
Potassium chloride Sigma-Aldrich, UK 
ProLong diamond antifade mount Thermo Fisher Scientific, UK 
Prostacyclin  BioTechne, UK 
Prostaglandin E1  Sigma-Aldrich, UK 
Rabbit anti-C4 Abcam, UK 
Rabbit anti-ErP57 Abcam, UK 
Rabbit anti-fibrinogen Thermo Fisher Scientific, UK 
Seahorse XF 1.0 M Glucose Solution Agilent, USA 
Seahorse XF 100 mM Pyruvate Solution Agilent, USA 
Seahorse XF 200 mM Glutamine Solution Agilent, USA 
Seahorse XF Base Medium Agilent, USA 
Seahorse XF Cell Mito Stress Test Kit Agilent, USA 
Seahorse XF24 FluxPak Agilent, USA 
Sodium bicarbonate  Sigma-Aldrich, UK 
Sodium chloride  Sigma-Aldrich, UK 
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Sodium Dodecyl Sulfate Sigma-Aldrich, UK 
Sodium hydroxide Sigma-Aldrich, UK 
Sodium phosphate dibasic  Sigma-Aldrich, UK 
Superfrost slides VWR, UK 
Thiazole Orange Sigma-Aldrich, UK 
TRAP-6 amide Bachem, UK 
Trisodium Citrate Sigma-Aldrich, UK 
Triton X-100 Sigma-Aldrich, UK 
Trizma  Sigma-Aldrich, UK 
Trypan Blue Solution, 0.4% Thermo Fisher Scientific, UK 
U46619 Enzo Life Sciences, UK 
µ-Slide 8 Well Glass Bottom IBIDI, UK 
 
 Equipment  
Product Company 
BD FACS Aria III Fusion Cell Sorter BD Bioscience, UK 
BD LSRII BD Bioscience, UK 
Bio/Data PAP-8E aggregometer Alpha Laboratories, UK 
Bioshake plate IQ shaker Quantifoil, Germany 
Centrifuge 5247 R Eppendorf, Germany 
Heraeus Megafuge 16 Thermo Scientific, UK 
Image streamX MKII Amnis, USA 
LSM880 Confocal Microscope with airyscan Zeiss, Germany 
Nanodrop Spectrophotometer ND-1000 Thermo Scientific, UK 
NanoSight NS300 NanoSight UK 
pH meter PH1100L VWR, UK 
Seahorse XF24 Analyser Agilent, USA 
Tecan Sunrise plate reader Tecan, Switzerland 
Transsonic T310 CamLab, UK 
Vortex Genie VWR, UK 
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 Software  
Product Company 
FACSDiva acquisition software BD Bioscience, UK 
FlowJo Software v.8 TreeStar Inc, USA 
GraphPad Prism version 8 GraphPad Inc, USA 
IDEAS software Amnis, USA 
ImageJ software NIH, USA 
Ingenuity pathway analysis Qiagen, USA 
Nano Tracking Analysis (NTA2.1) software NanoSight UK 
Perseus Max Plank Institute, Germany 
STRING STRING Consortium, Switzerland 
Zen Software 2.3 SP1 Zeiss, Germany 
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 Investigating platelet activation dynamics 
 
 Introduction 
 
Platelet activation is a highly regulated process initiated by the binding of an agonist 
to its receptor on the platelet surface, proceeding in a largely sequential manner. 
This initial interaction stimulates intracellular signalling pathways, facilitating 
increases in intracellular calcium, cytoskeletal rearrangement, and proceeds through 
to the fusion of granules with the plasma membrane and the release of secondary 
mediators.86 The successive nature of these events, allows for a rapid response 
needed to maintain haemostasis and prevent blood loss.85  
 
Recent evidence has indicated that platelets are highly metabolically active cells even 
under basal conditions.116 To control this balance and maintain platelets in a 
quiescent state, ion transporters are crucial to sequester cations into intracellular 
stores as well as causing the efflux into the extracellular milieu. These ion channels 
carry a high energy demand, requiring ATP to be fully functional, thus contributing 
to the high metabolic profile under basal conditions.116 Furthermore, the processes 
of platelet activation and subsequent thrombus formation are highly energy 
dependent. Interestingly, platelets have been described as being metabolically 
flexible, being able to switch readily between glycolysis and oxidative 
phosphorylation.115,208 Further, research has highlighted that these processes can act 
as compensatory mechanisms, as complete inhibition of platelet activation is 
achieved only when both pathways are inhibited.209  
 
As well as its essential need for haemostasis, platelet activation and aggregation is 
also a key contributor to pathological thrombosis.210–212 As such, therapeutics 
targeting platelet activation have been developed as treatment for the primary and 
secondary prevention of myocardial infarction and stroke.213 As platelets have a 
myriad of activation pathways, a number of classes of anti-platelet drugs have been 
developed. Aspirin, the most commonly prescribed anti-platelet therapy, exerts its 
anti-platelet effects by acetylating serine530 on the cyclooxygenase-1, thereby 
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inhibiting its enzymatic activity and preventing the conversion of arachidonic acid 
into prostaglandin H2 and subsequently thromboxane A2.110,214 Low dose aspirin 
reduces ex vivo platelet aggregation in response to arachidonic acid and low 
concentrations of collagen and its use is associated with a 25% reduction in recurrent 
thrombotic events. Some evidence suggests that in addition to inhibiting the 
formation of thromboxane A2, aspirin reduces granule secretion, as measured by P-
selectin and CD63 expression.215,216  
 
A second class of anti-platelet drug, the thienopyridines, are often used in 
combination with aspirin, as a dual anti-platelet treatment.217 These dugs exert their 
anti-platelet effect by inhibiting the P2Y12 receptors which mediate ADP-induced 
platelet aggregation.95,96,218 ADP, secreted from dense granules, is a weak platelet 
agonist involved in the secondary wave of aggregation, supporting the activation and 
subsequent binding of the fibrinogen receptor, GPIIb-IIIa. Thus, blockade of P2Y12 
receptors by therapeutics such as clopidogrel, ticagrelor and prasugrel, will affect the 
secondary wave of aggregation important for the potentiation of the aggregation 
response.217  
 
Broadly speaking, platelet function can be assessed in two different ways; either an 
end point assay, measuring the expression of activation markers or aggregation after 
a defined period, or an assay measuring the dynamics of the response.219 Whilst the 
first of these offers more flexibility in terms of the number of samples assessed 
simultaneously, it provides no information on the kinetics and dynamics of the 
response.  Thus, in this chapter I will explore the dynamics of calcium flux and P-
selectin exposure in platelets. Furthermore, I will investigate alterations in 
mitochondrial membrane potential (DYm) and mitochondrial respiratory capacity 
following stimulation. Finally, I will examine the effect of anti-platelet treatment on 
platelet activation pathways and mitochondrial function.  
 
 
 70 
 Methods 
 
 Blood collection 
 
Blood was obtained from pre-screened healthy volunteers by venepuncture using a 
19-gauge butterfly needle. Screening included the measurement of heart rate, blood 
pressure and body temperature. Exclusion criteria included smoking, >40 years of 
age and regular use of medication known to influence platelet function. All 
volunteers had abstained from taking any non-steroidal anti-inflammatory 
medication for at least 14 days prior to donation. Blood was drawn into 50ml syringes 
containing 3.2% trisodium citrate to achieve a final ratio of 1:9 anti-coagulant to 
blood. The procedure was approved by NHS St. Thomas’ Hospital Research Ethics 
Committee (reference 07/Q0702/24). 
 
 Preparation of platelet rich plasma (PRP) 
 
Citrated whole blood was transferred to 15ml Falcon tubes and centrifuged at 175 x 
g for 15 minutes at room temperature with a slow acceleration and deceleration to 
prevent white and red blood cell contamination. The straw-coloured plasma layer 
was transferred into a clean tube. The platelets were allowed to rest for 
approximately 30 minutes before beginning experiments.  
 
 Preparation of washed platelets 
 
Isolated PRP was centrifuged at 1000 x g for 10 minutes in the presence of 
prostacyclin (PGI2; 2μM) and apyrase (0.02 U/ml) to produce a platelet pellet. The 
pellet was resuspended in modified Tyrode’s HEPES buffer supplemented with 
glucose (0.1% w/v) and apyrase (0.02U/ml), and subsequently centrifuged at 1000 x 
g for 10 minutes with the addition of PGI2 (2μM). The supernatant was removed, and 
the pellet was resuspended in modified Tyrode’s HEPES buffer to produce a pure 
platelet sample. The platelet count was adjusted to 3 x 108/ml, the suspension 
allowed to rest for 30 minutes and subsequently supplemented with calcium chloride 
(CaCl2; 2mM). 
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 Assessing calcium flux in washed platelets 
 
Washed platelets were prepared and diluted to a concentration of 3 x 108/ml. Prior 
to the addition of CaCl2, platelets were stained with Fluo-4 AM (2µM) for 45 minutes 
at 37˚C in the dark, followed by CD61-APC (1:100) for a further 15 minutes. The 
stained washed platelet sample was then diluted 1 in 10 with modified Tyrode’s 
HEPES buffer and recalcified with 2mM CaCl2. Calcium dynamics were measured over 
a 210 second period. Firstly, baseline Fluo-4 AM fluorescence was recorded for 30 
seconds, followed by challenge with phosphate buffered saline (PBS), Thrombin 
Receptor Activator for Peptide 6 (TRAP-6; 25µM), or ionomycin (10µM) and 
subsequently recorded for a further 3 minutes. Samples were acquired on a BD LSRII 
flow cytometer using FACSDiva acquisition software and analysed using FlowJo v.8 
software. 
 
 Assessing P-selectin expression in washed platelets 
 
Washed platelets were prepared as described above, diluted to a concentration of 3 
x 108/ml and supplemented with CaCl2 (2mM).  The rested washed platelet sample 
was stained with CD61-FITC (1:100) and CD62P-APC (1:100) for 20 minutes in the 
dark, and subsequently diluted 1 in 10 with modified Tyrode’s HEPES buffer. 
 
P-selectin expression dynamics were measured using a BD LSRII flow cytometer. 
Briefly, basal P-selectin expression was measured (CD62P-APC fluorescence) over 30 
seconds to establish a baseline, followed by stimulation with PBS or TRAP-6 (25µM) 
for a further 180 seconds. Following acquisition, analysis was conducted was FlowJo 
v.8.  
 
 Assessing mitochondrial membrane potential 
Washed platelets were prepared and diluted to a concentration of 3 x 108/ml 
supplemented with CaCl2 (2mM). The washed platelet sample was stained with 
CD61-APC (1:100) and TMRM (Tetramethylrhodamine, Methyl Ester; 10nm) for 20 
minutes in the dark, and subsequently diluted 1 in 10 with modified Tyrode’s HEPES 
buffer.   
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Alterations in mitochondrial membrane potential (DYm) were measured using a BD 
LSRII flow cytometer; baseline TMRM fluorescence was established over 30 seconds, 
followed by addition of PBS or TRAP-6 (25µM) and recording for a further 180 
seconds. Data analysis was conducted using FlowJo v.8.  
 
 Seahorse: Oxygen Consumption Rate 
 
To understand platelet metabolism, the Agilent Seahorse XF24 was used to measure 
oxygen consumption rate under basal conditions and following stimulation. The XF24 
calibration plate was loaded with 500µl of XF Calibrant Fluid and placed along with 
the Seahorse cartridge in the XF 37°C incubator with 0% CO2 overnight.  
 
XF24 cell cultures plates were coated with Cell Tak as per the manufacturer’s 
guidelines. Briefly, 50µl of 2.4µg/ml Cell Tak was added to each well and incubated 
at room temperature for 20 minutes. The plates were then washed with sterile dH2O 
and allowed to air dry.  
 
Washed platelets were prepared as previously described and diluted to a 
concentration of 6 x 108/ml in Seahorse Base Medium supplemented with glutamine 
(2mM), glucose (25mM) and pyruvate (1mM) and allowed to rest for 30 minutes. 
Subsequently, 100µl of the 6 x 108/ml platelet sample was added to each well of the 
Cell Tak coated plate; achieving a final platelet concentration of 6 x 107 per well, 
leaving four empty wells as blanks. The plate was then spun for 20 seconds at 200 x 
g, the plate was rotated 180° and spun for a further 20 seconds to encourage the 
platelets to adhere. To the blank wells, 100µl of base medium was added. The plate 
was then transferred to the 37°C incubator with 0% CO2 for 15 minutes. Afterward, 
400µl of warmed Seahorse Base Medium (containing 2mM glutamine, 25mM glucose 
and 1mM pyruvate) supplemented with CaCl2 (2mM) was added and the plate 
returned to the incubator for a further 30 minutes.  
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The Agilent XF MitoStress kit was used to assess mitochondrial function. Reagents 
were prepared according to the manufacturer’s guidelines achieving a final 
concentration of 1µM Oligomycin, 0.7µM FCCP (Carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone), 0.5µM Rotenone and Antimycin A, and 
subsequently loaded into the appropriate wells in the XF cartridge (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Injection port layout for the XF24 Seahorse cartridge 
Orientation of the injection ports for the XF24 Seahorse cartridge which are sequentially 
injected. Port A was loaded with 56µl of vehicle or agonist (TRAP-6 20µM). Port B was loaded 
with 62µl of oligomycin (10µM) to achieve a final concentration of 1µM. Port C was loaded 
with 69µl of FCCP (7µM) to achieve a final concentration of 0.7µM and Port D was loaded 
with 75µl of rotenone and antimycin A (5µM) to achieve a final concentration of 0.5µM.  
 
 
 
 
 
 
 
 
D C 
B A 
Port A: 56µl – Agonist/Vehicle 
Port B: 62µl – Oligomycin 
Port A: 69µl – FCCP 
Port B: 75µl – Rotenone & Antimycin A 
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The calibrant plate and cartridge were placed in the XF24 Seahorse Analyser and the 
protocol shown in Figure 3.2 was initiated. After the initial calibration phase of the 
protocol, the calibrant plate was ejected and the plate containing the platelets was 
inserted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Agilent Seahorse running protocol  
MitoStress Seahorse injection port protocol. The sequential injection of the four ports (A-D) 
allows the measurement of oxygen consumption rate following exposure to agonist or 
vehicle (Port A), and subsequently following the inhibition of individual complexes of the 
electron transport chain; Port B – injection of oligomycin inhibits ATP synthase; Port C – 
injection of FCCP inhibits complex IV; Port D – injection of rotenone and antimycin A inhibit 
complex I and III. 
 
 
 
Start 
Load Cartridge 
Calibration 
Mix, wait, measure 
 
Load platelet plate 
Basal Measurements 
Mix, wait, measure x 3 
Inject Port B: Oligomycin 
Mix, wait, measure x 3 
Inject Port C: FCCP 
Mix, wait, measure x 3 
Inject Port D: Rotenone & Antimycin A 
Mix, wait, measure x 3 
Inject Port A: Agonist 
Mix, wait, measure x 3 
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The Seahorse analyser measures the oxygen consumption rate over 95 minutes, 
producing a characteristic trace indicated in Figure 3.3. The injection of oligomycin, 
inhibits ATP synthase, causing a reduction in oxygen consumption. The subsequent 
injection of FCCP inhibits Complex IV, causes the uncoupling of the electron transport 
chain and subsequent increase in oxygen consumption. Finally, the dual injection of 
rotenone and antimycin A inhibits Complex I and III, thereby completely shuts down 
the electron transport chain and causes a reduction in oxygen consumption.  
 
 
 
Figure 3.3 Representative trace diagram for XF Seahorse MitoStress test 
The MitoStress test is measured based on the oxygen consumption rate following the 
injection of inhibitors of the electron transport chain to assess a number of parameters 
including basal respiration, ATP production, maximal respiration and spare reserve capacity. 
The arrows indicate the injection of oligomycin which inhibits ATP synthase, therefore 
preventing ATP generation; FCCP inhibits Complex IV of the electron transport chain causing 
mitochondrial uncoupling, allowing the measurement of maximal respiration; rotenone and 
antimycin A inhibit Complex I and III respectively, and cause the complete inhibition of the 
oxidative phosphorylation machinery.  
 
 
0 20 40 60 80 100
0
50
100
150
200
250
300
Time (minutes)
O
xy
ge
n 
C
on
su
m
pt
io
n 
R
at
e 
(p
M
ol
es
/m
in
)
Oligomycin FCCP Rotenone + Antimycin A
Basal 
Respiration
ATP Production Maximal 
Respiration
Spare capacity
Non-mitochondrial respiration
 76 
 Anti-platelet treatment of washed platelets 
 
The effects of anti-platelet drugs on platelet activation, calcium flux and P-selectin 
expression, as well as mitochondrial function including mitochondrial membrane 
potential and respiratory capacity were assessed.  
 
Briefly, washed platelets were prepared at 3 x 108/ml as previously described in 3.2.3. 
Following resting of the samples for 30 minutes, the platelets were treated with 
aspirin (30µM), AR-C66096 (1µM) or vehicle for 30 minutes at 37°C. Samples were 
then processed following the protocols detailed in sections 3.2.4-3.2.7 
 
 Statistical analysis 
Graphs and statistical analysis were generated using GraphPad Prism v.8. Data were 
expressed as mean±SEM and all statistics were generated using a paired students t-
test or a one-way ANOVA, with Dunnett’s multiple comparisons test. Significance was 
defined as p<0.05. 
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 Results 
 
 Platelet activation causes a rapid increase intracellular calcium  
  
Calcium flux is integral to platelet activation and is a convergent point in all platelet 
activation pathways. Given that activation signals vary in strength and activate 
different intracellular signalling cascades, it is predictable that the calcium flux will 
vary amongst different pathways. Following exposure to PBS, Fluo-4 fluorescence 
remained relatively stable indicating no fluctuations in intracellular calcium over the 
3-minute recording period (Figure 3.4A-C, G). The addition of the thromboxane A2 
mimetic, U46619, caused an increase in intracellular calcium which was sustained 
above baseline for the recording period (Figure 3.4A, B, D and H). Stimulation with 
the stronger agonist, TRAP-6, induced a more rapid increase in intracellular calcium, 
reaching its peak fluorescence at 20 seconds post stimulation, compared to 40 
seconds post U46619 stimulation. Furthermore, the intracellular calcium signal was 
maintained at a higher level when stimulated with TRAP-6 compared to U46619 
(Figure 3.4A, B, E and I). As expected, the addition of the calcium ionophore, 
ionomycin, caused a rapid and substantial rise in intracellular calcium levels, reaching 
a peak 20 seconds after addition (Figure 3.4A, B, F and J). Further, the percentage of 
platelets positive for Fluo-4 fluorescence at the end of the 3-minute recording, was 
significantly higher following stimulation with ionomycin (PBS, 1.1±0.1; U46619, 
6.1±1.3; TRAP-6, 18.1±3.7; ionomycin, 71.7±1.8; p<0.01 for ionomycin vs. PBS, 
U46619 and TRAP-6; Figure 3.4G-J). 
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Figure 3.4: Measurement of calcium flux during platelet activation 
A. Representative calcium (Fluo-4) dynamic traces following incubation of platelets with PBS 
(blue), U46619 (orange), TRAP-6 (magenta) and ionomycin (green). B. Quantification of area 
under the curve of Fluo-4 fluorescence following incubation with PBS, U46619, TRAP-6 and 
ionomycin. Representative density plot of Fluo-4 fluorescence over time following 
incubation with C. PBS D. U46619 E. TRAP-6 and F. Ionomycin. Representative dot plots 
showing the percentage of Fluo-4 positive platelets following incubation with G. PBS H. 
U46619 I. TRAP-6 and J. ionomycin after 210 seconds. Data presented as mean±SEM, 
significance was determined by one-way ANOVA with Dunnett’s multiple comparisons (n=6, 
*p<0.05, **p<0.01). 
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 Platelet activation causes P-selectin expression to change at a slower rate 
than calcium flux 
 
Granule secretion is a key step in platelet activation, facilitating the release of soluble 
mediators which potentiate the activation response by causing a secondary wave of 
aggregation. As granule secretion occurs secondary to calcium flux, it can be 
predicted that the release and exposure of P-selectin from a-granules would occur 
at a slower rate than calcium flux. Stimulation of washed platelets with PBS caused 
no alteration in CD62P fluorescence, indicative that there was no change in the 
expression of P-selectin on the outer leaflet of the platelet membrane (Figure 3.5A-
B). Stimulation with U46619, caused a weak and gradual increase in P-selectin 
expression over the 3-minute recording period (Figure 3.5A-B). Consistent with the 
calcium flux, TRAP-6 stimulation elicited a stronger and more rapid increase in P-
selectin expression. Indeed, quantification of area under the curve of the P-selectin 
expression dynamics indicated that TRAP-6 activation provokes a response that was 
more than twice as strong as that triggered by U46619.  
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Figure 3.5: Measurement of P-selectin expression during platelet activation  
A. Representative P-selectin (CD6P-PE) dynamic traces following incubation of platelets with 
PBS (blue), U46619 (orange) and TRAP-6 (magenta). B. Quantification of area under the curve 
of CD62P-PE fluorescence following incubation with PBS, U46619 and TRAP-6. Data 
presented as mean±SEM, significance was determined by one-way ANOVA with Dunnett’s 
multiple comparisons (n=6, *<0.05, **p<0.01). 
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 Platelet activation causes alterations in mitochondrial membrane potential 
 
The effect of platelet activation on P-selectin expression and calcium flux is well 
documented, however the influence of platelet activators on mitochondrial 
membrane potential remains unknown. The transmembrane potential of the 
mitochondria is crucial for maintaining cellular health, regulated by the proton 
motive force generated during the transfer of electrons along the electron transport 
chain. Given its dynamic nature, mitochondrial membrane potential can become 
hyperpolarised or depolarised. Sustained hyper- or depolarisation can lead to 
deleterious effects and cause mitochondrial damage. Here I have shown that 
activation with U46619, caused an initial increase in TMRM fluorescence, suggesting 
the mitochondrial membrane has become hyperpolarised (Figure 3.6A; orange line) 
Interestingly, after approximately 60 seconds the TMRM fluorescence begins to 
reduce, returning towards baseline. After 170 seconds the membrane potential 
passes baseline reading, indicating that the mitochondrial membrane potential is 
becoming more positive. Consistent with the calcium flux and P-selectin expression, 
TRAP-6 caused mitochondrial membrane hyperpolarisation to a greater extent than 
U46619 and with a consistently greater area under the curve (Figure 3.6).  
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Figure 3.6: Assessment of mitochondrial membrane potential following stimulation  
A. Representative change from baseline (blue) of mitochondrial membrane potential 
(TMRM) dynamic traces in response to U46619 (orange) and TRAP-6 (magenta). B. 
Quantification of area under the curve of TMRM fluorescence following incubation with PBS, 
U46619 and TRAP-6. Data presented as mean±SEM, significance was determined by one-way 
ANOVA with Dunnett’s multiple comparisons (n=6, **p<0.01, ***<0.001). 
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 Platelet activation causes an increase in mitochondrial respiration 
 
Following on from the identification of alterations in mitochondrial membrane 
potential following activation raised the question as to whether this is influencing the 
respiratory capacity. Oxygen consumption rate, as a measure of mitochondrial 
activity, was assessed in washed platelets following the addition of TRAP-6 or vehicle. 
Using the Agilent Seahorse Analyser, I determined that under basal conditions, 
washed platelets (6 x 107) consume 105±5pmoles of oxygen per minute. The addition 
of TRAP-6 (20µM) caused a significant increase in oxygen consumption rate to 
137±18pmoles/minute, which was maintained over the 15-minute recording period 
(Figure 3.7A-B).  
 
After the addition of the platelet agonist or vehicle, a series of mitochondrial 
inhibitors were injected to assess if platelet activation influences other parameters 
of the respiratory chain. Injection of the ATP synthase inhibitor, oligomycin (1µM), 
allows for the calculation of the oxygen consumption rate coupled to ATP production. 
Following stimulation with TRAP-6, the oxygen consumption coupled to ATP 
production was significantly higher than that in the presence of vehicle 
(95±9pmoles/min vs. 61±8pmoles/min, p<0.05; Figure 3.7C). The injection of the 
subsequent two mitochondrial inhibitors, caused marginal but not significant 
changes in respiratory parameters. Indeed, maximal respiration, as assessed by FCCP 
(0.7µM) treatment, showed a slight increase in platelets incubated with TRAP-6 
compared to vehicle (135±27pmoles/min vs. 110±18pmoles/min; Figure 3.7D). 
Consistent with an increased oxygen consumption rate following the addition of 
TRAP-6, the spare respiratory capacity was reduced compared to vehicle 
(-2±11pmoles/min vs. 14±10pmoles/min; Figure 3.7E). Finally, there was no 
significant change in the non-mitochondria respiration following exposure to TRAP-6 
compared to vehicle (12±6pMoles/min vs. 8±5pMoles/min; Figure 3.7F).  
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Figure 3.7: Seahorse oxygen consumption rate following physiological stimulation 
A. Agilent Seahorse oxygen consumption rate trace following the addition of vehicle (blue) 
or TRAP-6 (magenta) and the subsequent injection of the mitochondrial inhibitors 
oligomycin, FCCP and rotenone and antimycin A B. Quantification of oxygen consumption 
rate under basal conditions (red) and following the addition of vehicle or TRAP-6 (blue) C. 
Quantification of oxygen consumption rate linked to ATP production, assessed by inhibition 
of ATP synthase with oligomycin D. Quantification of the maximal oxygen consumption rate 
assessed following uncoupling of the electron transport chain, by inhibiting complex IV 
following the addition of FCCP E. Quantification of the spare respiratory capacity calculated 
from the maximal respiration and agonist induced oxygen consumption F. Quantification of 
the non-mitochondrial respiration measured following the addition of rotenone and 
antimycin A which inhibit complex I and III, completely shutting down the electron transport 
chain. Data presented as mean±SEM, significance was determined by paired t-test (n=4, 
*p<0.05). 
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 Aspirin treatment does not affect calcium flux in platelets 
 
It is well established that aspirin causes a reduction in platelet aggregation, however 
the effect of this anti-platelet drug on calcium flux is less clear. As indicated in Figure 
3.8, pre-treatment of platelets for 30 minutes with aspirin did not affect calcium flux 
following exposure to U46619 (AUC vehicle vs. aspirin, 270325±85551AU vs. 
259523±133025AU; Figure 3.8B), TRAP-6 (AUC vehicle vs. aspirin, 529080±156104AU 
vs. 430378±16753AU; Figure 3.8D) or ionomycin (AUC vehicle vs. aspirin, 
1273262±212867AU vs. 1088789±125238AU).  Despite no change in the area under 
the curve of Fluo-4 fluorescence (Figure 3.8B, D and F), the kinetics of the U46619 
response appeared altered following incubation with aspirin. As indicated in the 
representative trace in Figure 3.8A, platelets pre-treated with aspirin took longer to 
exhibit an increase in intracellular calcium which was subsequently sustained over 
the 3-minute recording period. On the other hand, TRAP-6 and ionomycin 
stimulation elicited a similar calcium dynamic trace (Figure 3.C, E). 
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Figure 3.8: The effect of aspirin treatment on calcium flux following platelet activation 
Representative calcium (Fluo-4) dynamic traces in response to A. U46619 C. TRAP-6 and E. 
ionomycin in the presence of vehicle (red) or aspirin (blue). Quantification of area under the 
curve of Fluo-4 fluorescence following incubation with: B. U46619, or aspirin (ASA) plus 
U46619; D. TRAP-6, or aspirin (ASA) plus TRAP-6; and F. ionomycin or aspirin (ASA) plus 
ionomycin. Data presented as mean±SEM, significance was determined by paired t-test (n=4) 
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 Aspirin treatment reduces P-selectin exposure following stimulation of 
platelets with U46619 
 
As detailed above, platelet activation is a sequential process with P-selectin exposure 
occurring secondary to rises in intracellular calcium. Here I have identified that 
treatment of platelets with aspirin caused a reduction in P-selectin expression 
following exposure to U46619 over a 3-minute recording period (AUC vehicle vs. 
aspirin, 6694±307AU vs. 4374±810AU; Figure 3.9A-B). Interestingly, this reduction in 
expression was not observed following incubation with the stronger agonist, TRAP-6 
(AUC vehicle vs. aspirin, 20078±3250AU vs. 18233±3487AU; Figure 3.9C-D).  
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Figure 3.9: The effect of aspirin treatment on P-selectin expression following platelet 
activation 
Representative P-selectin (CD62P) expression traces following incubation with A. U46619 
and C. TRAP-6 in the presence of vehicle (red) or aspirin (blue). Quantification of area under 
the curve of CD62P fluorescence following incubation with: B. U46619, or aspirin (ASA) plus 
U46619; and D. TRAP-6, or TRAP-6 plus aspirin (ASA). Data presented as mean±SEM, 
significance was determined by paired t-test (n=4, *<0.05). 
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 Aspirin treatment does not alter fluctuations in mitochondrial membrane 
potential observed following platelet activation 
 
As I identified that platelet activation caused mitochondrial membrane 
hyperpolarisation, I wanted to assess the effect of aspirin treatment on 
mitochondrial membrane potential. Platelet stimulation with U46619 caused 
mitochondrial membrane hyperpolarisation to a similar extent in vehicle treated and 
aspirin treated platelets (AUC vehicle vs. aspirin, 3005±596AU vs. 2603±842AU; 
Figure 3.10A-B). Consistent with P-selectin expression and calcium flux, there was no 
change in mitochondrial membrane potential following TRAP-6 stimulation between 
vehicle-treated and aspirin-treated platelets (AUC vehicle vs. aspirin, 4053±1074AU 
vs. 4887±646AU; Figure 3.10C-D). Interestingly, despite no change in area under the 
curve, the mitochondrial membrane hyperpolarisation exhibited a more sustained 
response in the presence of aspirin (Figure 3.10A, C).  
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Figure 3.10: The effect of aspirin treatment on mitochondrial membrane potential 
following platelet activation 
Representative TMRM fluorescence traces as an indicator of mitochondrial membrane 
potential in response to A. U46619 and C. TRAP-6 in the presence of vehicle (red) or aspirin 
(blue). Quantification of area under the curve of TMRM fluorescence following stimulation 
with: B. U46619, or aspirin plus U46619; and D. TRAP-6, or aspirin plus TRAP-6. Data 
presented as mean±SEM, significance was determined by paired t-test (n=6). 
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 Aspirin treatment does not affect mitochondrial respiration  
 
Consistent with no alterations in mitochondrial membrane potential, aspirin did not 
cause alterations in oxygen consumption rate as an indicator of mitochondrial 
activity (Figure 3.11A). Indeed, 30-minute pre-treatment of platelets with aspirin 
caused no changes in basal mitochondrial respiration (vehicle vs. aspirin, 
127±46pmoles/min vs. 131±41pmoles/min; Figure 3.11B) or ATP-linked oxygen 
consumption (vehicle vs. aspirin, 72±15pmoles/min vs. 86±23pmoles/min; Figure 
3.11C). Further, the maximal respiratory capacity was unchanged following aspirin 
treatment (vehicle vs. aspirin, 196±93pmoles/min vs. 218±104pmoles/min; Figure 
3.11D) and thus the spare respiratory capacity remained unaltered (vehicle vs. 
aspirin, 69±49pmoles/min vs. 87±62pmoles/min; Figure 3.11E). Finally, aspirin 
treatment did not affect non-mitochondrial respiration (vehicle vs. aspirin, 
66±48pmoles/min vs. 51±33pmoles/min; Figure 3.11F). 
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Figure 3.11: The effect of aspirin treatment on oxygen consumption rate  
A. Agilent Seahorse oxygen consumption rate trace following incubation of platelets with 
vehicle (red) or aspirin (blue) and the subsequent injection of the mitochondrial inhibitors 
oligomycin, FCCP and rotenone plus antimycin A. Quantification of oxygen consumption 
rate: B. under basal conditions; C. linked to ATP production, assessed by inhibition of ATP 
synthase with oligomycin; D. maximal oxygen consumption rate; E. spare respiratory 
capacity; and F. non-mitochondrial respiration. Data presented as mean±SEM, significance 
was determined by paired t-test (n=5). 
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 Inhibition of the P2Y12 receptor causes a reduction in agonist-induced rises 
in intracellular calcium and P-selectin exposure in response to U46619 
 
Aspirin is the gold-standard of antiplatelet therapies, however P2Y12 receptor 
antagonists, such as prasugrel and clopidogrel, are now commonly prescribed for the 
secondary prevention of myocardial infarction. Given that the mode of action of this 
class of antiplatelet drugs differs from aspirin, I sought to identify if they have 
differential effects on platelet activation and mitochondrial function. 
 
Interestingly, treatment with the P2Y12 receptor antagonist, AR-C66096, caused a 
reduction in calcium flux following incubation of platelets both U46619 or TRAP-6 
compared to vehicle (AUC U46619 vehicle vs. AR-C66906, 236277±7812AU vs. 
160856±23164AU; AUC TRAP-6 vehicle vs. AR-C66906, 412503±23928AU vs. 
242832±10444AU; Figure 3.12A-D). However, the maximal calcium flux capacity of 
platelets treated with AR-C66096 remained unchanged compared to vehicle (AUC 
ionomycin vehicle vs. AR-C66096, 1111457±84318AU vs. 1172395±86723AU).  
 
Consistent with a reduced calcium flux, P2Y12 inhibition caused a reduction in P-
selectin expression following incubation with U46619 (AUC U46619 vehicle vs. AR-
C66906, 5402±1411AU vs.1927±753AU; Figure 3.13A-B). On the other hand, P2Y12 
inhibition did not affect P-selectin expression following exposure to TRAP-6 (AUC 
TRAP-6 vehicle vs. AR-C66906, 34348±9878AU vs.36968±18284AU; Figure 3.13C-D). 
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Figure 3.12: The effect of P2Y12 inhibition on calcium flux during platelet activation 
Representative calcium (Fluo-4) dynamic traces in response to A. U46619 C. TRAP-6 and E. 
ionomycin in the presence of vehicle (red) or AR-C66096 (blue). Quantification of area under 
the curve of Fluo-4 fluorescence following incubation with: B. U46619, or AR-C66096 plus 
U46619; D. TRAP-6, or AR-C66096 plus TRAP-6; and F. ionomycin or AR-C66096 plus 
ionomycin. Data presented as mean±SEM, significance was determined by paired t-test (n=3, 
*p<0.05). 
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Figure 3.13: The effect of P2Y12 inhibition on P-selectin expression  
Representative P-selectin (CD62P) expression traces following exposure to A. U46619 and C. 
TRAP-6 in the presence of vehicle (red) or AR-C66096 (blue). Quantification of area under 
the curve of CD62P fluorescence following incubation with: B. U46619, or AR-C66096 plus 
U46619; D. TRAP-6, or AR-C66096 plus TRAP-6. Data presented as mean±SEM, significance 
was determined by paired t-test (n=4, *p<0.05). 
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 Inhibition of the P2Y12 receptor alters the dynamic of mitochondrial 
membrane hyperpolarisation following U46619 activation 
 
As detailed above, platelet activation after incubation with both U46619 and TRAP-
6, caused mitochondrial membrane hyperpolarisation. Here I have shown that P2Y12 
inhibition caused alterations in the DYm dynamics. Interestingly, the initial rapid 
increase in TMRM fluorescence following U46619 stimulation, indicative of DYm 
hyperpolarisation, was not observed following pre-treatment of platelets with AR-
C66096. Indeed, 10 seconds after the addition of U46619, there was a significant 
difference in TMRM fluorescence between vehicle and AR-C66096 treated platelets 
(251±91AU vs. -70±45AU, respectively; p<0.001; Figure 3.14A). Despite this initial 
DYm depolarisation, a subsequent sustained membrane hyperpolarisation equated 
to no significant change in the area under the curve (AUC U46619 vehicle vs. AR-
C66096, 7955±4610AU vs. 3596±2732AU; Figure 3.12B). On the other hand, 
exposure of platelets to TRAP-6 in the presence of P2Y12 inhibition caused DYm 
hyperpolarisation to a similar extent as that seen in vehicle treated platelets (AUC 
TRAP-6 vehicle vs. AR-C66096, 13014±8161AU vs.12651±6345AU; Figure 3.14C-D).  
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Figure 3.14: The effect of P2Y12 inhibition on mitochondrial membrane potential 
Representative TMRM fluorescence traces as an indicator of mitochondrial membrane 
potential in response to A. U46619 and C. TRAP-6 in the presence of vehicle (red) or AR-
C66096 (blue). Quantification of area under the curve of TMRM fluorescence following 
stimulation with: B. U46619, or AR-C66096 plus U46619; and D. TRAP-6, or AR-C66096 plus 
TRAP-6. Data presented as mean±SEM, significance was determined by paired t-test (n=5). 
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 Inhibition of the P2Y12 receptor with AR-C66096 causes a reduction in 
mitochondrial respiration 
 
Unlike treatment of platelets with aspirin, treatment with AR-C66096 caused a 
significant reduction in basal oxygen consumption rate (129±34pmoles/min vs. 
72±10pmoles/min in vehicle and AR-C66096 respectively; Figure 3.15B) and 
subsequent reduction in ATP-linked oxygen consumption from 87±24pmoles/min in 
vehicle treated platelets to 36±15pmoles/min in AR-C66096 treated platelets (Figure 
3.15C). Despite a marked reduction in maximal respiratory capacity following AR-
C66096 treatment (Figure 3.15A), this did not reach significance; 193±70pmoles/min 
vs. 114±38pmoles/min for vehicle and AR-C66096, respectively (Figure 3.15D). 
Further, there was no significant change in the spare respiratory capacity following 
AR-C66096 treatment; 85±20pmoles/min vs. 57±41pmoles/min; Figure 3.15E). 
Likewise, there was no significant change in the non-mitochondrial respiration; 
43±40pmoles/min vs. 32±20pmoles/min in vehicle and AR-C66096 treated platelets 
(Figure 3.15F).  
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Figure 3.15: The effect of P2Y12 inhibition on oxygen consumption rate 
A. Agilent Seahorse oxygen consumption rate trace following treatment with vehicle (red) or 
AR-C66096 (blue) and the subsequent injection of the mitochondrial inhibitors oligomycin, 
FCCP and rotenone and antimycin A. Quantification of oxygen consumption rate: B. under 
basal conditions; C. linked to ATP production, assessed by inhibition of ATP synthase with 
oligomycin; D. maximal oxygen consumption rate; E. spare respiratory capacity; and F. non-
mitochondrial respiration. Data presented as mean±SEM, significance was determined by 
paired t-test (n=4, * p<0.05). 
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 Discussion  
 
Platelet activation initiated by an external agonist binding to surface receptors 
facilitates intracellular signalling cascades, involving PLC and IP3 which stimulate 
release of calcium from intracellular stores. Subsequently, this stimulates influx of 
calcium through the plasma membrane which is controlled by a number of 
mechanisms, including store-operated calcium entry mediated by STIM1 and Orai1.87 
Furthermore, the receptor-operated calcium channel, P2X1 and TRPC6 facilitate the 
entry of calcium through the plasma membrane.87 Here I have shown that platelet 
activation with both U46619 and TRAP-6, causes a significant increase in intracellular 
calcium. Unsurprisingly, activation with the stronger agonist, TRAP-6, causes a more 
rapid and sustained increase in intracellular calcium. Interestingly, the maximal 
calcium flux capacity of these platelets, examined using the calcium ionophore 
ionomycin, is approximately four times higher than the response elicited by TRAP-6. 
This observation could lead me to speculate that platelets may not require their 
maximal calcium signalling capacity to stimulate platelet activation. However, 
ionomycin elicits its function by creating pores within the membrane, thus allowing 
a substantial influx of calcium from the extracellular environment, which could 
subsequently overwhelm the intracellular calcium signalling. To better understand a 
platelets endogenous maximal calcium signalling capacity, the assay could be 
repeated without recalcification of the sample. This would allow for an indication of 
the release of calcium from within the intracellular stores, and would be less affected 
by the influx of calcium from the extracellular milieu.  
 
Measuring calcium flux using flow cytometry has a number of limitations. Firstly, 
when using flow cytometry, the samples need to be diluted enough to ensure that 
the platelets do not aggregate, as this may cause obstruction in the cytometer. The 
dilution of platelets allows for a read out of the initial platelet activation pathways, 
but may be limited in terms of the secondary wave, following the release of 
secondary mediators. Thus, in this assay, I am looking at the calcium response 
following platelet activation, but not aggregation. Indeed, this assay may not be 
sensitive enough to fully understand the effect of anti-platelet therapies on calcium 
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signalling. Both aspirin and P2Y12 antagonist target the secondary wave of 
aggregation, involving the release of secondary mediators, which given the diluted 
nature of the samples may not have elicited their full affects.  
 
Whilst this data provides indications as to the nature of the effect of different 
agonists and anti-platelet drugs on calcium signalling, the technical limitations of the 
equipment means I have to be careful in drawing solid conclusions. Platelets 
inherently want to stick together, therefore measuring calcium flux in system where 
I am trying to prevent the samples aggregating does not mimic a physiological 
environment. Indeed, when looking at a growing thrombus, research has indicated 
that platelets exhibit a sustained high intracellular calcium which subsequently 
undergoes oscillations. Further, it has been proposed that platelets with high 
intracellular calcium communicate the calcium activation status to adjacent 
platelets.220 Although far more time consuming and technically challenging, using a 
more physiological system, looking at calcium dynamics using adherent platelets and 
fluorescence microscopy may provide a better measure of calcium response during 
platelet aggregation, activation and thrombus formation, and subsequent effect of 
anti-platelet therapeutics.  
 
The initial rise in intracellular calcium facilitates cytoskeletal rearrangement, 
promoting the movement and fusion of granules with the plasma membrane. 
Following the binding of vSNAREs on the granule and tSNAREs on the membrane, the 
granular content is released into the extracellular milieu and exerts its actions 
through both autocrine and paracrine manners.60 Here I have shown that the 
exposure of P-selectin on the outer leaflet of the plasma membrane occurs at a 
slower rate than the rise in intracellular calcium, confirming the sequential nature of 
platelet activation. Further, stronger platelet stimulation with TRAP-6 causes a 
quicker and more robust increase in P-selectin expression than following stimulation 
with U46619. Interestingly, although TRAP-6 and U46619 activate different surface 
receptors, PAR-4 and TP respectively, the intracellular signalling pathways are 
overlapping, which raises the question as to why the responses are different.82 The 
differences may be accounted for due to their role in the haemostatic response; 
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thrombin and therefore TRAP-6 is a strong platelet agonist, which stimulates the 
primary wave of aggregation, whilst thromboxane A2 and therefore U46619, is an 
important secondary mediator which amplifies the activation response.  
Furthermore, these differences in the strength of the signal may be accounted in part 
by different receptor copy numbers which may limit the rate of response. 
 
In recent years there has been growing interest in understanding mitochondrial 
function in platelets. Given the ease of isolation, platelets may provide a potential 
system to understand mitochondrial function and health at a more global level.71 
Thus, understanding platelet mitochondrial parameters; such as DYm and oxygen 
consumption rate, in healthy individuals under both basal and activated conditions 
may allow us to establish if this information can be more widely applicable to 
mitochondrial health and function within other cells, and may allow the 
characterisation of differences in disease pathologies. In other cell types, it is well 
established that maintaining healthy mitochondria with an intact DYm, is necessary 
for the maintenance of cellular functionality, however it still remains elusive as to the 
importance of mitochondria function in platelets. Here I have shown that following 
activation, platelet mitochondria undergo a short, transient period of 
hyperpolarisation, as marked by an increase in the fluorescence of the mitochondrial 
membrane dye, TMRM. This increase in fluorescence is indicative of a more negative 
membrane potential as a result of increased proton motive force generated by an 
increase in oxidative phosphorylation.221  
 
Interestingly, the kinetics of mitochondrial membrane potential follow a similar 
pattern to calcium dynamics, suggesting these two processes may be intimately 
linked. Whilst it has long been established that mitochondria are a reservoir of 
calcium, acting a buffer for cytosolic calcium. The data presented here may suggest 
that a rise in intracellular calcium is important for the transient DYm 
hyperpolarisation. Indeed, research has shown that calcium imported into 
mitochondria may participate in the oxidation of mitochondrial substrates, therefore 
increasing the oxidative phosphorylation capacity.222 Whilst it has been established 
calcium is essential for mitochondrial function in other cell types, the relationship in 
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platelets remains unknown. To examine the role of mitochondrial calcium during 
platelet activation, inhibition of the mitochondrial calcium uniporter (MCU) may 
provide interesting insights into the association between calcium flux and DYm in 
platelets. Furthermore, the use of the mitochondrial specific calcium probe Rhod-2 
would provide additional understanding of these processes. In this work, I have 
demonstrated that platelet activation causes a transient DYm hyperpolarisation, 
whilst recent research has indicated that sustained DYm hyperpolarisation enhances 
procoagulant platelet formation. Further, genetic deletion of MCU has highlighted 
an positive association between DYm hyperpolarisation, calcium entry through 
MCU, and subsequent formation of the mitochondrial permeability transition pore 
(mPTP).122,223  
 
The changes I identified in DYm following platelet activation led me to speculate that 
platelet activation would cause an increase in mitochondrial respiration through 
oxidative phosphorylation. Under resting conditions, platelets derive approximately 
60% of their ATP from glycolysis with the remaining 40% derived from oxidative 
phosphorylation within the mitochondria.116 Using a Seahorse analyser, I found that 
platelet activation with TRAP-6 causes a significant increase in oxygen consumption 
rate, indicative of an increase in oxidative phosphorylation. Despite this increase 
from baseline oxygen consumption rate, platelet activation does not cause 
subsequent alteration to any additional respiration parameters. Interestingly, 
research has indicated that platelets have a relatively high basal oxygen consumption 
rate in comparison to some leukocytes, such as monocytes.116 Given that platelets 
are far smaller than leukocytes, it may be surprising that their basal oxygen 
consumption is higher. The reasons behind the high basal oxygen consumption 
remain unknown, however as detailed previously, it may be due to platelets having 
to maintain their quiescent state and prevent inappropriate activation. In addition, 
platelets may need to maintain strong ion gradients such that they are able to 
respond rapidly to breaks within the vasculature or to soluble mediators thereby 
preventing excessive blood loss.   
 104 
The Seahorse analyser is a useful tool to look at oxygen consumption, however there 
are a number of limitations with using this method for the measurement of 
mitochondrial function in platelets. Firstly, platelet activation is a rapid process in 
which platelets lose their discoid shape undergoing cytoskeletal rearrangement and 
thereby facilitating granule secretion. These processes are largely complete within 5-
10 minutes following activation, however the Seahorse analyser protocol is limited 
by the time and frequency of the measurements. Following the injection of TRAP-6, 
the oxygen consumption rate was not measured for 3 minutes, therefore any initial 
alterations would have been missed. Despite this time delay in measuring the oxygen 
consumption, I was still able to demonstrate an increase in oxygen consumption, 
suggesting that the increased respiration is maintained past the initial platelet 
activation period. These findings support previous work showing an increase in 
oxygen consumption following activation of platelets by thrombin.209,224 An 
alternative approach to measure mitochondrial respiration in platelets, would be 
using high resolution respirometry. This technique is more sensitive to small changes 
in oxygen consumption and would allow for the determination of earlier alterations 
in mitochondrial function following the addition of a platelet activator.224 Whilst 
more labour intensive, high resolution respirometry is a more flexible and sensitive 
assay. Unlike Seahorse analyser, it allows for the manual injection of numerous 
compounds, through ports within the chamber stopper, and consistently measures 
the oxygen consumption within the sealed chamber. This technique would provide 
more detailed analysis of the rapid, dynamic nature of the platelet activation 
response. The measurement of oxygen consumption as an indicator of mitochondrial 
respiration is widely used, however it can be a misleading measurement as it does 
not consider the oxygen consumption contribution of oxidative enzymes, such as 
cyclooxygenase-1.225 Thus, the increase in oxygen consumption following platelet 
activation may in part be attributable to the activation of cyclooxygenase-1 and 
lipoxygenases, facilitating the conversion of arachidonic acid into thromboxane A2 
and hydroxyeicosatetraenoic acids (HETEs).226,227 
 
Anti-platelet therapeutics are commonly prescribed for the secondary prevention of 
cardiovascular events. There is a plethora of literature demonstrating alterations in 
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platelet aggregation, and the effectiveness of aspirin and P2Y12 inhibitors in reducing 
platelet activity, however the dynamics of these responses have not been 
investigated. In this work, I have shown that P2Y12 inhibition, but not aspirin 
treatment causes a reduction in calcium flux following stimulation with U46619 and 
TRAP-6, without affecting the overall calcium signalling capacity following incubation 
with ionomycin, supporting recent work indicating reduced calcium signalling 
following ticagrelor or AR-C69931.228 As discussed previously, given the dilute nature 
of the sample, the inhibition of the secondary wave of aggregation may be masked, 
therefore not showing the true effect of these anti-platelet treatments.  
 
Interestingly, recent work has indicated that aspirin affects the release of pro-
inflammatory mediators independent of cyclooxygenase, by influences on calcium 
signalling pathways.229 This work has highlighted that low and high concentrations of 
aspirin have differential effects on calcium entry into mast cells. Indeed, low 
concentrations stimulate a stronger influx of calcium, whilst high concentrations 
inhibit the uptake of calcium.229 The anti-platelet effects of aspirin occur at low doses, 
and as such one might expect to see an increase in calcium signalling following 
activation. These reports have highlighted a modification in calcium signalling in T 
cells and mast cells, so may not be directly applicable to platelets, however repeating 
the calcium flux assay using a spectrofluorometer may provide a more accurate and 
sensitive assessment of calcium signalling. Further, using a spectrofluorometer 
would provide a more physiologically relevant environment as the samples do not 
need to be diluted, therefore allowing the platelets to aggregate and trigger the 
secondary wave of aggregation.  
 
Further investigation of platelet activation pathways revealed that blockade of the 
P2Y12 receptor and inhibition of cyclooxygenase-1 reduces P-selectin exposure 
following stimulation with U46619, but not TRAP-6. This data supports recent work 
that has shown that both the P2Y12 and P2Y1 receptors are involved in the secretion 
and exposure of P-selectin on the platelet surface.217  
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Interestingly, in the presence of aspirin, mitochondrial function was unaltered, 
following a similar dynamic DYm hyperpolarisation following platelet activation, and 
a consistent oxygen consumption rate under basal conditions. This data indicates 
that pharmacological inhibition of cyclooxygenase-1 does not cause alterations in 
platelet metabolism. Conversely, pharmacological inhibition of the P2Y12 receptor 
causes alterations in mitochondrial function. Notably, in response to U46619, the 
initial DYm hyperpolarisation is replaced with a DYm depolarisation, which was not 
observed in response to TRAP-6. Furthermore, analysis of mitochondrial respiration 
revealed that under basal conditions, AR-C66096 treated platelets had a significantly 
lower oxygen consumption rate than vehicle treated platelets, suggesting that 
pharmacological blockade of the P2Y12 receptor is affecting mitochondrial function 
and health. This reduction in mitochondrial respiration could be a toxic side effects 
of AR-C66096 or as a result of disruption of the ADP associated pathways within the 
platelet. To determine if these findings are as a result of toxic effects, additional 
experiments using alternative P2Y12 inhibitors could be performed. Interestingly, 
work has indicated the presence of P2Y12 receptors on mitochondria within 
astrocytes.230 While it is unknown whether platelets also express P2Y12 receptors 
within their mitochondrial membranes, if they do it may provide an alternative 
explanation for the disruption in mitochondrial function following incubation with a 
P2Y12 receptor antagonist.  
 
Whilst in this work I have investigated the role of mitochondrial energy production 
within a small number of platelet activation pathways, further work exploring the 
contribution of glycolysis to these processes would provide interesting insights into 
platelet metabolism and compensatory mechanisms between these two pathways. 
Indeed, it would be exciting to explore whether either of these two pathways is 
engaged preferentially in response to certain agonists. In general terms, I have 
discussed the process of platelet activation occurring in a sequential manner, which 
in terms of soluble agonist induced activation appears to be true. However, it 
remains unclear whether platelet activation following from other stimuli, high shear 
stress being a particular example, proceeds in the same sequential nature.65  My data  
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 illustrates that measuring the dynamics of platelet activation pathways allows a 
deeper understanding of the response can be achieved and through this an 
opportunity to unpick differences in responses. As an example, using an end point 
fluorescence assay to measure TMRM fluorescence rather than a dynamic assay 
would not have allowed measurement of any of the changes seen in the initial stages 
of platelet activation and so a much poorer understanding of DYm.  
 
This data presented in this chapter confirms the sequential nature of platelet 
activation, highlighting an importance of changes in mitochondrial membrane 
potential and increases in mitochondrial respiration. Anti-platelet treatment with 
AR-C66096, but not aspirin, affects calcium flux and P-selectin expression following 
activation. Furthermore, AR-C66096 affects mitochondrial function, under basal 
conditions causing a significant reduction in the oxygen consumption rate. This 
interesting observation warrants further investigation to unpick the impact of this 
reduction in oxygen consumption and its significance on platelet function.  
 
The work presented in this chapter investigates response of platelets when 
considered as a whole population, however it is well established that platelets form 
a heterogenous population of ages, sizes and function. In the next chapter, I will 
explore differences in platelet function and composition in two subpopulations of 
different ages.   
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 Characterisation of differently aged platelets 
 
 Introduction 
 
Blood platelets form a heterogenous population of different ages which exist within 
the circulation of a healthy individual for approximately 10 days. During platelet 
biogenesis from the progenitor megakaryocyte, platelets are packaged with mRNA, 
lipids, proteins and organelles which are needed for their functionality within the 
circulation.231 Given that platelets are anucleate, they lack the capacity to generate 
new mRNA, and as such, following release from the parent megakaryocyte, the 
mRNA rapidly degrades within the first few days.73 This results in a small 
subpopulation of platelets, the newly formed, having the highest levels of mRNA.  
 
Along with RNA, platelets also inherit ribosomes and translational machinery from 
the progenitor megakaryocyte. Historically, it was thought that the platelet 
proteome is stable, with the vast majority of proteins obtained during platelet 
biogenesis or taken up from the plasma via endocytic pathways. However, emerging 
evidence has revealed that platelets have a limited capability to translate mRNA into 
protein, although it remains to be established under what circumstances this 
occurs.232 In addition to these recent observations that platelets are able to translate 
RNA, there are reports that they can also transfer RNA to other cells within the 
circulatory system and so influence their function.233–235 
 
Understanding the functional changes across platelet lifespan is of particular 
research interest as newly formed platelets have been described as being hyper-
reactive and associated with an increased risk of thrombotic disease.236 Interestingly, 
in a number of diseases such as chronic kidney disease and diabetes mellitus, there 
are reports of increased platelet turnover resulting in a higher proportion of young 
platelets in the circulation, with a related increase occurrence of acute coronary 
events.237 Furthermore, increased platelet turnover and the associated increase in 
the proportion of newly formed platelets have been linked to suboptimal responses 
to anti-platelet therapies.238 Despite many reports of these newly formed platelets 
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being hyper-reactive, there are few systematic studies that have sought to 
understand functional changes between young and old platelets in healthy 
individuals.  
 
In this chapter, I use proteomics, immunofluorescence and functional assays to 
investigate the differences between young and old platelets isolated from peripheral 
blood of healthy individuals.  
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 Methods 
 
 Blood collection and preparation of PRP 
 
Blood was collected from healthy volunteers and PRP was prepared as previously 
described in sections 3.2.1 and 3.2.2.  
 
 Flow cytometric sorting of young, intermediate and old platelets 
 
Using flow cytometry cell sorting, platelets of different ages were separated for 
functional studies. Briefly, PRP was incubated with 200ng/ml thiazole orange for 30 
minutes at room temperature in the dark. The sample was diluted 1 in 8 with filtered 
modified Tyrode’s HEPES buffer (pH 7.4) and supplemented with prostaglandin E1 
(PGE1; 2µM). Platelets were sorted on a BD FACS Aria III Fusion Cell Sorter (70μm 
nozzle, 70 Ps) into three subpopulations based on gating on thiazole orange 
fluorescence intensity (Figure 4.1). The sorting protocol identified platelets on 
forward scatter area (FSC-A) and side scatter area (SSC-A), removed doublets based 
on side scatter width (SSC-W) and subsequently gated on thiazole orange 
fluorescence intensity; young platelets were defined as top 10%, thiazole orange 
bright; intermediate platelets were defined as middle 50%; and old platelets were 
defined as bottom 30%, thiazole orange dim. Following cell sorting on thiazole 
orange intensity, platelet subpopulations were pelleted at 1000 x g for 10 minutes in 
the presence of prostacyclin (PGI2; 2μM) and resuspended in modified Tyrode’s 
HEPES buffer and allowed to rest for 30 minutes. 
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Figure 4.1 Thiazole orange isolation of young, intermediate and old platelets  
Flow cytometric cell sorting protocol based on A. SSC-A/FSC-A and SSC-W/Thiazole Orange 
fluorescence intensity B. Representative dot plot of SSC-A/Thiazole Orange demonstrating 
the gating strategy to isolate young platelets (top 10%), intermediate platelets (middle 50%) 
and old platelets (bottom 30%) based on thiazole orange fluorescence intensity.  
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 Proteomic analysis of sorted platelet subpopulations 
 
Following sorting of 65 million platelets per subpopulation, platelet pellets were 
lysed on ice in 250µl buffer containing 100mM TRIS (pH 7.4), 2% sodium dodecyl 
sulfate (SDS) with 1 cOmplete™ Mini Protease Inhibitor Cocktail Tablet. The samples 
were sonicated twice at 20W for 5 seconds, and centrifuged at 18,000 x g for 7 
minutes at 4˚C. The supernatant was removed, placed in a fresh microcentrifuge tube 
and stored at -80˚C until required. Protein content of platelet subpopulations was 
measured using a Nanodrop Spectrophotometer ND-1000.  
 
The extracted protein samples were sent to Simone Marcone at University College 
Dublin, Ireland for liquid chromatography tandem mass spectrometry analysis (LC-
MS/MS). Samples were prepared as previously described239. From each sample, 50µg 
of protein was used for trypsin digestion and filter aided sample preparation (FASP). 
For LC-MS/MS analysis, 2µg of purified protein was injected using an Ultimate3000 
nano-LC system coupled to a hybrid quadrupole-orbitrap mass spectrometer (Q 
Exactive). All data was acquired operating in automatic data-dependent acquisition 
mode (DDA, shotgun).  
 
Downstream analysis of the platelet proteomic data was performed by Perseus 
software (version 1.6.0.7); only proteins present in at least 50% of samples in at least 
one group of differently aged platelets were considered identified. The proteomic 
data is presented as a Z-score, expressing the relationship between each individual 
value and the mean of all values for that protein. Proteins found to be differentially 
expressed between groups (p value <0.05) were subjected to pathway mapping 
analysis using ingenuity pathway analysis (IPA) and STRING database (Version 10.5). 
The molecular activation prediction algorithm in IPA was used to predict upstream 
and downstream effects of activation and inhibition of associated network functions. 
STRING was used to generate protein-protein interaction networks. 
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 Immunofluorescence of young and old platelets 
 
Sorted young and old platelets (2 million per population) were fixed with 
paraformaldehyde (PFA; 4%) for 10 minutes and centrifuged onto poly-l-lysine 
coverslips at 600 x g for 5 minutes. Non-adherent platelets were removed from the 
coverslips by washing with filtered PBS. Samples were blocked and permeabilised 
with filtered permeabilising buffer (0.2 % Triton, 2% donkey serum and 1% bovine 
serum albumin; BSA, in PBS) for 30 minutes at room temperature. After removal of 
the blocking buffer, the coverslips were incubated with primary antibodies as 
indicated in Table 4.1 for 1 hour in the dark at room temperature. The primary 
antibody was removed with three wash steps using filtered PBS. Subsequently, the 
samples were incubated for 45 minutes with the secondary antibody in the dark at 
room temperature (Table 4.1). The secondary antibody was removed with three 
filtered PBS washes. The coverslips were mounted using ProLong Diamond antifade 
mount and allowed to set overnight in the dark at room temperature. Samples were 
then stored at 4°C and imaged on the Zeiss LSM880 confocal microscope with 
airyscan; 63x objective, 1.4 DICII; imaging at least 5 different fields of view per sample 
collecting a minimum of 30 platelets per sample. Image processing and analysis was 
conducted using Zen Software (2.3 SP1) and ImageJ.  
 
 
 
Table 4.1 Antibodies used for immunofluorescence of sorted platelets 
 
 
 
 
 
Target Primary antibody Dilution Secondary antibody Dilution 
Actin Phalloidin Alexa Fluor 647 1:200 - - 
Tubulin Mouse anti-aTubulin 1:500 anti-mouse Alexa Fluor 647 1:500 
Mitochondria Mouse anti-TOM20 1:500 anti-mouse Alexa Fluor 555 1:500 
Dense tubular system Rabbit anti-ErP57 1:200 anti-rabbit Alexa Fluor 647 1:500 
Fibrinogen Rabbit anti-fibrinogen 1:200 anti-rabbit Alexa Fluor 647 1:500 
Complement 4 Rabbit anti-C4 1:200 anti-rabbit Alexa Fluor 647 1:500 
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 Measuring mitochondrial membrane potential in young and old platelets 
 
Sorted young and old platelets (3 million per population in 250µl) were 
supplemented with 2mM CaCl2 and stained with MitoProbe™ DiIC1(5) (50nM) and 
CD42b BV421 (1:250) for 15 minutes at room temperature in the dark. Samples were 
acquired using the BD LSRII, collecting 10,000 CD42b events and assessing MitoProbe 
fluorescence. Samples were analysed using FlowJo v.8.  
 
 Measuring phosphatidylserine exposure in young and old platelets 
 
Sorted young and old platelets (3 million per population in 250µl) were 
supplemented with CaCl2 (2mM), diluted in 150µl Annexin V binding buffer and 
stained with annexin V APC (1:150) and CD42b BV421 (1:250) for 15 minutes at room 
temperature in the dark. Samples were acquired using the BD LSRII, collecting 10,000 
CD42b events and assessing annexin V fluorescence. Samples were analysed using 
FlowJo v.8.  
 
 Assessing platelet spreading on collagen in young and old platelets 
 
Glass coverslips were coated in collagen (100µg/ml) overnight at 4˚C and 
subsequently washed with filtered PBS. The coverslips were blocked with BSA (1%) 
for 1 hour at room temperature and then washed with filtered PBS.  
 
Following sorting, young and old platelets (3 million per population) were 
supplemented with CaCl2 (2mM) and allowed to adhere to collagen coated coverslips 
for 1 hour at 37˚C. Non-adherent platelets were removed by three washes with 
filtered PBS.  Samples were fixed with PFA (0.2%) for 10 minutes, washed with 
filtered PBS and subsequently permeabilised with Triton (0.2%). Following 
permeabilization, samples were once again washed with filtered PBS and stained 
with Phalloidin 647 (1:200) for 1 hour at room temperature in the dark. Platelet 
samples were washed with filtered PBS and mounted onto Super Frost coverslips 
using Prolong Diamond antifade mount. Samples were then stored at 4˚C and imaged 
on the Zeiss LSM880 confocal microscope with airyscan; 63x objective, 1.4 DICII, 
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imaging at least 5 different fields of view per sample collecting a minimum of 30 
platelets per sample. Image processing and analysis was conducted using Zen 
Software (2.3 SP1) and ImageJ. 
 
 Assessing calcium dynamics young and old platelets 
 
Sorted young and old platelets (10 million per population in 1000µl) were stained 
with Calbryte 630TM (2µM) for 30 minutes at 37°C, and CD42b BV421 (1:200) for 15 
minutes at room temperature and supplemented with CaCl2 (2mM). Baseline 
Calbryte 630TM fluorescence was recorded for 30 seconds, followed by challenge with 
Thrombin Receptor Activator for Peptide 6 (TRAP-6; 10µM and 25µM), or ionomycin 
(10µM) and subsequent recording of fluorescence for 2 minutes. Samples were 
acquired on a BD LSRII flow cytometer using FACSDiva acquisition software, and 
analysed using FlowJo software.  
 
 Statistical analysis 
Graphs and statistical analysis were generated using GraphPad Prism v.8. Data was 
expressed as mean±SEM and all statistics were generated using a paired students t-
test or a one-way ANOVA, with a Tukey’s post-test. Significance was defined as 
p<0.05. 
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 Results  
 
 Protein content declines with platelet age 
 
Measurement of the total protein concentration in differently aged platelets 
demonstrated a significant reduction in protein content as platelets age. Young 
platelets (thiazole orange high) contained 8.7±2.6pg of protein per platelet, reducing 
to 6.6±0.72pg per platelet in the intermediate subpopulation and 4.7±1.2pg per 
platelet in old platelets (Figure 4.2A).  
 
Mass spectrometry analysis revealed that the reduction in protein content was 
associated with a marked decrease in the number of different detectable proteins; 
484±23, 297±34 and 281±43 proteins in in young, intermediate and old platelet 
subpopulations, respectively (Figure 4.2B).  
 
 
 
 
 
 
 
 
 
Figure 4.2 Assessment of protein content and number in platelet subpopulations 
A. Quantification of protein content per platelet in young, intermediate and old 
subpopulations. B. Quantification of the number of detected proteins by mass spectrometry 
in young, intermediate and old subpopulations. Data presented as mean±SEM, significance 
was determined by one-way ANOVA with Tukey’s multiple comparisons test (n=4, **p<0.01). 
 
 
A B 
Young Intermediate Old
0
5
10
15
Pr
ot
ei
n 
co
nt
en
t (
pg
/p
la
te
le
t)
**
ns
ns
Young Intermediate Old
0
200
400
600
N
um
be
r o
f p
ro
te
in
s 
de
te
ct
ed
**
ns**
 117 
 Platelet ageing causes alterations in protein expression 
 
Shotgun mass spectrometry identified a total of 583 different proteins (Figure 4.3; 
Appendix 1) within the three platelet subpopulations. When comparing all three 
subpopulations, there was a significant difference in the expression of 94 different 
proteins (Figure 4.3B; Appendix 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Hierarchal clustering of the sorted platelet proteome 
A. Hierarchal clustering heat map of 583 proteins identified in the proteomic analysis of 
platelet subpopulations B. Hierarchal clustering heat map of the 94 proteins significantly 
altered between the three platelet subpopulations. Data presented as z-score (red indicates 
a relative increase, green indicates a relative decrease in expression). 
A B 
Intensity 
-2.5    -2   -1.5     -1   -0.5     0    0.5       1      1.5     2 
 118 
Focussed analysis looking at differences in protein expression specifically between 
young and old platelets indicated a significant modulation in 78 different proteins 
(Figure 4.4; Appendix 3). Hierarchal clustering of these proteins indicated 64 proteins 
had a relatively higher expression in young platelets, whilst old platelets had a 
relatively higher expression of 14 proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Protein alterations between young and old platelets 
Hierarchal clustering heat map of 78 proteins significantly altered between young and old 
platelets. Data presented as z-score (red indicates a relative increase, green indicates a 
relative decrease in expression). 
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 Alterations in protein expression affect key biological functions 
 
Downstream analysis of the protein alterations using STRING analysis indicated that 
the proteins expressed relatively more highly in young platelets have a strong 
interaction network. Of particular interest, STRING analysis highlighted a large 
number of mitochondrial proteins and cytoskeletal-proteins with significantly higher 
expression levels in young platelets (Figure 4.5A). The analysis also indicated that 
there was an interaction between a number of mitochondrial (shown in red) and 
cytoskeletal proteins (blue). Further investigation examining the biological functions 
that may be affected as a result of higher expression of these proteins indicated that 
15 of these proteins are involved in haemostasis (shown in green) and form 
interactions with cytoskeletal-associated proteins. Interestingly, only a small number 
of these proteins do not have an interaction partner within the group, suggesting the 
reduction in the protein levels may be due to specific degradation of proteins 
involved in certain pathways or potential release of these proteins in microvesicles. 
 
The number of proteins that were identified as having a higher expression in old 
platelets was far lower than that identified in young platelets. Interestingly, however, 
these proteins tended to be circulating proteins suggesting they may have 
accumulated over the platelet’s lifespan. STRING analysis demonstrated that these 
proteins are involved in the immune system response (red) and the stress response 
(blue), which may suggest that old platelets have a different function compared to 
young platelets (Figure 4.5B).  
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Figure 4.5 STRING analysis of protein interactions and associated functions affected by 
protein alterations  
A. STRING analysis showing proteins more highly expressed in young platelets indicating 
mitochondrial (red) and cytoskeletal-associated proteins (blue) and proteins involved in 
haemostasis (green). B. STRING analysis showing proteins more highly expressed in old 
platelets involved in the immune system response (red) and the stress response (blue). 
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Downstream analysis of the altered proteome profile using ingenuity pathway 
analysis identified a total of 29 biological functions and pathways that may be 
affected by the altered protein expression (Figure 4.6). Of these, 22 functions were 
predicted to be higher in the young platelets; including haemostasis, binding and 
adhesion of blood platelets and organisation of the cytoskeleton. On the other hand, 
old platelets had a predicted increase in necrosis, apoptosis and senescence 
pathways, as well as an increase in the generation of reactive oxygen species.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Biological functions affected by protein alterations  
Ingenuity pathway analysis of biological functions and pathways predicted to be affected by 
the identified protein alterations between young and old platelets. Data presented as z-
score; orange indicates a predicted increase, blue indicates a predicted decrease in biological 
function. 
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Targeted analysis looking at the proteins involved in the predicted increase in 
haemostasis in young platelets identified 11 proteins that were differentially 
expressed and which may be contributing towards this enhanced function (Figure 
4.7). All but two of these proteins were more highly expressed in the young platelets, 
however the plasma protein fibrinogen was detected at higher levels in the old 
platelets. In further support of young platelets having a predicted higher haemostatic 
function, IPA also indicated young platelets have a predicted increase in calcium flux, 
a process fundamental for platelet activation pathways (Figure 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Proteins contributing to the predicted difference in haemostasis 
IPA functional protein network indicating the expression and contribution of differentially 
expressed proteins to haemostatic function in A.  young platelets and B. old platelets. IPA 
predicted regulatory relationships between upregulated (red) and downregulated (green) 
proteins contributing to an expected increase in haemostasis in young platelets indicated 
(indicated by orange lines), and a negative regulation in old platelets (indicated by blue lines).  
 
 
 
A B 
 123 
 
 
Figure 4.8 Proteins contributing to the predicted difference in calcium flux 
IPA functional protein network indicating the expression and contribution of differentially 
expressed proteins on calcium flux in A.  young platelets and B. old platelets. IPA predicted 
regulatory relationships between upregulated (red) and downregulated (green) proteins 
contributing to an expected increase in haemostasis in young platelets indicated (indicated 
by orange lines), and a negative regulation in old platelets (indicated by blue lines).  
 
 
 
Interrogation of the proteins involved in cytoskeletal organisation demonstrated a 
further 11 proteins influencing these processes (Figure 4.9A-B). Interestingly only a 
small number of these proteins are directly linked to the cytoskeleton; twinfilin-2, 
gesolin and cofilin-1. Indeed, a number of surface receptors were significantly altered 
between young and old platelets, highlighting an intimate link between membrane 
structures and the cytoskeleton.  
 
 
 
 
 
 
A B 
 124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Proteins contributing to the predicted difference in cytoskeletal organisation 
IPA functional protein network indicating the expression and contribution of differentially 
expressed proteins to the organisation of the cytoskeleton in A.  young and B. old platelets 
and microtubule dynamics in C. young and D. old platelets. IPA predicted regulatory 
relationships between upregulated (red) and downregulated (green) proteins contributing 
to an expected increase in haemostasis in young platelets indicated (indicated by orange 
lines), and a negative regulation in old platelets (indicated by blue lines).  
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Given that old platelets had a predicted downregulation in conventional platelet 
function pathways, it is interesting to note that they had a predicted increase in 
pathways associated with cell death; both necrosis and apoptosis (Figure 4.10). The 
functional protein networks indicated the contribution of over 19 proteins to the 
upregulation of these pathways in old platelets compared to young platelets. A 
reduction in the expression of 21 proteins including RhoA, CS, HK1, ITGB3, PTPN6, 
GSN in old platelets would facilitate the activation of pathways causing the induction 
of necrosis. Similarly, downregulation of the expression of 16 proteins in old platelets 
led to a prediction of increased apoptotic pathways in old platelets compared to 
young platelets. 
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Figure 4.10 Proteins contributing to the predicted difference in necrosis and apoptosis 
IPA functional protein network indicating the expression and contribution of differentially 
expressed proteins to necrosis in A.  young platelets and B. old platelets and apoptosis in C. 
young and D. old platelets. IPA predicted regulatory relationships between upregulated (red) 
and downregulated (green) proteins contributing to an expected increase in haemostasis in 
young platelets indicated (indicated by orange lines), and a negative regulation in old 
platelets (indicated by blue lines).  
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 Platelet ageing causes a reduction in mitochondrial parameters 
 
Proteomics and STRING analysis revealed a reduction in key mitochondrial proteins 
in old platelets including citrate synthase, ATP synthase subunit beta and cytochrome 
c oxidase subunit 2. Interestingly, further examination of mitochondrial 
characteristics identified reduction in a number of features in old platelets compared 
to young platelets (Figure 4.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Analysis of mitochondrial parameters 
Representation of the percentage differences in mitochondrial parameters in young (red) 
and old (green) relative to an unsorted population. 
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Most notably, using confocal microscopy, it was established that the decreased 
expression of mitochondrial proteins was accompanied by a reduction in the number 
of mitochondria per platelet. In unstimulated conditions, young platelets have 10±1 
mitochondria per platelet compared to 5±1 mitochondria per platelet in old platelets 
(Figure 4.12A-C).  
 
As mitochondria are dynamic organelles, having the capacity to undergo fission and 
fusion, I sought to establish if the reduction in mitochondria number in old platelets 
was as result of mitochondrial-fusion events, giving rise to fewer but larger 
mitochondria. Quantification of mitochondrial cross-sectional area, as a surrogate 
for mitochondria volume, indicated that there was no significant difference in the 
mitochondrial area 176±13nm2 vs. 151±28nm2 in young vs. old platelets (Figure 
4.12D). Given that the mitochondria do not change size, this data indicates that loss 
of mitochondria during platelet ageing was not a result of mitochondrial fusion 
events. Indeed, further analysis of mitochondrial shape revealed there was no 
significant difference in overall shape, as indicated by mitochondrial elongation and 
circularity (Figure 4.12E-F).  
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Figure 4.12 Immunofluorescence of mitochondria in young and old platelets 
Immunofluorescence showing α-tubulin (green) and TOM20 (magenta; mitochondria) in A. 
young platelets and B. old platelets. Scale bar represents 2µm. Quantification of C. average 
number of mitochondria per platelet D. mitochondrial area E. mitochondrial elongation and 
F. mitochondrial circularity in young and old platelets. Data presented as mean±SEM, 
significance was determined by paired t-test (n=4, **p<0.01).  
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The reduction in mitochondrial number in old platelets supports the ingenuity 
pathway analysis prediction of a reduction in transmembrane potential of 
mitochondria. Flow cytometric analysis of MitoProbeTM DilC1(5) indicated that old 
platelets may have a significantly lower mitochondrial membrane potential 
compared to young platelets 86.4±9.7 arbitrary units (AU) vs. 191.7±28AU (Figure 
4.13A). Interestingly, the lower mitochondrial membrane potential in old platelets 
was accompanied by an increase in phosphatidylserine exposure on the outer leaflet 
of the membrane, as indicated by a 3.1±1.3-fold change in annexin V binding relative 
to young platelets (Figure 4.13B).  
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Figure 4.13 Flow cytometric analysis of young and old platelets 
 A. Flow cytometric analysis of mitochondrial membrane potential (MitoProbeTM DilC1(5) 
fluorescence) in young and old platelets B. Representative histogram of MitoProbeTM DilC1(5) 
fluorescence in young (green) and old (red) platelets. C. Analysis of phosphatidylserine 
exposure (annexin V binding) in young and old platelets. D. Representative histogram of 
annexin V fluorescence in young (green) and old (red) platelets. Data presented as 
mean±SEM, significance was determined by paired t-test (n=4, *p<0.05).  
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 Platelet ageing causes a decrease in cytoskeletal-associated proteins and 
reduction in adhesive capacity 
 
In addition to a reduction in mitochondrial proteins, proteomic analysis also 
identified a reduction in a number of cytoskeletal-associated proteins including 
gesolin, emerin, and twinfilin-2. Therefore, using immunofluorescence and confocal 
microscopy, I sought to understand if this reduction in cytoskeletal-binding proteins 
was associated with an altered cytoskeletal structure. Staining of resting platelets for 
α-tubulin demonstrated that old platelets have a significantly lower integrated 
fluorescence intensity of α-tubulin compared to young platelets seen as a reduction 
from 2435±354AU to 1034±79AU (Figure 4.14A-C). Notably, despite a reduction in α-
tubulin there was no significant difference in platelet cross-sectional area, 
8.0±0.5µm2 vs. 7.6±0.6µm2 in young vs. old platelets (Figure 4.14D).  
 
Consistent with the loss of α-tubulin during platelet ageing, further investigation into 
the cytoskeletal structure identified a significant reduction in the integrated 
fluorescence intensity of F-actin from 2166±110AU in young platelets to 
1364±139AU in old platelets (Figure 4.15).   
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Figure 4.14 Immunofluorescence of α-tubulin in platelet subpopulations 
Representative confocal images of A. young and B. old platelets stained for α-tubulin. Scale 
bar represents 2µm.  C. Quantification of integrated fluorescence intensity of α-tubulin D. 
Quantification of platelet cross-sectional area.  Data presented as mean±SEM, significance 
was determined by paired t-test (n=4-6, *p<0.05). 
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Figure 4.15 Immunofluorescence of F-actin in platelet subpopulations 
Representative confocal images of A. young and B. old platelets stained for F-actin. Scale bar 
represents 2µm. C. Quantification of integrated fluorescence intensity of F-actin. Data 
presented as mean±SEM, significance was determined by paired t-test (n=4, *p<0.05). 
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As there was a notable decrease in the abundance of both α-tubulin and F-actin, it 
raised the question as to whether this alteration in the cytoskeletal structure 
impacted on the ability of platelets to adhere and spread. Using a static adhesion 
assay, it was established that old platelets have a marked defect in the adhesion and 
spreading response (Figure 4.16A-B). Following incubation on collagen, young 
platelets had adhered and spread, reaching a spread area of 14.8±3.2µm2 (Figure 
4.16A, C). Conversely, old platelets adhered, but did not spread, covering a 
significantly smaller area 6.2±0.5µm2 (Figure 4.16B-C). Platelet adhesion and 
spreading proceeds through four stages (i) adherent but not spread, (ii) filopodia, (iii) 
lamellipodia and (iv) fully spread. Interestingly old platelets seem to arrest at the 
filopodia stage, whereas young platelet advance through to forming lamellipodia 
(Figure 4.16D).  
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Figure 4.16 Immunofluorescence of adherent platelets spread on collagen 
Representative confocal images of A. young and B. old platelets spread on collagen and 
stained for F-actin. Scale bar represents 2µm.  C. Quantification of spread platelet area D. 
Quantification of stage of platelet spreading; adhered but not spread (i), filopodia (ii), 
lamellipodia (iii) and fully spread (iv). Data presented as mean±SEM, significance was 
determined by paired t-test (n=4, **p<0.01). 
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 Intracellular protein components alter as platelets age 
 
Amongst the proteins identified to have a significantly higher expression in young 
platelets were an array of organelle-associated proteins (Table 4.2). In addition to 
the reduction in mitochondria in old platelets, there is also a reduction in proteins 
associated with granules and the dense tubular system. 
 
Table 4.2 Organelle-associated proteins with altered expression levels 
 
Gene 
Name 
Protein Name 
Young 
Z-score 
Old Z-
score 
p value 
ATP5F1B ATP synthase subunit beta, mitochondrial  1.168 -0.991 0.0001 
CS Citrate synthase 0.957 -0.812 0.0063 
ESYT1 Extended synaptotagmin-1  0.854 -0.799 0.0247 
GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial  0.813 -0.894 0.0147 
HADHB Trifunctional enzyme subunit beta, mitochondrial  0.957 -0.304 0.0224 
HK1 Hexokinase-1  0.697 -1.049 0.0234 
HSP70-10 10 kDa heat shock protein, mitochondrial 0.656 -1.105 0.0074 
HSPA9 Stress-70 protein, mitochondrial  0.719 -1.007 0.0107 
ME2 Malic enzyme 1.102 -0.534 0.0014 
MT-CO2 Cytochrome c oxidase subunit 2  1.208 -0.325 0.0039 
NNT NAD (P) transhydrogenase, mitochondrial  0.927 -0.856 0.0096 
RTN1 Reticulon-1  1.159 -0.534 0.0032 
SLC25A3 Phosphate carrier protein, mitochondrial  0.996 -0.448 0.0127 
SLC25A5 ADP/ATP translocase 2  0.805 -0.858 0.0305 
SNAP23 Synaptosomal-associated protein 23  1.069 -0.134 0.0388 
STIM1 Stromal interaction molecule 1 1.164 -0.671 0.0038 
TUFM Elongation factor Tu, mitochondrial  1.114 -0.908 0.0001 
 
 
Immunofluorescence and confocal microscopy were used to confirm the proteomic 
analysis detailing a reduction in proteins associated with the dense tubular system. 
Analysis of unstimulated young and old platelets indicated a significant reduction in 
the fluorescence of ERp57 (Endoplasmic Reticulum protein 57), a protein localised 
within the dense tubular system, in old platelets compared to young platelets 
(93.5±10.7AU vs. 929.3±62.0AU; Figure 4.17).  
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Figure 4.17 Immunofluorescence of ERp57 in platelet subpopulations 
Representative confocal images of A. young and B. old platelets stained for ERp57 (magenta) 
and α-tubulin (green). Scale bar represents 2µm. C. Quantification of integrated fluorescence 
intensity of ERp57. Data presented as mean±SEM, significance was determined by paired t-
test (n=4, *p<0.05). 
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Despite proteomic analysis revealing a relative decline in protein content, 
interestingly there was a small subset of proteins with a higher expression level in 
old platelets (Table 4.3). This subset was largely composed of circulating proteins 
including complement proteins, fibrinogen and haemoglobin, which may have been 
bound and internalised as the platelet aged within the circulation.  
 
 
 
Table 4.3 Proteins with higher expression levels in old platelets 
 
Gene 
Name 
Protein Name 
Young Z-
score 
Old Z-
score 
p value 
A1BG Alpha-1B-glycoprotein  -0.943 0.837 0.0193 
C1S Complement C1s subcomponent -0.659 1.091 0.0063 
C4A Complement C4-A  -1.125 0.436 0.0153 
C8G Complement component C8 gamma chain -0.983 0.956 0.0065 
CFL1 Cofilin-1  -0.943 0.784 0.0149 
CO5 Complement C5  -1.169 0.718 0.0042 
FGA Fibrinogen alpha chain -0.639 1.059 0.0218 
HBA Hemoglobin subunit alpha  -0.284 1.080 0.0309 
IGLL5 Immunoglobulin lambda-like polypeptide 5  -0.980 1.008 0.0008 
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 -0.881 0.755 0.0160 
ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4  -1.222 0.895 0.0002 
PKHD1L1 Fibrocystin-L  -0.999 0.766 0.0023 
PON1 Serum paraoxonase/arylesterase 1  -0.926 0.801 0.0248 
PTBP1 Polypyrimidine tract binding protein 1,  -0.799 0.955 0.0207 
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To further explore the observed increases in protein expression, 
immunofluorescence analysis of complement proteins and fibrinogen was 
performed. In support of the proteomics, confocal microscopy confirmed that old 
platelets have significantly higher levels of fibrinogen compared to young platelets, 
1438±178.8AU vs. 751.8±93.3AU (Figure 4.18). In further agreement with the 
proteomics, immunofluorescence indicated a significant increase in complement C4 
levels from 1044±150.4AU in young platelets to 1866±180.7AU in old platelets 
(Figure 4.19). Interestingly, both fibrinogen and complement C4 were predominantly 
localised within the platelet cytoplasm, suggesting they are being bound and 
endocytosed. 
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Figure 4.18 Immunofluorescence of fibrinogen in platelet subpopulations 
Representative confocal images of A. young and B. old platelets stained for fibrinogen 
(magenta) and α-tubulin (green). Scale bar represents 2µm. C. Quantification of integrated 
fluorescence intensity of fibrinogen. Data presented as mean±SEM, significance was 
determined by paired t-test (n=4, *p<0.05). 
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Figure 4.19 Immunofluorescence of complement C4 in platelet subpopulations 
Representative confocal images of A. young and B. old platelets stained for complement C4 
(magenta) and α-tubulin (green). Scale bar represents 2µm. C. Quantification of integrated 
fluorescence intensity of fibrinogen. Data presented as mean±SEM, significance was 
determined by paired t-test (n=4, *p<0.05). 
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 Young platelets have an increased calcium signalling capacity 
 
 
Proteomic analysis identified differential expression of a number of proteins involved 
in calcium handling and mobilisation, most notably STIM1, and subsequent ingenuity 
pathway analysis predicted that young platelets have an enhanced calcium flux as 
well as increased calcium quantity, compared to old platelets (Figure 4.8). As calcium 
signalling is fundamental for platelet activation pathways, it may be a contributing 
factor towards the predicted reduction in haemostatic function in old platelets. 
Therefore, to confirm the predicted differences, I sought to explore differences in 
calcium dynamics in young and old platelets.  
 
Following stimulation with TRAP-6, young platelets had a more rapid and sustained 
calcium signal compared to old platelets. This stronger calcium signal was observed 
both at 10µM (AUC 7712±1684 vs. 2532±1221 in young vs. old platelets; Figure 
4.20A-B) and 25 µM (AUC 8548±3024 vs. 3726±2053 in young vs. old platelets; Figure 
4.20C-D). Indeed, stimulation with ionomycin revealed that young platelets have a 
higher maximal calcium signalling capacity compared to old platelets (AUC 
69830±12864 vs. 27973±10195 in young vs. old platelets; Figure 4.20E-F).  
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Figure 4.20 Calcium signalling in young and old platelets 
Representative calcium dynamic trace (Calbryte 630 fluorescence) showing young (green) 
and old (red) platelets following incubation with A. 10µM TRAP-6 C. 25µM TRAP-6 E. 10µM 
ionomycin. Quantification of the area under the curve of Calbryte 630 fluorescence following 
incubation with B. 10µM TRAP-6 D. 25µM TRAP-6 F. 10µM ionomycin. Data presented as 
mean±SEM, significance was determined by paired t-test (n=4, *p<0.05). 
 
 
 
0 20 40 60 80 100
0
50
100
150
200
Time (seconds)
M
FI
 o
f C
al
br
yt
e 
63
0 
(A
U
)
0 20 40 60 80 100
0
50
100
150
200
Time (seconds)
M
FI
 o
f C
al
br
yt
e 
63
0 
(A
U
)
0 20 40 60 80 100
0
200
400
600
800
1000
Time (seconds)
M
FI
 o
f C
al
br
yt
e 
63
0 
(A
U
)
Young Old
0
5000
10000
15000
A
U
C
 o
f M
FI
 o
f C
al
br
yt
eT
M
 6
30
 (A
U
)
Young Old
0
5000
10000
15000
20000
A
U
C
 o
f M
FI
 o
f C
al
br
yt
eT
M
 6
30
 (A
U
)
Young Old
0
20000
40000
60000
80000
100000
A
U
C
 o
f M
FI
 o
f C
al
br
yt
eT
M
 6
30
 (A
U
)
*
*
*
A B 
C D 
E F 
 145 
 Discussion 
 
Understanding differences in platelet function across their lifespan is of particular 
interest due to emerging evidence suggesting alternative functions beyond 
haemostasis. In addition, young platelets are often described as being hyper-
reactive, with a number of diseases in which there is heightened platelet turnover 
being associated with elevated thrombotic risk. Despite a number of studies 
indicating that young platelets are hyper-reactive, this work has been conducted 
using samples from individuals with underlying disease, such as diabetes or coronary 
artery syndrome, which may well influence other aspects of platelet function and the 
haemostatic response.37 
 
The use of nucleic acid dyes to differentiate newly formed platelets is not a new 
technique and has been harnessed for routine assessment of platelet turnover.41,240–
242 However, our group is the first to use this approach to isolate differently aged 
platelet sub-populations with preserved function based on their RNA content. 
Interestingly, recent research has shown that thiazole orange staining correlates with 
the immature platelet fraction assessed by Sysmex XE-2100, however it has 
highlighted a stronger correlation with the nucleic acid dye, SYTO 13, and shows a 
long-lasting staining in comparison to thiazole orange.243 Thus it may be beneficial to 
explore alternative nucleic acid staining protocols to ensure robust, long-lasting 
staining.  
 
There have been conflicting reports on the utility of using nucleic acid dyes and 
platelet size to differentiate between newly formed and old platelets.241 However, in 
my work I have definitively shown that separation of platelets based on thiazole 
orange fluorescent intensity results in two populations of platelets with comparable 
cross-sectional areas.  
 
Proteomic analysis of sorted platelet subpopulations allowed me to gain a global 
understanding of changes in protein levels during platelet ageing and subsequently 
the pathways that could be affected. Given that platelets lack a nucleus and have a 
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very limited translation capacity, it is unsurprising that protein content progressively 
declines during platelet ageing, along with the number of detectable proteins. Using 
the absorbance 280nm (A280) protein setting on the NanoDrop may not have been 
the most accurate method to calculate the protein content of the sorted platelets as 
these values may have been influenced by the absorbance of RNA.244 Whilst there is 
inbuilt intelligence technology to detect nucleic acid contaminants and correct the 
protein concentration based of this, these values should be used with caution. Using 
the bicinchoninic acid (BCA) assay would have been preferable to establish a more 
robust protein concentration however in these circumstances I was restricted by the 
volume of sample I was able to use before the proteomic analysis.244  
 
Analysis of protein expression patterns in the whole platelet proteome indicated that 
intermediate and old platelets cluster together with a similar expression profile, 
suggesting that the progressive degradation of protein begins very soon after release 
into the circulation. In addition to protein degradation pathways, the reduction in 
proteins may be as result of microvesicle release, a process that has been well 
documented in platelets.152 Classically, the shedding of microvesicles occurs in 
response to stimuli such as activation, sheer stress or apoptosis, however it may be 
possible that microvesicles are passively released as platelets age within 
circulation.151 Interestingly, the proteins that exhibited the greatest decline were 
proteins involved in dynamic processes, most notably those associated with 
mitochondria and the cytoskeleton. Here I propose, that the reduction in these 
subsets of proteins may be influencing two main pathways; platelet activation and 
apoptosis.  
 
The striking reduction in mitochondrial proteins revealed by proteomic analysis 
raised the question as to whether the number of mitochondria changes as platelets 
age. In agreement with the proteomic data, confocal microscopy demonstrated a 
reduction in the overall number of individual mitochondria. This observed reduction 
supports recent work indicating that old murine platelets have fewer mitochondria 
than newly formed platelets.245 
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The mechanism behind the reduction in mitochondria remains unclear, however I 
speculate that it could be as a result of the engagement of two pathways; firstly, 
mitochondrial fusion and secondly, mitophagy. Mitochondria are dynamic organelles 
with the ability to undergo both fission and fusion. During mitochondrial fusion, the 
dynamin-related GTPases Mfn1 and Mfn2 facilitate the coordinated fusion of the 
outer and inner membranes, forming a larger mitochondrion or network of 
mitochondria.246 As there was no observed increase in the cross-sectional area of 
mitochondria it can be concluded that the reduced number of mitochondria was not 
as a result of fusion events. The use of confocal microscopy to determine 
mitochondria number and size needs to be used with caution. As platelet 
mitochondria are small, I was working close to the resolution limit of the airyscan 
confocal microscope, meaning that it may not have provided accurate 
measurements of the mitochondria size. Quantification of mitochondria number 
using the airyscan microscope is more robust than mitochondria size, however it may 
be an underestimation of number. Whilst Z-stack images allow the for the 
visualisation of mitochondria in multiple fields of view, there is a possibility that some 
of the mitochondria may be masked behind each other. The ideal method to 
determine mitochondria number and size would be to use electron microscopy as 
the resolution limit is far greater. This technique would prove challenging, as the 
quantities of platelets that can be sorted is too low to create a visible pellet, and thus 
the samples would not be suitable to be prepared of electron microscopy.  
 
As mitochondrial fusion appears to be unaltered during platelet ageing, I therefore 
propose that the reduction of mitochondria is as a result of mitophagy. As platelets 
age within the circulation, they will encounter cellular stresses leading to the 
accumulation of mitochondrial damage. Mitochondrial stress will lead to a loss of 
mitochondrial membrane potential initiating the PINK1/PARKIN mediated mitophagy 
pathway.247 In this process, loss of mitochondrial membrane potential causes PINK1 
to remain on the outer mitochondrial membrane therefore recruiting PARKIN from 
the cytosol to the outer mitochondrial membrane. The presence of PARKIN facilitates 
the ubiquitination of membrane substrates, subsequently recruiting cytoplasmic 
factors, such as p62 and LC3.248 The engagement of these proteins, may target the 
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damaged mitochondria for autophagosomal degradation leading to a reduced 
number of mitochondria in old platelets. Whilst I have shown that old platelets have 
a mitochondrial membrane potential, which may be a trigger for the engagement of 
mitophagy, this data may be misleading as the lower fluorescence intensity may be 
indicative of the reduction in the number of mitochondria rather than membrane 
potential. To fully understand whether there is a reduction in membrane potential in 
old platelets, flow cytometry using two mitochondrial dyes; a mitochondrial mass 
dye and a mitochondrial membrane potential dye, would allow for the calculation of 
a ratio between mass and membrane potential. Unfortunately, the mitochondrial 
mass dye has substantial spectral overlap with thiazole orange and thus this was not 
possible.  
 
My data indicates that platelet ageing is associated with a loss in mitochondria which 
may affect two functional pathways; platelet activation and apoptosis. Platelets are 
highly metabolically active, relying on both glycolysis and oxidative phosphorylation, 
the latter of which accounts for approximately 40% of the total ATP synthesis.116  
Following activation, the energy demand for platelets rapidly increases resulting in 
an upregulation in ATP synthesis via oxidative phosphorylation at the 
mitochondria.209 The dramatic reduction in mitochondrial number observed in old 
platelets will result in a markedly reduced capacity for ATP synthesis via oxidative 
phosphorylation that may well reduce old platelets’ ability to undergo full activation 
and adhesion, resulting in an impairment in haemostasis. In addition to the data 
presented here, our laboratory has shown that old platelets have a reduced capacity 
to synthesise eicosanoids and express P-selectin on their surface, supporting the 
notion that as platelets age their haemostatic function declines. 
 
The decline in cytoskeletal proteins may also be a contributing factor towards the 
reduction haemostatic function. It is well documented that the cytoskeleton is 
intimately linked to platelet activation, adhesion and secretion, therefore a loss of 
cytoskeletal proteins will affect platelet haemostatic functions.249 Here, I have shown 
that old platelets have an impaired ability to spread on collagen, arresting at the 
filopodia stage, failing to form lamellipodia and fully spread. Proteomic analysis 
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revealed a decline in several actin-binding proteins including twinfilin-2, emerin and 
gelsolin. These proteins are involved in actin dynamics facilitating the conversion 
between globular and fibrillar actin via polymerisation at the actins barbed ends.250 
Platelet adhesion and spreading begins by platelets losing their characteristic discoid 
shape, becoming smaller and rounder. The cytoskeletal rearrangement then 
proceeds by the polymerisation of actin leading to the formation of long protrusions 
called filopodia.50 The marked defect in spreading of old platelets is highly suggestive 
of the loss of cytoskeletal-associated proteins having a detrimental effect on these 
processes.  
 
Mitochondria loss may also influence the engagement of apoptotic pathways. As 
detailed above, a key step of mitophagy, is the loss of mitochondrial membrane 
potential, this phase is also a trigger for the exposure of phosphatidylserine on the 
outer leaflet of the platelet membrane.251 Further supporting the higher levels of 
phosphatidylserine exposure, emerging evidence suggests that the cytoskeleton 
plays an important role in maintaining the asymmetric distribution of anionic 
phospholipids within the platelet plasma membrane.252,253 Degradation of actin and 
tubulin as identified in old platelets, may cause an instability, leading to an imbalance 
in the asymmetry of the lipid membrane and so facilitating the exposure of 
phosphatidylserine on the platelet outer membrane.254   
 
The exposure of phosphatidylserine has two functions; firstly, acting as procoagulant 
platform, and secondly, and perhaps more relevantly, acting as an apoptotic 
signal.255 In my work, phosphatidylserine exposure was found to be significantly 
higher in unstimulated old platelets. Under these circumstances, it is unlikely that 
the increased phosphatidylserine exposure would be a procoagulant trigger, as these 
platelets were unstimulated and did not demonstrate elevation in additional markers 
of activation, such as P-selectin, nor did they show an increase in size associated with 
ballooning procoagulant activity.256 Therefore, I suggest that old platelets may be 
committing to an apoptotic fate, with the phosphatidylserine exposure acting as an 
‘eat-me’ signal, marking them for destruction and clearance from the circulation.  
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Interestingly, knockout murine models two of proteins identified as having 
significantly lower expression levels in old platelets, twinfilin-2 and SNAP23, have 
shown an accelerated platelet turnover suggesting these proteins may be 
instrumental in determining platelet lifespan.257,258 However, these studies reported 
that hyper-reactive platelets may be a contributing factor to an enhanced clearance, 
and therefore turnover. Conversely, I speculate that the decline in twinfilin-2 in my 
work, may be contributing to a reduction in structural integrity and therefore a 
decline in function.  
 
My data provides novel insights into the mechanisms that may be influencing platelet 
lifespan. Understanding the increased exposure of phosphatidylserine, which may be 
controlled by both mitochondrial and cytoskeletal loss, may provide interesting 
insights into the increased platelet turnover in pathological states. Emerging 
evidence has revealed that oxidative stress plays an important role in the progression 
and pathogenesis of diabetes mellitus, a disease associated with accelerated platelet 
turnover. Further research has indicated that oxidative stress is linked to alterations 
in mitochondrial function in diabetic patients.259 This interesting research in the 
context of the data presented in the chapter may indicate that oxidative stress 
experienced during the pathogenesis of diabetes mellitus leads to the accumulation 
of mitochondrial damage within the platelet. The resulting depolarisation of the 
mitochondrial membrane facilitates the exposure of phosphatidylserine on the outer 
leaflet of the plasma membrane, acting as a signal for the destruction of the platelets 
and so accelerating platelet turnover. In confirmation of this theory, a recent study 
has demonstrated that mitochondrial dysfunction in platelets isolated from diabetic 
patients is associated with higher phosphatidylserine exposure and increased 
mitophagy.148 
 
It is widely debated whether newly formed platelets are larger, with a number of 
studies showing an association between mean platelet volume and thrombotic 
risk.236,260 However, in my work I demonstrate clearly no association between 
platelet age and size, despite the significant reduction in structural proteins. These 
findings may support research from the 1980s, in which it was proposed that buoyant 
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density, but not size, is an accurate indicator of platelet age.261 With the loss of large 
quantities of structural proteins as well as mitochondria and dense tubular proteins, 
it seems probable that the old platelets will be less dense than young platelets 
despite maintaining a similar size. Interestingly, the report from the 1980s, the 
indicated that platelets with a greater buoyant density were more metabolically 
active, which may be indicative of a greater mitochondrial number.261 Despite the 
discrepancies in platelet size, a recent proteomic study looking at differences 
between large and small platelets revealed a reduction in a number of mitochondrial 
and cytoskeletal proteins in small platelets.262  
 
Here I have shown that the decline in protein content associated with ageing is linked 
to a reduction in calcium signalling capacity, suggesting a reduction in haemostatic 
function. Indeed, this work supports research conducted by my colleague indicating 
that old platelets have a marked reduction in both a- and dense granule secretion, 
measured by P-selectin expression and ATP luminescence (unpublished data). 
Interestingly the ingenuity pathway analysis predicted a reduction in calcium flux and 
quantity of calcium, which I confirmed using flow cytometry. However, these samples 
were analysed in the presence of extracellular calcium and as such it is surprising that 
there were large changes in the calcium signal induced following stimulation with 
ionomycin. This could be for two reasons: firstly, the intracellular stores of calcium 
could be significantly lower in old platelets, such that they can’t potentiate the signal 
from outside; secondly, given the observed differences in the cytoskeletal structure, 
this might be affecting the membrane and the subsequent uptake of the calcium dye.  
 
Platelet ageing is associated with a general decline in protein content, but 
interestingly I identified a small subset of proteins that increase in abundance as 
platelets age within the circulation. Within this subset, the majority are circulating 
proteins which could be bound and accumulate within the platelet as they circulate 
within the vasculature. It is now widely accepted that platelets have the ability to 
sequester molecules from within the circulation, with a number of studies indicating 
a role for platelets in the transport of angiogenic and metastatic factors. 263,264 Here, 
I have shown that old platelets have increased levels of proteins involved in immune 
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responses such as complement proteins and immunoglobulin polypeptides. 
Interestingly, these proteins localise predominantly within the cytoplasm suggesting 
they are being bound by the platelet and actively endocytosed. With the growing 
body of evidence detailing the role of platelets in inflammation and immunity, the 
accumulation of this subset of proteins raises the question as to whether platelet 
ageing may be associated with a switch in phenotype from a rapid haemostatic role 
to an inflammatory regulatory role.265,266  
 
The data presented in the chapter may provide insights into the mechanisms 
governing platelet lifespan and the associated changes in function. Here I propose, 
that platelet ageing is characterised by a progressive decline in mitochondrial and 
cytoskeletal proteins, affecting the buoyant density, but not the overall size of the 
platelet. In addition, newly formed, young platelets are rapid haemostatic 
responders with an enhanced adhesive ability coupled to strong calcium signalling 
capacity. Whilst beyond the scope of this work, the increased levels of circulating 
proteins associated with old platelets, raises interesting questions as to whether old 
platelets may have a role distinct from young platelets.  
 
Given the importance and central role of mitochondria highlighted here, the 
following chapter will explore the effect of platelet activation on platelet 
mitochondria and the subsequent effects these may have upon other cells.  
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 Investigating mitochondrial dynamics during platelet 
activation and the significance of the production of 
platelet-derived microvesicles 
 
 Introduction 
 
Mitochondria have a myriad of functions from energy production, calcium buffering, 
and reactive oxygen species metabolism to involvement in apoptosis pathways.267  
Extensive characterisation of mitochondria in other cell types such as neurons has 
revealed controlled transport of mitochondria and their appropriate distribution is 
essential for cell survival.268 Indeed, mitochondrial distribution is controlled through 
complex coordination of microtubules and actin microfilaments, mediating long-
range and short-range movement respectively.269–271 Given that platelets are 
significantly smaller than neurons and they do not exhibit the same cell polarisation, 
the need for mitochondrial trafficking is unclear.  
 
In addition to appropriate mitochondrial distribution, maintenance of mitochondrial 
health is crucial to support cellular integrity. Highly regulated processes seek to 
resolve mitochondrial impairments, through fission and fusion, and subsequently 
remove damaged mitochondria, through mitophagy. As platelets have a short 
lifespan of approximately 10 days, the necessity of these pathways to control 
mitochondrial health can be questioned. Interestingly, two mitophagy pathways 
have been described in platelets, PINK1/PARKIN and the FUNDC1 pathway, the latter 
of which is engaged under hypoxic conditions.128,131 Despite the identification of 
these two pathways, recent work has demonstrated that PINK1, a fundamental part 
of PINK1/PARKIN mitophagy is dispensable for platelet function.129 However, the 
induction of mitophagy in platelets from diabetic patients has been shown to be 
beneficial, protecting the platelets from severe oxidative stress.148 
 
Beyond the pathways involved in maintaining mitochondrial health, the majority of 
interest in platelet mitochondria has focussed on their role in supplying energy 
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required for adhesion, aggregation and secretion. However, the role of mitochondria 
in platelets is ever expanding. Recent evidence suggests an important role in 
mitochondria in apoptosis and the control of platelet lifespan, with the progressive 
decline of Bcl-XL, facilitating BAX activation and subsequent permeabilization of the 
outer mitochondrial membrane (OMM).123 Consequently, loss of mitochondrial 
membrane potential allows the release of cytochrome C, thereby enabling the 
exposure of phosphatidylserine on the platelet outer membrane.24 
 
Moreover, strong agonist stimulation, has been shown to cause mitochondrial 
membrane depolarisation, and subsequent opening of the mPTP in the inner 
mitochondrial membrane (IMM).272 This process is reliant on the mitochondrial 
matrix protein, cyclophilin D, interacting with the adenine nucleotide translocator, in 
the IMM and the voltage-dependent anion channel in the OMM.273 Interestingly, 
recent work has shown that the formation of the mPTP is involved in some of the 
initial stages of platelet activation, including phosphatidylserine exposure and 
fibrinogen retention.273,274  However, the opening of the mPTP occurs only in a small 
subset of platelets, enabling them to become highly activated, and often 
procoagulant. While potentially very important, the molecular processes governing 
the mPTP formation and its functional significance remain elusive.275  
 
Interestingly, recent research has indicated that platelets have the capacity to 
release their mitochondria.156 The functional relevance of this process remains to be 
demonstrated, but early data indicates that they may be acting as an inflammatory 
stimulus to other target cells. Indeed, mitochondria release has been identified from 
a number of cell types, with mitochondria released from activated monocytes 
exerting an inflammatory response on endothelial cells.276 Despite many 
observations classifying mitochondria as damage-associated molecular patterns 
(DAMPs), and therefore inducing inflammatory responses, other research has 
detailed transfer of mitochondria between cells, which has been shown to be 
beneficial as it can rescue deficiencies in respiration, and replenishment of 
mitochondrial DNA.277 This research demonstrates that mitochondria can be 
released as free organelles or encapsulated within a single membraned 
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microvesicles. It is well established, that platelets readily produce microvesicles 
during activation as well as apoptotic pathways, with higher levels being reported in 
a number of pathological states.152 This poses the question as to whether 
microvesicle and mitochondria release may cooperate in affecting other cells within 
the vasculature, either through alterations in surface marker expression or by uptake 
and changes intracellularly.  
 
To date, research into platelet organelles has focussed primarily on granules, 
presumably as these are a unique feature to platelets, and are fundamental for the 
haemostatic response. As such, until recently, research into platelet mitochondria 
has been largely overlooked, as their role was thought to be limited to energy 
production. However, current work has highlighted that mitochondria may play an 
important role beyond energy production both in modulating platelet phenotype, as 
well as influencing the behaviour of other cells within the circulation. Despite the 
recent advances in platelet mitochondrial research, the contribution of mitochondria 
to platelet function still remains to be fully explored. Thus, in this chapter I will 
investigate the role of mitochondria dynamics during platelet activation, and the 
subsequent effect of the presence of extracellular mitochondria on leukocyte 
function.  
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 Methods 
 
 Blood collection, preparation of PRP and washed platelets 
 
Blood was collected from healthy volunteers and PRP was prepared as previously 
described in sections 3.2.1-3.2.3 
 
 Immunofluorescence confocal microscopy of activated platelet samples 
 
Washed platelets (3 x 108/ml) were stained with MitoTracker Orange CMTMRos 
(20nm) for 15 minutes at room temperature in the dark and subsequently incubated 
with eptifibatide (4µM) for 5 minutes. Platelets were incubated with PBS or TRAP-6 
(25µM) for 5 minutes at 1200rpm, 37˚C and subsequently fixed with pre-warmed PFA 
(4%) for 10 minutes. Samples were prepared for immunofluorescence as described 
in 4.2.4. Briefly, samples were centrifuged onto poly-l-lysine coverslips at 600 x g for 
5 minutes. Non-adherent platelets were removed from the coverslips by washing 
with filtered PBS. Samples were blocked and permeabilised with filtered 
permeabilising buffer (0.2 % Triton, 2% donkey serum and 1% BSA in PBS) for 30 
minutes at room temperature. After removal of the blocking buffer, the coverslips 
were incubated with mouse anti-a-tubulin (1:200) for 1 hour at room temperature 
in the dark. The primary antibody was removed with three wash steps using filtered 
PBS. Subsequently, the samples were incubated with anti-mouse Alexa Fluor 488 
(1:500) for 45 minutes in the dark at room temperature. The secondary antibody was 
removed with three filtered PBS washes. The coverslips were mounted using ProLong 
Diamond antifade mount and allowed to set overnight in the dark at room 
temperature. Samples were then stored at 4˚C and imaged on Zeiss LSM880 with 
airyscan; 63x objective, 1.4 Oil DICII; imaging at least 5 different fields of view per 
sample collecting a minimum of 30 platelets per sample. Image processing and 
analysis was conducted using Zen Software (2.3 SP1) and ImageJ.  
 
 
 
 
 157 
 Assessing mitochondrial fission following platelet activation 
 
Washed platelets (3 x 108/ml) were stained with MitoTracker Orange CMTMRos 
(20nm) for 15 minutes at room temperature in the dark and subsequently incubated 
with eptifibatide (4µM) for 5 minutes. Platelets were activated with PBS or TRAP-6 
(25µM) for 5 minutes or 30 minutes at 1200rpm, 37˚C and subsequently fixed with 
pre-warmed PFA (4%) for 10 minutes. Samples were prepared for 
immunofluorescence as outlined in 5.2.2. 
 
 Microvesicle production in response to collagen activation 
 
Ibidi chambers were incubated with collagen (100µg/ml) for 1 hour, subsequently 
blocked with fatty acid free BSA (1%) for 1 hour and then washed with modified 
Tyrode’s HEPES buffer. Washed platelets were stained by incubation (37˚C in the 
dark) with Fluo-4 AM (2µM) for 30 minutes and MitoTracker Orange CMTMRos 
(10nm) for 15 minutes. Stained platelets were allowed to settle and activate on the 
collagen coated chambers and images were recorded for 15 minutes, capturing 2 
frames per second.  
 
 Preparation of platelet-derived microvesicles  
 
Washed platelets were statically incubated with PBS or TRAP-6 (25µM) at 37˚C for 2 
hours in non-stick Eppendorf microcentrifuge tubes. Subsequently, platelets were 
centrifuged at 1000 x g for 10 minutes and the supernatant was removed and 
transferred into a fresh non-stick Eppendorf microcentrifuge tube. The supernatant 
was then centrifuged at 18,000 x g for 45 minutes to pellet the platelet-derived 
microvesicles. The supernatant was removed and discarded, and the microvesicle 
pellet was resuspended in 100µl of filtered PBS. Samples were stored at -80˚C until 
required.  
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 NanoSight Tracking analysis 
 
NanoSight tracking analysis (NS300 NTA) was used to determine the size and 
concentration of platelet-derived microvesicles. Briefly, nanoparticle tracking is 
based on Brownian motion, and measures the diffusion constant as determined by 
the scattering of a laser beam by the particles which is detected by an 
ultramicroscope. Based on the laser scattering, the software tracks the particles’ 
movement and provides a measure of their size and concentration. Microvesicles 
samples were diluted 1 in 10 in 1ml filtered PBS and analysed using a flow rate of 
50AU. To determine microvesicle size and concentration, 5 videos of 60 seconds 
were acquired and analysed per sample.  
 
 Flow cytometric characterisation of platelet-derived microvesicles 
 
Platelet microvesicles were prepared as described in 5.2.5. However, prior to 
stimulation, washed platelets were stained with MitoTracker Orange CMTMRos 
(10nm) for 15 minutes. Following stimulation, the remaining platelet pellet was 
retained, stained with CD61-APC (1:200) and analysed on a BD LSRII to determine the 
fluorescence of MitoTracker Orange CMTMRos. The purified platelet-derived 
microvesicles were stored at -80˚C until required. Samples were thawed at 4˚C prior 
to staining and incubated with antibody cocktails detailed in Table 5.1 for 30 minutes 
in the dark and analysed on either a BS LSR II or an Image Streamx MKII.  
 
To determine differences in the number of microvesicles produced following 
incubation with PBS or TRAP-6, samples were analysed for 60 seconds based on side 
scatter for basal number or PE triggered for mitochondria positive vesicles.  
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Table 5.1 Antibodies used for flow cytometric analysis of platelet microvesicles  
 
 Antibody Concentration 
Sample 1 Cell Trace Violet 
CD41 APC 
1:50 
1:200 
Sample 2 CD41 Pacific blue 
CD62P APC 
1:200 
1:150 
Sample 3 CD41 Pacific blue 
Annexin V APC 
1:200 
1:150 
 
 
 Assessment of mitochondrial function, measure by oxygen consumption in 
a XF24 Seahorse in platelet-derived microvesicles 
 
To understand if the mitochondria in platelet-derived microvesicles are active, the 
Agilent Seahorse XF24 was used to measure oxygen consumption rate under basal 
conditions. The Seahorse XF24 plate and cartridge were prepared as described in 
section 3.2.7. Briefly, the XF24 calibration plate was loaded with 500µl of XF Calibrant 
Fluid and placed along with the Seahorse cartridge in the XF 37°C incubator with 0% 
CO2 overnight. XF24 cell cultures plates were coated with Cell Tak as per the 
manufacturer’s guidelines. Briefly, 50µl of 2.4µg/ml Cell Tak was added to each well, 
and incubated at room temperature for 20 minutes. The plates were then washed 
with sterile dH2O and allowed to air dry.  
 
 
Platelet-derived microvesicles were prepared as described in 5.2.5, however with the 
modification that the microvesicles isolated from the platelet preparation were 
resuspended in 100µl of warmed Seahorse base medium (containing 2mM 
glutamine, 25mM glucose and 1mM pyruvate) and transferred to the Cell Tak coated 
XF24 seahorse plate (Figure 5.1) The plate was spun at 200 x g for 1 minute. To the 
blank wells, 100µl of base medium was added. The plate was then transferred to the 
37°C incubator for 15 minutes. Afterward, 400µl of warmed Seahorse Base Medium 
(containing 2mM glutamine, 25mM glucose and 1mM pyruvate) supplemented with 
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2mM CaCl2 was added and the plates returned to the incubator for a further 30 
minutes. The calibrant plate and cartridge were then placed in the XF24 Seahorse 
Analyser for initial calibration. Subsequently, the calibrant plate was ejected and the 
plate containing the platelet-derived microvesicles was inserted and the oxygen 
consumption rate was measured over a period of 20 minutes.  
 
 
 
Figure 5.1 Agilent XF24 Seahorse plate layout for platelet microvesicles 
Plate layout for the measurement of oxygen consumption rate in platelet microvesicles 
(indicated EV) and platelets (indicated as Plt) to act as controls. Wells A1, B4, C3 and D6 were 
left blank and only contained Seahorse Base Medium.  
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 Neutrophil isolation 
 
Citrated whole blood was transferred into a 50ml Falcon tube and centrifuged at 130 
x g for 20 minutes with a slow acceleration and deceleration. Subsequently, the 
majority of the PRP was removed and 10ml of filtered PBS (without calcium or 
magnesium) was gently layered on top of the remaining red and white blood cells. 
On top of the PBS, 8ml of filtered 6% dextran was layered. The sample was slowly 
inverted to mix together the sample layers and subsequently left for 15 minutes at 
room temperature to sediment the red blood cells. After transfer to a fresh 50ml 
Falcon, 10ml of room temperature Histopaque 1077 was added and the leukocyte 
layer removed from the dextran separated sample. The Histopaque-leukocyte 
sample was centrifuged at 400 x g for 30 minutes. The remaining platelets, PBMC 
layer and Histopaque were removed and discarded. To lyse the red blood cells in the 
remaining layer, 9ml of ice cold dH2O was added to the sample and left for 30 
seconds. The sample was then diluted with 1ml of 10 x Hank’s Balanced Salt Solution 
(HBSS) and made up to 50ml with filtered PBS (without calcium and magnesium). The 
sample was centrifuged at 300 x g for 10 minutes to wash the neutrophils. Lastly, the 
neutrophil pellet was resuspended in 1ml of filtered PBS (without calcium and 
magnesium), and the cell count determined using trypan blue staining.  
 
  Visualising platelet and neutrophil interactions with platelet microvesicles 
containing mitochondria 
 
Washed platelets (3 x 107/ml) or isolated neutrophils (5 x 106/ml) were incubated 
with platelet-derived microvesicles stained with MitoTracker Orange CMTMRos for 
30 minutes or 60 minutes. Samples were prepared for immunofluorescence and 
confocal microscopy as described in 5.2.2. Platelet-platelet microvesicle samples 
were stained with mouse anti-a-tubulin (1:200), and anti-mouse Alexa Fluor 488 
(1:500). Neutrophil-platelet microvesicle samples were stained with anti-mouse 
LAMP1 (1:200), followed by anti-mouse Alexa Fluor 488 (1:500) and DAPI (10nm).  
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 Cell sorting of platelet-derived microvesicles 
 
To separate microvesicles containing mitochondria from the rest of the population, 
microvesicles were prepared as described in 5.2.5, stained with MitoTracker Orange 
CMTMRos (10nm). Prior to storing at -80˚C, samples were sorted using a BD FACS 
Aria III Fusion Cell Sorter (70μm nozzle, 70 Ps), based on the fluorescence intensity 
of MitoTracker Orange CMTMRos. The gating strategy is shown in Figure 5.2, with 
the top 20% of MitoTracker fluorescence sorted as mitochondria positive (mitoPMV) 
and the bottom 80% as mitochondria negative (PMV) Following sorting, 
microvesicles were pelleted at 18,000 x g for 45 minutes, resuspended in filtered PBS 
and stored at -80˚C until required.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Gating strategy for sorting of mitochondria positive microvesicles 
Flow cytometric scatter plot showing the A. forward and side scatter of the microvesicle 
population and B. the fluorescence intensity of MitoTracker Orange within the microvesicle 
population and the sorting gates to isolate mitochondria positive (mitoPMV) and 
mitochondria negative vesicles (PMV). 
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81.2 
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19.8 
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 Assessment of neutrophil activation markers following incubation with 
platelet-derived vesicles 
 
 Isolated neutrophils (5 x 105) were incubated with mitochondria negative 
microvesicles (5 x 106), mitochondria positive microvesicles (5 x 106), or PBS as 
control for 30 minutes at 37˚C. Subsequently, the samples were fixed with PFA (2%) 
for 10 minutes and stained with an antibody cocktail described in Table 5.2. Samples 
were analysed using a BD LSRII, acquiring at least 5,000 CD45 positive events.  
 
 
 
Table 5.2 Antibodies used for flow cytometric analysis of neutrophils  
 
 Antibody Concentration 
Sample 1 CD45 PerCPCy5.5 
CD66b Pacific blue 
1:150 
1:100 
Sample 2 CD45 PerCPCy5.5 
CD11b BV421 
1:150 
1:100 
Sample 3 CD45 PerCPCy5.5 
CXCR2 BV421 
1:150 
1:100 
 
 
 
 Statistical analysis 
Graphs and statistical analysis were generated using GraphPad Prism v.8. Data were 
expressed as mean±SEM and all statistics were generated using a paired students t-
test or a one-way ANOVA, with a Dunnett’s or Tukey’s multiple comparison test. 
Significance was defined as p<0.05. 
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 Results 
 
 Platelet activation causes a reduction in the number of mitochondria  
 
Immunofluorescence and confocal microscopy revealed that platelet activation by 
TRAP-6 caused a significant reduction in the number of mitochondria per platelet 
from 8±1 in resting platelets to 3±0.5 in stimulated platelets (Figure 5.3A, B and D). 
This was accompanied by a significant reduction in the platelet cross-sectional area 
from 8.2±1.2µm2 to 4.2±0.2µm2 (Figure 5.3A, B and C). Analysis of the mitochondrial 
size indicated that the reduction in mitochondria number was not as a result of 
mitochondrial fusion events as there was no significant difference in the 
mitochondria cross-sectional area; 151±5nm2 in unstimulated platelets and 
147±4nm2 in stimulated platelets (Figure 5.4A-C).  
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Figure 5.3 Airyscan confocal microscopy of mitochondria in unstimulated and stimulated 
platelets 
Representative confocal microscopy images stained for a-tubulin (green) and MitoTracker 
Orange (magenta) in A. resting and B. TRAP-6 stimulated platelets. Scale bar represents 2µm. 
Quantification of C. platelet cross-sectional area and D. number of mitochondria per platelet. 
Data presented as mean±SEM, significance was determined by paired t-test (n=4, *p<0.05, 
***p<0.005). 
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Figure 5.4 Assessment of mitochondrial size in unstimulated and stimulated platelets 
Zoom of representative confocal images stained with a-tubulin (green) and MitoTracker 
Orange (magenta) in A. resting and B. TRAP-6 stimulated platelets. Scale bar represents 1µm. 
C. Quantification of mitochondria cross-sectional area. Data presented as mean±SEM, 
significance was determined by paired t-test (n=4). 
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 Mitochondria in platelets have the capacity to undergo fission 
 
Proteomic analysis of platelets has identified that platelets have the machinery 
required for mitochondrial fission and fusion, however it remains unknown if they 
have the ability to undergo these dynamic processes. Interestingly, following the 
initial decrease in mitochondria after TRAP-6 stimulation, there is a subsequent 
increase in the number of mitochondria at 30 minutes post-stimulation; from 8±0.7 
in unstimulated to 3±0.3 at 5-minute stimulation, and 5±0.2 at 30-minute 
stimulation.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Platelet mitochondria have the capacity to undergo fission 
Representative confocal microscopy images stained with a-tubulin (green) and MitoTracker 
Orange (magenta) in A. resting (0-minute), B. 5-minute TRAP-6 and C. 30-minute TRAP-6 
stimulated platelets. Scale bar represents 2µm. D. Quantification of mitochondria number 
per platelet over the activation time course. Data presented as mean±SEM, significance was 
determined by paired one-way ANOVA with Dunnett’s multiple comparisons (n=4, *p<0.05). 
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 Platelets produce microvesicles through passive and active pathways 
 
As the reduction in mitochondria number was not as a result of fusion events and 
there was a significant decrease in platelet cross-sectional area, I speculated that the 
mitochondria were being packaged and released into microvesicles.  
 
Microvesicles can be isolated from both unstimulated (PBS) and TRAP-6 stimulated 
washed platelets. Flow cytometry was used to quantify microvesicle number, 
highlighting microvesicles released following incubation with PBS were produced at 
a lower concentration than following TRAP-6 activation (14926±5096 and 
168075±65345 per sample following PBS and TRAP-6 stimulation respectively, Figure 
5.6A). Furthermore, there was a higher number of microvesicles positive for the 
mitochondrial dye, MitoTracker Orange, produced when platelets were stimulated 
with TRAP-6; 26262±9153 vs. 2727±528 per sample (Figure 5.6B). Consistent with an 
increase in microvesicles containing mitochondria following TRAP-6 stimulation, the 
residual platelet pellet following microvesicle isolation had a significantly lower 
number of mitochondria positive events compared to the PBS incubated platelets 
(643825±90438 compared to 792307±106309 in the presence of PBS; Figure 5.6C). 
Furthermore, platelet activation on collagen coated coverslips causes the production 
and release of microvesicles which bleb from long pseudopodia (Figure 5.6D).   
 
NanoSight analysis indicated that microvesicles generated from TRAP-6 stimulated 
platelets ranged in size from 30±1nm to 739±41nm (Figure 5.7). The modal value of 
detected vesicles was 129±4nm (Table 5.3).  
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Time 
 
Figure 5.6 Platelets produce microvesicles through passive and active pathways 
Flow cytometric analysis of microvesicles produced following incubation with PBS or TRAP-6 
measured for 60 seconds triggered on A. side scatter and B. MitoTracker Orange 
fluorescence (PE). C. Flow cytometric analysis of the remaining platelet pellet following 
microvesicle production, measured for 60 seconds and triggered on MitoTracker Orange 
fluorescence (PE). D. Qualitative assessment of platelet activation on collagen. Platelets form 
pseudopodia (indicated by white arrows) and subsequently produce microvesicles (indicated 
by red arrows). Data presented as mean±SEM, significance was determined by paired t-test 
(n=4, *p<0.05). 
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Figure 5.7 NanoSight tracking analysis of platelet-derived microvesicles 
A. Representative image from the NanoSight tracking analysis showing the individual 
microvesicles (blue) tracked to estimate the size and concentration of the particles. B. 
Histogram showing the size range of microvesicles produced by platelets following 
incubation with TRAP-6.  
 
 
Table 5.3 Size and concentration of platelet-derived microvesicles 
 
Size (nm±SEM)  
Range  Mean  Mode Concentration 
29.9±1.1 – 738.6±140.6 193±7.5 128.7±3.6 3.7±0.4 x 109/ml 
 
 
 
A 
B 
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 A subpopulation of platelet-derived microvesicles contain mitochondria 
and express high levels of activation markers 
 
Characterisation of platelet microvesicles using imaging flow cytometry (Figure 5.8) 
revealed that 95% expressed CD41 (integrin alpha-IIb), 82% expressed annexin V 
(phosphatidylserine), 30% expressed P-selectin and 20% were positive for 
MitoTracker Orange (Figure 5.9).  
 
 
 
 
Figure 5.8 Image stream pictures of platelet-derived microvesicles 
Representative image stream pictures of platelet microvesicles showing the localisation of 
the platelet marker (CD41), a cytoplasm dye (Cell Trace), mitochondria (MitoTracker Orange) 
and P-selectin (CD62P).  
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Figure 5.9 Characterisation of surface markers on platelet-derived microvesicles 
Expression of surface and intracellular markers in platelet-derived microvesicles identify high 
levels of CD41 and annexin V, with lower levels of P-selectin and mitochondria. Data 
presented as mean±SEM (n=4). 
 
 
As indicated in Figure 5.10A, the small proportion of microvesicles containing 
mitochondria (in red) were found to be generally the largest microvesicles within the 
population. Focused characterisation of microvesicles containing a mitochondrion 
(mitoPMV) revealed that the binding of annexin V remains constant to that of the 
whole population, with 80% of the microvesicles being positive for annexin V. 
Interestingly, when looking at P-selectin expression, this increased from 30% within 
the whole population to 95% in the mitochondria containing subpopulation, 
suggesting these microvesicles blebbed from the plasma membrane following 
release of the granular content (Figure 5.10B). 
 
 
CD41 Annexin V P-selectin Mitochondria
0
20
40
60
80
100
Pe
rc
en
ta
ge
 o
f p
la
te
le
t m
ic
ro
ve
si
ce
s 
(%
)
 173 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Characterisation of surface markers on mitochondria positive platelet-derived 
microvesicles 
A. Scatter plot displaying size distribution of platelet microvesicles based on the forward 
scatter against the cytoplasm dye (Cell Trace), showing mitochondria containing vesicles in 
red and the rest of the population in blue. B. Expression of surface markers on microvesicle 
containing mitochondria. Data presented as mean±SEM (n=4-5). 
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 Platelet-derived microvesicles contain active mitochondria 
 
Despite identifying mitochondria within platelet microvesicles, the data thus far did 
not indicate whether they remained functional. As the primary role of mitochondria 
is in energy production through respiration, I sought to investigate if the 
mitochondria were respiring, and therefore consuming oxygen. As detailed in Figure 
5.11, platelet microvesicles consume 36pmoles of oxygen per minute compared to 
98pmoles of oxygen per minute in platelets, thus indicating the mitochondria are 
active, but to a lesser extent than in intact platelets.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Basal oxygen consumption in platelet-derived microvesicles and platelets 
Basal oxygen consumption rate of platelet microvesicles, normalised to starting platelet 
concentration (3x108/ml) and platelets (6x107) measured in an Agilent Seahorse analyser. 
Data presented as mean±SEM (n=4). 
 
 
 
Vesicles Platelets
0
50
100
150
O
xy
ge
n 
C
on
su
m
pt
io
n 
R
at
e 
(p
M
ol
es
/m
in
)
 175 
 Platelet-derived microvesicles containing mitochondria interact with 
platelets and neutrophils 
 
Activated platelets readily interact with other platelets as well as leukocytes, and 
growing evidence suggests that platelet microvesicles interact with leukocytes, 
therefore I wanted to determine if mitoPMVs interact with platelets and neutrophils.  
 
Platelets interacted with mitoPMVs, in a time dependent manner, with an average 
of 3±0.1 mitoPMVs interacting with a platelet after 30 minutes, increasing to 5±0.5 
after 60 minutes (Figure 5.12). Interestingly, mitoPMVs interacted more readily with 
isolated neutrophils than platelets, increasing in a time dependent manner; from 
11±2 at 30 minutes to 33±6 at 60 minutes (Figure 5.13).  
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Figure 5.12: Platelet-derived mitochondria positive vesicles interact with platelets in a time 
dependent manner 
Representative confocal microscopy images of platelets stained for a-tubulin (green) 
incubated with mitoPMVs (magenta) A. under basal conditions and for B. 30 minutes and C. 
60 minutes. Scale bar represents 2µm.  D. Quantification of the average number of mitoPMV-
platelet interactions. Data presented as mean±SEM, significance was determined by one-
way ANOVA with Tukey’s multiple comparisons (n=4, **p<0.01). 
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Figure 5.13: Platelet-derived mitochondria positive vesicles interact with neutrophils in a 
time dependent manner 
Representative confocal microscopy images of neutrophils stained for LAMP1 (green) and 
DAPI (blue) incubated with mitoPMVs (magenta) A. under basal conditions and for B. 30 
minutes and C. 60 minutes. Scale bar represents 5µm. D. Quantification of the average 
number of mitoPMV-neutrophils interactions. Data presented as mean±SEM, significance 
was determined by one-way ANOVA with Tukey’s multiple comparisons (n=4, ***p<0.005).  
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 Platelet microvesicles containing mitochondria alter the expression of 
neutrophil activation markers 
 
Given that I had identified that mitoPMVs have higher expression levels of P-selectin, 
it raised the question as to whether they may be more likely to affect neutrophil 
function and phenotype than the remainder of the microvesicle population. To 
understand the functional significance of the impact of mitoPMVs on neutrophils, I 
sorted platelet microvesicles based on the fluorescence intensity of MitoTracker 
Orange into two subpopulations; mitochondria negative platelet microvesicles 
(PMVs) and mitochondrial positive platelet microvesicles (mitoPMVs).  
 
Following incubation of neutrophils with mitoPMVs, there was a significant 
upregulation in two neutrophil activation markers, CD66b (carcinoembryonic 
antigen-related cell adhesion molecule 8) and CD11b (integrin αM), compared to that 
seen in control neutrophils. Interestingly, however, PMVs did not alter the expression 
levels of these surface markers (Figure 5.12A-B). Furthermore, incubation with 
mitoPMVs caused the downregulation of CXCR2 (C-X-C chemokine receptor type 2), 
whilst PMVs had no effect on the expression levels (Figure 5.14C).  
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Figure 5.14: Characterisation of neutrophil surface markers following incubation with 
PMVs and mitoPMVs 
Quantification of the expression of neutrophil surface markers after incubation with PMVs 
and mitoPMVs. Data expressed as a fold change in the expression of A. CD66b B. CD11b and 
C. CXCR2 in neutrophils under basal conditions. Data presented as mean±SEM, significance 
was determined by one-way ANOVA with Dunnett’s multiple comparisons (n=5, *p<0.05). 
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 Discussion  
As platelets are small and anucleate, interest in their organelles to date has been 
limited. For the first time, using confocal microscopy I have shown that platelet 
activation causes a reduction in the number of mitochondria. The reduction in 
number of mitochondria could be explained by the engagement of two pathways; 
mitochondrial fusion or mitochondria release into microvesicles. Platelets are 
equipped with the machinery to support both mitochondrial fission and fusion, 
however neither of these processes have ever been documented in platelets. To 
understand if mitochondrial fusion had occurred, I quantified the cross-sectional area 
of individual mitochondria as an estimate of mitochondria size. As there was no 
change in the cross-sectional area it suggested that mitochondrial fusion was not the 
mechanism responsible for the reduction in mitochondrial number.  
 
Mitochondrial fusion and fission are highly regulated processes in response to 
mitochondria stress, to ensure the maintenance of cellular health. Proteomic analysis 
has revealed that platelets contain the proteins responsible for these processes, 
namely mitofusin 1 and 2.127  However, there is no literature indicating either of these 
processes occurs within platelets, so these proteins may be residual from the parent 
megakaryocyte. Although I identified that platelet activation does not cause 
mitochondrial fusion, I wanted to understand if platelet mitochondria have the 
capacity to undergo fission. Thus, following the initial reduction in mitochondria 
number following five minutes activation, I allowed the platelets to continue their 
cellular processes for a further 25 minutes. Interestingly, after the initial decrease, 
there was a subsequent increase in the number of mitochondria per platelet, 
suggesting the remaining mitochondria have undergone fission. In recent years 
research into platelet mitochondria has expanded greatly with reports 
demonstrating mitophagy occurring as a protective mechanism, however to date, 
mitochondrial fission and fusion dynamics have not been reported. Thus, this data 
may indicate that mitochondria within platelets have the ability to undergo 
mitochondrial fission. This is an interesting observation, but its significance is 
unknown and additional work using higher resolution microscopy is need to further 
 181 
explore these pathways. However, it may suggest that despite having a short 
lifespan, mitochondria play an important role in platelet cellular function and thus 
need their health to be regulated. Indeed, given the small number of mitochondria 
contained within a platelet, it would seem necessary for them to have the ability to 
undergo fission therefore limiting the effect of accumulation of damage by extruding 
the damaged portion of the mitochondria.  
 
Interestingly and somewhat unsurprisingly, platelet mitochondria are significantly 
smaller than those seen in other cells. Indeed, megakaryocytes have elaborate, 
interconnected mitochondrial networks, which raises the question as to when the 
alteration in mitochondrial architecture occurs leading to the small, discrete 
mitochondria seen in platelets. Recent research has demonstrated that dynamin-1 
like protein 1 (Drp1) is essential in modulating mitochondrial fission during platelet 
biogenesis. Conditional knockout of Drp1 in the megakaryocyte lineage resulted in 
mitochondria within platelets forming extended networks, in contrast to the 
characteristic punctate mitochondria in wild type platelets.278 Whilst the study of 
granule biogenesis and trafficking from megakaryocytes is well studied, there is 
limited information on the trafficking of mitochondria during platelet biogenesis. 
Thus, exploring mitochondrial trafficking in megakaryocytes could provide an 
exciting avenue of research, and may provide insights into the behaviour of platelet 
mitochondria.  
 
In this work, I have shown that the reduction in mitochondria number is not as 
consequence of mitochondrial fusion, but rather the packing and release in 
microvesicles. Whilst it is well established that platelets produce microvesicles during 
physiological activation and apoptosis, here I have shown that they additionally 
release microvesicles through passive pathways. Interestingly, the concentration of 
microvesicles and mitochondrial content of microvesicles varies depending on the 
stimulus. Indeed, those release through passive pathways, are produced at a lower 
concentration and contain fewer mitochondria. On the other hand, strong 
stimulation with TRAP-6 produces a higher concentration of microvesicles, with a 
greater number of mitochondria positive microvesicles. The release of mitochondria 
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from platelets was first established by Boudreau et al, who demonstrated that the 
supernatant of activated platelets consumed oxygen, suggesting the presence of 
extracellular mitochondria.156 Since this initial observation, mitochondria have been 
visualised in microvesicles using electron microscopy. Building on this work, I have 
used imaging flow cytometry to show microvesicles containing mitochondria are the 
largest, accounting for approximately 20% of the microvesicle population. 
Furthermore, supporting the work of Boudreau et al., I have shown that these 
platelet microvesicles consume oxygen indicative of functional mitochondria within 
them. However, this oxygen consumption could additionally be as a result of the 
presence of oxidative enzymes such as cyclooxygenase-1 within the microvesicles.158  
Focussed characterisation of mitoPMVs, revealed that these microvesicles had high 
levels of annexin V binding and high P-selectin expression. This data is interesting for 
two reasons. Firstly, it suggests that granule exocytosis may be higher in regions that 
are in close proximity to a mitochondrion. This raises the question as to whether 
mitochondria are trafficked towards the membrane, to facilitate the efficient 
transfer of energy needed during activation, or are granules that are resident close 
to a mitochondrion are more likely to undergo release reactions. Secondly, with 
higher P-selectin expression, are these microvesicles more likely to interact with 
leukocytes and endothelial cells, and therefore modulate their behaviour. The 
former of these would be a fascinating area of research, but given the intrinsic nature 
of platelets to want to activate, it would prove very challenging to live image platelets 
under resting conditions.  
 
Platelet microvesicles express a wide array of surface receptors and molecules, and 
are thought of as important intracellular communication modulators. Indeed, 
evidence suggests that platelet microvesicles are selectively packaged with varying 
cargoes, therefore eliciting a variety of functions on other cells within the circulation. 
Here I have shown that mitoPMVs interact with platelets in a time dependent 
manner, with some evidence that they may be internalised, as indicated by the 
presence of the mitochondrial dye within the platelet cytoplasm. It is now widely 
known that platelets have the ability to endocytose plasma proteins, such as 
fibrinogen, albumin and vWF, but would it be possible for them to endocytose 
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mitochondria?279 Interestingly, research has indicated that extracellular 
mitochondria have the ability to interact directly with platelets, forming complexes 
that have an increased procoagulant phenotype.280 Despite evidence of these 
interactions between platelets and mitoPMVs, it is challenging to elucidate whether 
this is causing a change in platelet phenotype, as detection of alterations in surface 
receptors using flow cytometry will not discriminate between whether the 
fluorescence is coming from the platelet or mitoPMV. 
 
In addition to interacting with platelets, I have shown that mitoPMVs readily interact 
with isolated neutrophils in a time dependent manner, supporting previous evidence 
showing that platelet microvesicles and mitochondria interact with and are 
internalised by neutrophils both in vitro and in vivo.156,281 To understand if mitoPMVs 
elicit different functional effects on neutrophils in comparison to the rest of the PMV 
population, I sorted two distinct populations based on the fluorescence of 
MitoTracker Orange. Interestingly, incubation of neutrophils with mitoPMVs but not 
PMVs caused a change in the expression of several surface markers. Neutrophils 
express an extensive repertoire of surface receptors which facilitate the initiation of 
signalling pathways and alter neutrophil function. Amongst the vast array of 
molecules important in responding to physiological stimuli is CD66b, a glycoprotein 
present on granulocytes, which following neutrophil activation is increased on the 
cell surface.282 Interestingly, following incubation of platelets with mitoPMVs, but 
not PMVs, expression of CD66b was significantly upregulated.  Further evidence for 
mitoPMVs promoting neutrophil activation is the upregulation of CD11b.283,284 This 
surface receptor is expressed basally on the neutrophil surface, however following 
activation, additional molecules are rapidly mobilised from within secretory 
granules.282 Increased expression of CD66b and CD11b are important not only in 
neutrophil activation but also in their subsequent adhesion and migration within the 
vasculature. In addition to the upregulation in two activation markers, this work also 
demonstrates that incubation with mitoPMVs but not PMVs causes a downregulation 
of CXCR2. Consistent with neutrophil activation and subsequent alteration in 
phenotype, evidence has revealed a reduction in the expression of the chemokine 
receptors, CXCR1 and CXCR2 following phagocytosis.285,286 
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Neutrophils are mediators of the innate immune response, functioning through 
phagocytosis and degranulation. Here I suggest that mitoPMVs cause neutrophil 
activation and in doing so, facilitates their phagocytosis. The downstream effects of 
this remain to be elucidated, however I speculate that the phagocytosis of mitoPMVs 
may be affecting a number of pathways. Firstly, microvesicle clearance rates and 
mechanisms remain undefined, with some work suggesting they are engulfed within 
minutes of generation by phagocytic cells.163,287 To understand if neutrophils are 
mediating the clearance of mitoPMVs, experiments investigating the levels of the 
autophagosomal machinery, namely LC3 may prove worthwhile. Secondly, 
phagocytosis of mitoPMVs may confer a functional benefit to the neutrophil, by 
increasing their respiratory capacity. I and others, have demonstrated that platelets 
release functional mitochondria, measured by their oxygen consumption capacity, 
which allows us to consider that following phagocytosis, the mitoPMVs may be able 
to combine with the existing neutrophil mitochondrial network and contribute 
towards the cellular energy generation.156 To understand if mitoPMVs are indeed 
affecting neutrophil metabolism, measurement of oxygen consumption and 
glycolytic rates using the Aligent Seahorse Analyser or high resolution respirometry 
could provide insights into the neutrophil metabolic profile.116 
 
MitoPMVs may also be acting as priming mediators of neutrophils, with their 
interaction promoting the upregulation of activation markers, which subsequently 
would promote neutrophil adhesion and migration within the vasculature.288 To 
assess the role of mitoPMVs in neutrophil adhesion, flow adhesion assays on collagen 
or endothelial cell coated channels could be conducted. Furthermore, to elucidate if 
in vitro results are applicable in vivo, intravital microscopy could be performed 
following the injection of mitoPMvs, which would provide additional information on 
the transmigration capacity of the neutrophils. To support the flow adhesion assays, 
chemotaxis assays would provide insights into alterations in responses to 
chemokines, which may affect neutrophil adhesion and migration responses.  
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The relevance of mitochondria release from platelets and their subsequent effect on 
other cells remains to elucidated. However, there are numerous reports of elevated 
circulating levels of platelet microvesicles in pathological states, including diabetes 
mellitus, chronic kidney disease and cardiovascular diseases.152 As my work has 
indicated that mitochondria are present within approximately 20% of microvesicles, 
it can be speculated that in diseases with elevated levels of platelet microvesicles 
there will also be higher mitoPMVs levels and that these would contribute to the 
underlying inflammatory phenotypes. Indeed, there is evidence that extracellular 
mitochondria have deleterious influences in traumatic injury where they promote 
procoagulant activity in platelets.280 Furthermore, recent work has shown that 
microvesicles are abundant in platelet concentrates and that transfusions of platelet 
concentrates with higher levels of mitochondria DNA, as an indicator of mitoPMVs, 
are associated with increased adverse reactions.289  
 
The data presented in this chapter shows that platelet mitochondria are dynamic in 
nature, and following the engagement of platelet activation pathways are packaged 
into microvesicles and released. These mitoPMVs express high levels of P-selectin on 
their surfaces and interact readily with neutrophils. Interestingly, mitoPMVs but not 
PMVs alter neutrophil activation markers, suggesting mitoPMVs are an important 
subject for microvesicle research. Indeed, my initial observations suggest that 
mitoPMVs are phagocytosed by neutrophils and promote neutrophil activation 
which may be relevant to the many diseases outlined above associated with 
enhanced inflammatory responses.  
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 General Discussion 
 
Platelets are fundamental for maintaining haemostasis, but following inappropriate 
activation can contribute to pathological thrombosis.82 Following vascular injury, 
platelet activation proceeds through a serious of tightly regulated pathways, 
involving cytoskeletal rearrangement facilitating platelet shapes changes, and the 
activation of intracellular signalling pathways to promote the fusion and release of 
platelet granular contents50,67. These pathways facilitate the formation of platelet-
platelet and platelet-leukocyte aggregates, encouraging the arrest of bleeding at the 
site of injury.  Whilst the traditional function of platelets is to prevent blood loss, in 
recent years their role in other processes such as inflammation and immunity have 
been highlighted.67 Indeed, platelets express a number of proteins and surface 
receptors that play no clear role in haemostasis, and as such there has long been 
speculation of alternative functions.  
 
Platelets form a heterogenous population of ages, sizes and functions, primed to be 
activated when in the presence of stimuli such as exposed extracellular matrix 
components or soluble mediators. Whilst particular attention is paid to how platelets 
behave as a whole population, evidence indicates that only a small proportion of the 
total circulating platelets are needed for haemostasis. This interesting finding raises 
the questions as to why the remaining platelets are needed. The study of platelets is 
generally conducted at a whole population level in which, although there may be 
differences in the functions of certain subpopulations of platelets, the aggregate 
response is taken and assessed to whether it lies within the desirable ranges.290 
Whilst research has indicated there are subpopulations of platelets with different 
behavioural characteristics, the mechanisms underlying these differences remain 
elusive. One potential explanation for the observed differences between populations 
is the age of the platelets. It is well documented that platelets have a relatively short 
lifespan, approximately 10 days, but the changes in function and composition as they 
progress through their lifespan within the circulation have not been fully studied.  
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Platelet aggregation and activation assays fall within two categories; dynamic 
recordings over a set period, or endpoint assays, both of which have advantages and 
disadvantages.219 Light transmission aggregometry was first developed in the 1960s 
by Gustav Born, and measures light transmission as an indicator of platelet 
aggregation.291 Often referred to as the gold standard of platelet aggregation testing, 
this assay provides information as a dynamic trace on both aggregation and 
disaggregation within a sample. This assay is considered laborious and requires a 
relatively large sample volume. In response to this, the Optimul assay, a 96-well 
plate-based end point test, has been developed allowing for the more rapid testing 
of a much broader range of agonists.292 The Optimul assay is easy and provides the 
user with the ability to run significantly more replicates in parallel, however it 
generally provides data at only a single time point, so evidence as to the dynamic 
nature of the response is lacking. Given that platelet activation is a sequential 
process, I sought to understand the dynamics of key phases of platelet activation 
including calcium signalling, granule release and changes in mitochondrial function.  
 
In this thesis, I was able to show that calcium signalling precedes granule release, 
occurring in parallel with a transient DYm hyperpolarisation indicative of an increase 
in the proton motive force generated via oxidative phosphorylation. Sustained 
changes in DYm can lead to deleterious effects to the mitochondria, and so loss of 
membrane integrity, which could lead to the engagement of mitophagy or apoptotic 
pathways. Despite this transient DYm hyperpolarisation, changes in mitochondrial 
function, as measured by oxidative phosphorylation can be measured up to 20 
minutes following platelet stimulation. This data supports previously published 
research indicating that thrombin activation causes an increase in mitochondrial 
consumption224,293. Furthermore, I have shown that treatment of platelets with a 
P2Y12 receptor blocker, but not with aspirin, causes a significant reduction in calcium 
flux during platelet activation with TRAP-6 and U46619. Interestingly, both anti-
platelet drugs cause a reduction in P-selectin expression following stimulation with 
U46619. This data supports previously published literature detailing a reduction in P-
selectin expression in patients taking aspirin and P2Y12 inhibitors. The use of flow 
cytometry to assess the effect of anti-platelet drugs on calcium flux and P-selectin 
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expression may not have been the most appropriate assay to accurately measure the 
dynamics of these responses. Indeed, both of these anti-platelet drugs target the 
secondary wave of aggregation and the generation of secondary mediators. In a 
system where the sample is dilute and passing through an artificial flow system, there 
may well not be the opportunity for the accumulation of secondary mediators and 
so observed differences may well not truly reflect genuine alterations in these 
pathways. Using a system with a spectrofluorometer would provide a more accurate 
assessment of the effects of inhibition of cyclooxygenase-1 and P2Y12 receptors, as 
the platelets within the sample could aggregate and would not be removed from the 
tube for measurement, as happens during flow cytometric analysis. This would allow 
the accumulation of secondary mediators and so facilitate amplification of the 
activation response.  
 
Interestingly, blockade of P2Y12 receptors with AR-C66096 caused a significant 
reduction in the basal respiratory capacity of platelet mitochondria. The reasons for 
this reduction in oxygen consumption remain unclear, however there is evidence of 
P2Y12 receptor expression on mitochondria within astrocytes, which suggests these 
receptors could also be present on platelet mitochondria.230 Inhibition of P2Y12 
receptors within the mitochondrial membrane may affect the flow of ADP and could 
cause an imbalance in DYm and so alter mitochondrial function. This interesting 
observation may provide additional insights into the mechanisms causing a reduction 
in platelet function following P2Y12 receptor inhibition. Platelets have previously 
been described as metabolically plastic, having the ability to be able to switch readily 
between glycolysis and oxidative phosphorylation, providing compensatory 
mechanisms if needed. Thus, it would be intriguing to further explore the metabolic 
profile of platelets treated with a P2Y12 receptor antagonist, to understand if the 
reduction in mitochondrial respiration is compensated for by an increase in 
glycolysis.  Furthermore, in this work, I have only used one P2Y12 antagonist, AR-
C66096, so it would be beneficial to investigate whether this effect is specific to this 
compound or generally common to P2Y12 receptor blockers. The data presented in 
this thesis come from studies looking at the acute treatment of platelets in vitro, 
however it would be exciting to look at the metabolism of platelets from healthy 
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individuals taking anti-platelet treatments for two weeks, and compare these to 
clinical samples from patients taking anti-platelet drugs as a secondary preventative 
measure. 
 
As detailed previously, platelets form a heterogenous populations of sizes, ages and 
functions which work together to maintain vascular integrity and prevent blood loss. 
Interestingly however, research has indicated that only 5% of the total platelet count 
is required to maintain haemostasis, which raises the question, what are the other 
platelets needed for? Research in recent years has highlighted platelet 
subpopulations which respond differently to stimulation, but the triggers and 
determinants for these different responses remain unknown.290,294,295 Despite this 
lack of information it is possible to arrive at the conclusion that platelet age is a key 
determinant of differences in function.  
 
Research into platelet ageing within the circulation has become an interesting and 
somewhat controversial area of research. As the mechanisms controlling platelet 
lifespan remain unclear, there is no obvious way in which old platelets can be 
differentiated from young platelets. Nevertheless, evidence shows that following   
their initial entry into the circulation RNA contained within platelets is translated into 
protein or rapidly degraded.73 Thus, there will be a small proportion of platelets, the 
most newly formed, that has a higher RNA content than the rest of the population. 
Using this knowledge, along with insights from commercially available machines such 
as the Sysmex, colleagues in my lab developed a cell sorting protocol that isolates 
platelets based on their RNA content, measured by thiazole orange fluorescence 
intensity.41,296 During the development of this protocol, platelet specific mRNAs were 
measured and it was confirmed that thiazole orange low platelets exhibited a 
significant reduction in mRNA levels for platelet factor 4 and integrin alpha-IIb. Since 
the development of this protocol, other groups have suggested that thiazole orange 
may not be the best nucleic acid dye to define young and old platelets. Hille et al, 
outline an alternative staining protocol using the nucleic acid dye SYTO13 which has 
shown a longer duration of retention, and shows a strong correlation with the 
immature platelet fraction measured by the Sysmex.243 As this paper has highlighted 
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differences in the retention of nucleic acid dyes, further work looking at identifying 
the most appropriate staining may be beneficial to enable a more robust 
characterisation of the platelet subpopulations.  
 
The work presented in this thesis is the first to extensively characterise platelet 
function and composition in young and old platelets from healthy individuals 
(summarised in Figure 6.1). Previous research has indicated that newly formed, 
young platelets may be more reactive than older platelets, however the majority of 
this work has been conducted using blood from patients with altered platelet 
turnover.21,37,38,297 Whilst these observations provide interesting insights, it is hard to 
unpick if platelet function is altered due to intrinsic changes in the platelet or as a 
consequence of changes in the vascular environment observed in these pathological 
states. One potential explanation that has been offered for this increased reactivity 
is that young platelets are larger, and therefore have more pro-thrombotic molecules 
packaged within them.236,260,298,299 Indeed, there is a wealth of literature indicating 
that platelet size declines as platelets age. However, using confocal microscopy I have 
shown that the cross-sectional area of the platelet does not significantly change as 
platelets age. Interestingly, research in the 1980s hinted that platelet buoyant 
density, but not size declined with age.261 This accords with the proteomic analysis 
conducted in this thesis, which demonstrated a decline in a number of subsets of 
proteins, notably cytoskeletal and mitochondrial proteins, as platelets age. Given 
that the cytoskeleton is a major component of maintaining platelet structure, this 
data would support the notion that platelet buoyant density but not size is reduced 
as platelets age within the circulation.  
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Figure 6.1 Summary of changes between young and old platelets 
Representation of the structural changes between a young platelet (blue) and old platelet 
(pink) within the circulation of a healthy individual.  
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A number of mechanisms determining platelet lifespan have been proposed 
including desialyation and intrinsic apoptosis, which are thought to control the 
platelet ‘molecular clock’. However the circumstances in which these pathways are 
engaged remains unknown.24,34 The data presented in this thesis offers a novel 
insight into an alternative mechanism that may trigger the clearance of platelets 
from the circulation. Indeed, there is literature indicating that the loss of cytoskeletal 
proteins causes an instability in the structural integrity and subsequently an 
imbalance in the membrane phospholipids.254 This imbalance causes the flipping of 
phosphatidylserine onto the outer leaflet membrane of the platelet, a well-known 
apoptotic trigger, which may act as an ‘eat-me signal’ and target older platelets for 
degradation. Furthermore, the reduction in mitochondria number may also 
contribute to the commitment of platelets to undergo degradation. Although I have 
shown that the number of mitochondria reduces as platelets age, the causes and 
mechanisms behind this still remain elusive. While mitochondria are dynamic 
organelles, there was no change in the size of the cross-sectional are of the 
mitochondria and therefore mitochondrial fusion is not responsible for the observed 
changes. Another explanation for this reduction could be the induction of mitophagy. 
During their lifespan within the circulation, platelets will experience cellular stresses 
which may lead to the accumulation of mitochondrial damage and cause the 
initiation of mitophagy. During the commitment of mitochondria to mitophagy, 
sustained DYm depolarisation causes the flipping of phosphatidylserine onto the 
outer leaflet of the plasma membrane.272 As detailed above, the exposure of 
phosphatidylserine is an important apoptotic regulator, and therefore the reduction 
in mitochondria number coupled with the decrease in cytoskeletal integrity may 
trigger the commitment of platelets to undergo degradation and removal from the 
circulation.  
 
As indicated above, previous research has suggested that newly formed platelets are 
hyper-reactive, but there was no definitive proof provided from studies in healthy 
individuals. In this work, I have demonstrated a reduction in calcium signalling in 
response to both TRAP-6 and ionomycin in old platelets, confirming the prediction of 
the ingenuity pathway analysis highlighting a reduction in calcium flux and quantity 
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of calcium in old platelets. Furthermore, I have shown that compared to young 
platelets, old platelets have marked reduction in adhesion and spreading to collagen. 
This interesting observation is likely a result of a reduction in cytoskeletal associated 
proteins such as gelsolin, emerin and myosin regulatory light chain 12A, which are 
important for both actin and tubulin dynamics. In addition, the reduction in calcium 
signalling may influence cytoskeletal dynamics, as a number of the motor proteins 
involved in the dynamic assembly and reorganisation of the cytoskeleton are calcium 
dependent.  
 
This work has highlighted fundamental changes in structural and organelle 
composition as platelets age. Previous work performed within my laboratory 
indicated there is a reduction in granule secretion associated with platelet ageing, 
this information coupled to the proteomic analysis of a reduction in P-selectin and 
SNAP-23 raises the question of whether old platelets have fewer granules or whether 
there is an impairment in granule secretion. In favour of the former conclusion, there 
are indications that as platelets age there is a reduction in the number of dense 
granules.300 Further work performing transmission electron microscopy on the 
sorted platelet samples would provide valuable information on the granule number, 
as well as providing confirmation on mitochondrial number and alteration in the 
cytoskeletal structure.  
 
As demonstrated within the proteomic analysis there was a small subset of proteins 
that were present at a higher level in old platelets. Further work to understand the 
consequences of the relative increase in these proteins could provide insights into 
their roles within old platelets. Interestingly, the majority of the increased proteins 
are circulating proteins including complement proteins, haemoglobin and fibrinogen, 
which led me to speculate that these proteins are being bound and endocytosed as 
platelets circulate within the blood stream.301 Indeed, using confocal microscopy, I 
was able to show that both fibrinogen and complement C4 were predominantly 
located within the platelet cytoplasm. However, recent research examining the 
transcriptome of differently aged platelets indicates a relative increase in 
complement protein mRNA in old platelets.302 This work raises the question as to 
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where the mRNA and protein is coming from. Indeed, it is well established that 
platelets are able to transfer mRNA to other cells, but it remains less clear if they are 
able to endocytose mRNA themselves. If platelets are not able to endocytose mRNA, 
it may suggest that there is differential regulation in mRNA degradation. The 
recognition that both complement protein mRNA and protein increases as platelets 
age could provide an alternative method to distinguish between differently aged 
platelets, i.e. these could be used as markers of old platelets.  
 
Whilst beyond the scope of this project, the significance of the upregulation of 
complement proteins warrants further investigation. The complement protein 
system is involved in innate immunity, promoting inflammation and assisting in the 
activation of phagocytic cells. As there was a relative increase in these proteins in old 
platelets, it may indicate a switch in phenotype and function as platelet age; 
potentially from rapid haemostatic responders to inflammatory modulators. To 
assess the inflammatory influences of these differently aged platelets, investigations 
into interactions with leukocytes and subsequent activation status and secretion of 
inflammatory molecules could provide interesting insights into functional switching 
during ageing.  
 
This work has made important advances in our understanding of changes in platelets 
as they age within the circulation, highlighting an important association between 
mitochondrial and cytoskeletal loss and platelet age. With further evidence that 
these processes may be contributing to the exposure of phosphatidylserine this could 
provide novel insights into the underlying mechanisms governing platelet lifespan. 
This research also provides a foundation for future work investigating changes in 
composition and function of platelets from patients with diseases associated with 
alterations in platelet lifespan. The molecular mechanisms underlying the increase in 
platelet turnover observed in pathologies such as diabetes mellitus and 
cardiovascular disease remain unknown, thus extensively characterising these 
platelets subpopulations may provide a unique insight into the control of these 
processes in disease. The data presented here, demonstrating the importance of 
mitochondria to the process of platelet ageing, coupled with published research 
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indicating mitochondrial dysfunction in patients with diabetes may provide an 
interesting avenue of future research to explore if this may be a contributing factor 
to altered platelet lifespan.148 
 
Research conducted in murine models to look at newly formed platelets generally 
depend upon depleting platelets by antibody treatment and then analysing the 
platelets that subsequently reappear. Whilst these studies provide useful 
understandings into the process of platelet production, it is unlikely that the rapidly 
reappearing platelets are ‘normal’.303 Total depletion of platelets using an anti-GPIba 
antibody may cause vast stimulation of megakaryocyte differentiation to restore the 
platelet count, and may bypass some of the key stages of platelet packaging. This 
model may be of more benefit to understanding the changes in platelet function and 
composition induced by traumatic injury. As with this in vivo model, major trauma 
resulting in extensive blood loss may well stimulate mass production and release of 
platelets from the megakaryocytes. Given the unpredictable nature of major trauma, 
analysis of these samples may prove problematic. However, elective surgery can be 
a form of controlled trauma and could offer a model to test influences on platelet 
production and lifespan. Indeed, utilising platelet samples from elective surgery 
patients would allow for analysis of samples from pre- and post- ‘trauma’ which 
would allow for a strong comparison. 
 
It is clear that mitochondria are important for platelet function, and may play a 
potential role in determining platelet lifespan. However, this thesis has highlighted a 
role for platelet mitochondria beyond haemostasis, and provided insights into the 
role of mitochondria packaged within platelet-derived microvesicles, in particular 
their ability to cause neutrophil phenotypic switching (discussed further below).  
 
With advances in technologies, the field of extracellular vesicle research is greatly 
expanding.150 Indeed, the ease of analysis using flow cytometry, and nanoparticle 
tracking analysis is providing potential avenues for the assessment of extracellular 
vesicles as biomarkers for the progression of conditions such as cardiovascular 
disease.152 It is well documented that within the circulation, platelet-derived 
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microvesicles account for the largest proportion of vesicles, but the roles of 
circulating microvesicles remain unclear.304 Interestingly, I was able to detect 
microvesicles within the circulation of healthy individuals, indicating they are not just 
involved in the progression of pathologies. Indeed, research has indicated that 
platelet derived-microvesicles are an important intracellular communicator, being 
able to transfer their contents to other cells within the circulation.201,305 In this thesis 
I have shown that platelet microvesicles containing mitochondria, express 
significantly higher P-selectin levels than the remainder of the microvesicle 
population. Recent work has highlighted a potential for differential release of 
granules, although the mechanisms for this remain unknown.67,68 As I have identified 
mitochondria encapsulated within microvesicles as having high P-selectin, and it is 
well established that platelet activation pathways are extremely energy dependent, 
it may be that granules with close proximity to a mitochondrion are preferentially 
secreted.  
 
It remains unknown whether mitochondria within platelets are motile and dynamic 
in nature as they are within other cell types. It is well established that in neurons, 
mitochondria are required to be transported large distances from the cell body down 
the axon to ensure that energy is readily available throughout the length of the 
nerves.270 Although there are several reports that platelets and neurons are similar, 
there are striking differences between these cell types, most notably the size and 
lifespan. Does a small platelet need the capacity for mitochondrial transport? This 
would be an exciting question to address, however there would be a number of 
technical issues, namely live imaging resting platelets is challenging. The inherent 
nature of platelets to readily activate makes it very difficult to attach them to a 
surface for imaging without some accompanying degree of activation.  
 
The high expression of P-selectin on mitochondria containing microvesicles led me 
to hypothesise that these microvesicles were more likely to interact with other cells 
within the vasculature. Indeed, in this thesis I was able to show that mitochondria 
containing microvesicles are able to interact with neutrophils, which I speculate is 
mediated by the interaction between P-selectin and PSGL-1. Interestingly, 
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mitochondria containing microvesicles cause the upregulation of the classical 
neutrophil activation markers, CD11b and CD66b whilst causing the downregulation 
of CXCR2. The change in expression pattern of these markers is suggestive of the 
neutrophils taking on a phagocytic phenotype.285,286,306 Further work investigating 
the downstream consequences of this platelet mitochondria-neutrophil interaction 
would be interesting in helping to understand if this is a clearance mechanism and if 
the microvesicles are degraded following internalisation. On the other hand, this 
interaction may be providing a functional benefit; if the platelet mitochondria are 
able to fuse into the resident neutrophil mitochondrial network, they may be able to 
increase the energy capacity and enhance the cells’ function. In addition to the 
influence on neutrophils, future work looking at the effect of mitochondria 
containing microvesicles on monocyte and endothelial cell function would be 
interesting given that both these cell types express PSGL-1.  
 
The release of mitochondria from platelets is an exciting concept, as it may have 
enormous ramifications for other cells. In the final stages of a platelet’s lifespan, do 
they expel their remaining mitochondria so that they can be taken up by other cells 
within the vasculature to enhance their mitochondria function? Mitochondria are 
dynamic organelles and can undergo fission, fusion and mitophagy to eliminate any 
mitochondrial damage, however these processes are finite. Therefore, having a new 
source of mitochondria donated from platelets may enhance the cellular respiratory 
capacity and replenish the store of mitochondrial DNA of various other cells so 
prolonging their healthy lifespans.  
 
More generally, it still remains unknown whether platelet-derived vesicles have a 
beneficial or negative effect on cells within the vasculature. Evidence would indicate 
that it depends on the circumstances underlying their production and the condition 
of the local environment. Indeed, levels of microvesicles have been associated with 
disease progression in both chronic pathologies such as chronic kidney disease and 
cardiovascular diseases, as well as in acute pathologies such as trauma.167,169,307,308 
Furthermore, platelet microvesicles have been shown to have enhanced 
procoagulant activity, and as such may be contributors to pathological thrombosis. 
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As a result of this link to pathological progression, targeting microvesicle release may 
be appealing therapeutically. As I have shown that a high percentage of microvesicles 
are positive for annexin V, targeting the exposure of phosphatidylserine, by inhibiting 
the scramblase responsible for the flipping of this negatively charged phospholipid 
onto the external surface of the platelet, may result in a reduction in microvesicle 
release and potentially a reduction in thrombotic events.309,310  
 
Together, the investigations performed in this thesis have highlighted the 
importance of mitochondria in platelet function, indicating a role beyond classical 
energy production via oxidative phosphorylation. The work presented here has 
provided an insight into a potential mechanism in which mitochondria loss, coupled 
with cytoskeletal degradation, throughout the platelet lifespan may be contributing 
to the exposure of phosphatidylserine, and subsequently commitment of old 
platelets to undergo degradation. Furthermore, this work has shown that 
mitochondria are packaged into platelet-derived microvesicles and released into the 
circulation following physiological stimulation, subsequently acting as an intracellular 
communicator by modulating the phenotype of neutrophils.   
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Appendix 1: The proteome of thiazole orange sorted platelets  
 
Protein ID Protein Protein Name 
Young Z 
score 
Intermediate 
Z Score 
Old Z 
Score 
P01624 KV315 Immunoglobulin kappa variable 3-15 -0.1474 -0.3070 0.4545 
H7BXI1 H7BXI1 Extended synaptotagmin-2 0.3308 -0.5546 0.2237 
B9A064 IGLL5 Immunoglobulin lambda-like polypeptide 5 -0.9803 -0.0275 1.0077 
O00139 KIF2A Kinesin-like protein KIF2A 0.1685 -0.0517 -0.1167 
O00151 PDLI1 PDZ and LIM domain protein 1 0.4820 -0.5625 0.0804 
O00161 SNP23 Synaptosomal-associated protein 23 1.0689 -0.9345 -0.1345 
O00194 RB27B Ras-related protein Rab-27B 0.5364 0.4026 -0.9389 
O00231 PSD11 26S proteasome non-ATPase regulatory subunit 11 0.5913 -0.4430 -0.1483 
O00264 PGRC1 
Membrane-associated progesterone receptor 
component 1 
0.8114 0.2005 -1.0119 
O00299 CLIC1 Chloride intracellular channel protein 1 0.3917 0.4727 -0.8644 
O00429 DNM1L Dynamin-1-like protein 0.7850 -0.8775 0.0926 
O00483 NDUA4 Cytochrome c oxidase subunit NDUFA4 0.4168 -0.6326 0.2158 
O14745 NHRF1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 -0.6044 0.3637 0.2407 
O14773 TPP1 Tripeptidyl-peptidase 1 -0.2922 -0.0538 0.3460 
O14791 APOL1 Apolipoprotein L1 -0.0103 -0.3329 0.3431 
P19105 ML12A Myosin regulatory light chain 12A 0.5900 0.4342 -1.0242 
O15117 FYB1 FYN-binding protein 1 0.6664 -0.0960 -0.5704 
O15127 SCAM2 Secretory carrier-associated membrane protein 2 0.2373 0.0334 -0.2707 
O15143 ARC1B Actin-related protein 2/3 complex subunit 1B 0.6574 -0.2447 -0.4127 
O15144 ARPC2 Actin-related protein 2/3 complex subunit 2 -0.4238 0.3461 0.0777 
O15145 ARPC3 Actin-related protein 2/3 complex subunit 3 0.5962 0.1430 -0.7392 
O15173 PGRC2 
Membrane-associated progesterone receptor 
component 2 
-0.8051 0.1953 0.6098 
O15400 STX7 Syntaxin-7 0.2862 -0.1618 -0.1244 
O15511 ARPC5 Actin-related protein 2/3 complex subunit 5 -0.2274 -0.0518 0.2791 
O43182 RHG06 Rho GTPase-activating protein 6 0.5095 -0.0513 -0.4582 
O43242 PSMD3 26S proteasome non-ATPase regulatory subunit 3 0.0495 -0.0980 0.0485 
O43294 TGFI1 
Transforming growth factor beta-1-induced transcript 1 
protein 
0.0042 -0.3130 0.3088 
O43396 TXNL1 Thioredoxin-like protein 1 -0.3235 0.3648 -0.0412 
O43399 TPD54 Tumor protein D54 -0.4045 0.8384 -0.4339 
O43488 ARK72 Aflatoxin B1 aldehyde reductase member 2 0.4159 0.3286 -0.7445 
O43639 NCK2 Cytoplasmic protein NCK2 0.2032 0.5176 -0.7208 
O43707 ACTN4 Alpha-actinin-4 0.7094 -0.1288 -0.5807 
O43852 CALU Calumenin 0.2445 -0.1638 -0.0807 
H7BXZ5 H7BXZ5 Kalirin 0.7039 -0.1638 -0.5401 
O60234 GMFG Glia maturation factor gamma -0.3571 0.2895 0.0676 
O60493 SNX3 Sorting nexin-3 0.5480 -0.3107 -0.2373 
O60496 DOK2 Docking protein 2 0.3402 -0.3667 0.0265 
A0A140T8Z0 A0A140T8Z0 Protein diaphanous homolog 1 0.8132 -0.4855 -0.3277 
O60664 PLIN3 Perilipin-3 -0.2622 0.1731 0.0890 
Q99879 H2B1M Histone H2B type 1-M 0.6530 -0.5617 -0.0912 
O75083 WDR1 WD repeat-containing protein 1 0.3186 -0.1524 -0.1662 
O75116 ROCK2 Rho-associated protein kinase 2 0.6090 -0.2670 -0.3420 
K7EMR7 K7EMR7 Reticulon 0.5958 -0.5897 -0.0060 
O75368 SH3L1 SH3 domain-binding glutamic acid-rich-like protein 0.7935 0.0317 -0.8252 
B4DJV2 B4DJV2 Citrate synthase 0.9785 -0.1853 -0.7932 
O75396 SC22B Vesicle-trafficking protein SEC22b -0.4229 -0.0011 0.4240 
O75558 STX11 Syntaxin-11 0.5805 -0.1788 -0.4017 
O75563 SKAP2 Src kinase-associated phosphoprotein 2 0.4727 -0.4048 -0.0679 
O75874 IDHC Isocitrate dehydrogenase [NADP] cytoplasmic 0.5785 -0.1520 -0.4265 
O75915 PRAF3 PRA1 family protein 3 0.3390 0.5713 -0.9102 
E9PN17 E9PN17 ATP synthase subunit g, mitochondrial 0.8459 -0.4409 -0.4050 
O76074 PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase 0.5675 -0.1024 -0.4651 
O94886 CSCL1 CSC1-like protein 1 0.4651 -0.5345 0.0694 
O94919 ENDD1 Endonuclease domain-containing 1 protein 0.5352 -0.1813 -0.3539 
O95336 6PGL 6-phosphogluconolactonase -0.1147 0.2583 -0.1436 
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O95721 SNP29 Synaptosomal-associated protein 29 -0.1028 0.0055 0.0973 
O95810 CAVN2 Caveolae-associated protein 2 -0.6124 0.0696 0.5428 
O95870 ABHGA Phosphatidylserine lipase ABHD16A 0.4504 0.2067 -0.6571 
P00338 LDHA L-lactate dehydrogenase A chain 1.1609 -0.7740 -0.3868 
P00387 NB5R3 NADH-cytochrome b5 reductase 3 0.4708 -0.5806 0.1098 
P00390 GSHR Glutathione reductase, mitochondrial 0.0430 -0.2538 0.2108 
P00403 COX2 Cytochrome c oxidase subunit 2 1.1537 -0.7474 -0.4063 
E9PFZ2 E9PFZ2 Ceruloplasmin 0.3836 -0.3125 -0.0711 
P00488 F13A Coagulation factor XIII A chain 0.6420 0.0848 -0.7268 
P00491 PNPH Purine nucleoside phosphorylase 0.0522 0.4891 -0.5413 
P00492 HPRT Hypoxanthine-guanine phosphoribosyltransferase 0.1173 -0.3906 0.2733 
P00505 AATM Aspartate aminotransferase, mitochondrial 0.2134 0.1097 -0.3231 
P00558 PGK1 Phosphoglycerate kinase 1 0.4851 -0.4472 -0.0379 
P00734 THRB Prothrombin -0.7134 0.3020 0.4114 
P00738 HPT Haptoglobin -0.7868 0.0861 0.7007 
P00747 PLMN Plasminogen -0.2407 0.4019 -0.1612 
P00751 CFAB Complement factor B -0.1651 -0.2591 0.4242 
E5RHP7 E5RHP7 Carbonic anhydrase 1 -0.7988 0.1774 0.6213 
P00918 CAH2 Carbonic anhydrase 2 0.0164 -0.3463 0.3299 
P01011 AACT Alpha-1-antichymotrypsin 0.2723 -0.4827 0.2103 
P01019 ANGT Angiotensinogen -0.0545 -0.1215 0.1760 
P01023 A2MG Alpha-2-macroglobulin -0.0315 -0.0573 0.0888 
P01024 CO3 Complement C3 -0.5167 0.2111 0.3056 
P01031 CO5 Complement C5 -1.1780 0.3225 0.8555 
P01042 KNG1 Kininogen-1 0.2735 0.0531 -0.3266 
P01137 TGFB1 Transforming growth factor beta-1 proprotein 0.6435 -0.0320 -0.6115 
C9JA05 C9JA05 Immunoglobulin J chain -0.5973 0.3554 0.2419 
P01619 KV320 Immunoglobulin kappa variable 3-20 -0.4159 -0.0974 0.5133 
P01834 IGKC Immunoglobulin kappa constant -0.4685 0.2527 0.2157 
P01857 IGHG1 Immunoglobulin heavy constant gamma 1 -0.4547 -0.1718 0.6265 
P01859 IGHG2 Immunoglobulin heavy constant gamma 2 0.7095 -0.8263 0.1168 
P01861 IGHG4 Immunoglobulin heavy constant gamma 4 0.3383 -0.5976 0.2593 
P01871 IGHM Immunoglobulin heavy constant mu -0.2259 -0.0999 0.3258 
P01876 IGHA1 Immunoglobulin heavy constant alpha 1 -0.0221 0.3126 -0.2905 
P01889 1B07 HLA class I histocompatibility antigen, B-7 alpha chain 0.1469 -0.3539 0.2070 
P02647 APOA1 Apolipoprotein A-I -0.5187 0.4593 0.0594 
P02649 APOE Apolipoprotein E -0.8205 0.0608 0.7598 
V9GYE3 V9GYE3 Apolipoprotein A-II -0.3954 0.4269 -0.0315 
K7ERI9 K7ERI9 Apolipoprotein C-I -0.0203 -0.0555 0.0758 
P02656 APOC3 Apolipoprotein C-III -0.3143 -0.0261 0.3404 
P02671 FIBA Fibrinogen alpha chain -0.6393 -0.4206 1.0598 
P02675 FIBB Fibrinogen beta chain 0.3155 -0.6102 0.2946 
P02679 FIBG Fibrinogen gamma chain 0.2556 0.0735 -0.3291 
P02747 C1QC Complement C1q subcomponent subunit C -0.4371 -0.2205 0.6576 
P02748 CO9 Complement component C9 -0.1710 -0.2786 0.4496 
P02751 FINC Fibronectin -0.6961 0.1441 0.5519 
P02765 FETUA Alpha-2-HS-glycoprotein 0.2250 0.1955 -0.4205 
P02774 VTDB Vitamin D-binding protein -0.8792 0.5003 0.3790 
P02775 CXCL7 Platelet basic protein 0.9185 -0.1984 -0.7201 
P02776 PLF4 Platelet factor 4 0.4097 0.1234 -0.5331 
P02787 TRFE Serotransferrin -0.1881 0.6245 -0.4364 
P02790 HEMO Hemopexin 0.1202 0.0687 -0.1889 
P04003 C4BPA C4b-binding protein alpha chain 0.6354 -0.2375 -0.3979 
P04004 VTNC Vitronectin 0.0939 -0.0037 -0.0903 
P04040 CATA Catalase 0.0518 -0.1180 0.0662 
P04075 ALDOA Fructose-bisphosphate aldolase A 0.8716 -0.5173 -0.3543 
P04114 APOB Apolipoprotein B-100 -0.8012 0.2129 0.5883 
P04179 SODM Superoxide dismutase [Mn], mitochondrial 0.7702 0.0397 -0.8098 
P04196 HRG Histidine-rich glycoprotein 0.3137 -0.3132 -0.0005 
M0R009 M0R009 Alpha-1B-glycoprotein -0.6742 -0.0513 0.7255 
P04275 VWF von Willebrand factor 0.7588 0.0430 -0.8018 
P04406 G3P Glyceraldehyde-3-phosphate dehydrogenase 0.5385 -0.4752 -0.0633 
P04632 CPNS1 Calpain small subunit 1 0.8143 -0.5378 -0.2764 
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P04792 HSPB1 Heat shock protein beta-1 -0.0924 -0.0969 0.1893 
P04843 RPN1 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
0.9500 -0.6285 -0.3214 
P04844 RPN2 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 
0.8019 0.1668 -0.9687 
P04899 GNAI2 Guanine nucleotide-binding protein G 0.1722 -0.5154 0.3433 
A0A0A0MRG2 A0A0A0MRG2 Amyloid-beta precursor protein 0.1229 0.2457 -0.3686 
P05090 APOD Apolipoprotein D 0.1229 -0.1271 0.0042 
P05106 ITB3 Integrin beta-3 1.1148 -0.5295 -0.5853 
P05121 PAI1 Plasminogen activator inhibitor 1 0.3155 0.0321 -0.3476 
P05141 ADT2 ADP/ATP translocase 2 0.7893 0.0635 -0.8528 
P05155 IC1 Plasma protease C1 inhibitor 0.6589 -0.2648 -0.3940 
P05546 HEP2 Heparin cofactor 2 -0.8674 0.1169 0.7505 
P05556 ITB1 Integrin beta-1 0.2930 0.3656 -0.6586 
P05771 KPCB Protein kinase C beta type 0.7954 -0.4960 -0.2994 
P05976 MYL1 Myosin light chain 1/3, skeletal muscle isoform 0.3953 -0.2455 -0.1498 
P06396 GELS Gelsolin 0.2257 -0.2591 0.0334 
P06576 ATPB ATP synthase subunit beta, mitochondrial 1.1680 -0.1766 -0.9914 
P06702 S10A9 Protein S100-A9 0.2012 0.1233 -0.3245 
R4GN98 R4GN98 Protein S100 -0.1548 0.1616 -0.0067 
P06727 APOA4 Apolipoprotein A-IV -0.9149 0.4312 0.4837 
P06733 ENOA Alpha-enolase 0.0896 -0.1775 0.0879 
P06737 PYGL Glycogen phosphorylase, liver form 0.4084 -0.4048 -0.0037 
P06744 G6PI Glucose-6-phosphate isomerase 0.9360 -0.6537 -0.2823 
P07195 LDHB L-lactate dehydrogenase B chain 0.9135 -0.3526 -0.5608 
A0A087WUQ6 A0A087WUQ6 Glutathione peroxidase 0.7072 -0.5574 -0.1497 
P07225 PROS Vitamin K-dependent protein S 0.5930 -0.5915 -0.0015 
P07237 PDIA1 Protein disulfide-isomerase 0.8638 -0.1058 -0.7580 
A0A1B0GW44 A0A1B0GW44 Cathepsin D 0.4187 -0.5287 0.1100 
A0A0C4DGZ8 A0A0C4DGZ8 Glycoprotein Ib 0.2228 -0.0713 -0.1514 
P07360 CO8G Complement component C8 gamma chain -0.8899 0.1192 0.7707 
P07384 CAN1 Calpain-1 catalytic subunit 1.0486 -0.4221 -0.6265 
Q5JP53 Q5JP53 Tubulin beta chain -0.1129 -0.0225 0.1354 
P07737 PROF1 Profilin-1 0.8387 -0.4228 -0.4160 
P07741 APT Adenine phosphoribosyltransferase 0.2597 -0.5326 0.2729 
P07900 HS90A Heat shock protein HSP 90-alpha 0.4970 0.0644 -0.5614 
P07948 LYN Tyrosine-protein kinase Lyn 0.5703 -1.1055 0.5352 
P07954 FUMH Fumarate hydratase, mitochondrial 0.4718 0.0257 -0.4976 
P08238 HS90B Heat shock protein HSP 90-beta 0.7131 0.0701 -0.7832 
P08514 ITA2B Integrin alpha-IIb 0.8581 -0.0641 -0.7940 
P08567 PLEK Pleckstrin 0.6812 -0.8487 0.1675 
B0YJC4 B0YJC4 Vimentin 0.4616 -0.2150 -0.2466 
P08697 A2AP Alpha-2-antiplasmin -0.0452 -0.5230 0.5682 
P09211 GSTP1 Glutathione S-transferase P 0.4351 -0.5854 0.1504 
P09486 SPRC SPARC 0.6691 0.0010 -0.6700 
P09496 CLCA Clathrin light chain A 0.2061 -0.4427 0.2366 
A0A087X232 A0A087X232 Complement C1s subcomponent -0.8260 -0.2758 1.1019 
P0C0L4 CO4A Complement C4-A -1.1248 0.6892 0.4356 
J3QS39 J3QS39 Polyubiquitin-B 0.9078 -0.3107 -0.5971 
P0DMV9 HS71B Heat shock 70 kDa protein 1B 0.5691 0.4524 -1.0215 
P0DOY3 IGLC3 Immunoglobulin lambda constant 3 -0.5571 0.3849 0.1722 
P0DP25 CALM3 Calmodulin-3 0.5700 0.2155 -0.7855 
P10124 SRGN Serglycin 0.3487 -0.2160 -0.1327 
P10316 1A69 HLA class I histocompatibility antigen, A-69 alpha chain 0.0831 -0.7798 0.6967 
O19617 O19617 HLA class I antigen 0.6290 -0.0160 -0.6130 
P10599 THIO Thioredoxin 0.2602 -0.0483 -0.2119 
P10619 PPGB Lysosomal protective protein 0.1571 -0.1601 0.0030 
P10644 KAP0 
cAMP-dependent protein kinase type I-alpha regulatory 
subunit 
0.3536 -0.5828 0.2292 
P10809 CH60 60 kDa heat shock protein, mitochondrial 0.5336 0.0798 -0.6134 
P10909 CLUS Clusterin -0.8031 0.4768 0.3262 
P11021 BIP Endoplasmic reticulum chaperone BiP 0.1261 0.0859 -0.2120 
P11142 HSP7C Heat shock cognate 71 kDa protein 0.4433 -0.2225 -0.2208 
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P11169 GTR3 
Solute carrier family 2, facilitated glucose transporter 
member 3 
0.7026 -0.5511 -0.1515 
P11177 ODPB 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial 
-0.4359 0.2224 0.2135 
P11216 PYGB Glycogen phosphorylase, brain form 0.7281 -0.3924 -0.3357 
P11234 RALB Ras-related protein Ral-B 0.7081 -0.2789 -0.4291 
P11413 G6PD Glucose-6-phosphate 1-dehydrogenase 0.9199 -0.6463 -0.2735 
P12236 ADT3 ADP/ATP translocase 3 0.3307 0.3484 -0.6791 
P12259 FA5 Coagulation factor V 1.0488 -0.2452 -0.8036 
P12814 ACTN1 Alpha-actinin-1 0.8861 -0.2685 -0.6177 
P12931 SRC Proto-oncogene tyrosine-protein kinase Src 0.7118 0.1840 -0.8958 
P13073 COX41 
Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial 
-0.0396 0.8311 -0.7916 
P13224 GP1BB Platelet glycoprotein Ib beta chain 0.7086 -0.4889 -0.2197 
P13489 RINI Ribonuclease inhibitor -0.1310 0.7623 -0.6314 
P13639 EF2 Elongation factor 2 -0.3593 -0.2274 0.5867 
P13667 PDIA4 Protein disulfide-isomerase A4 0.9672 -0.8148 -0.1523 
P13693 TCTP Translationally-controlled tumor protein 0.7447 -0.5084 -0.2362 
P13746 1A11 HLA class I histocompatibility antigen, A-11 alpha chain 0.5025 -0.0073 -0.4952 
A0A0A0MSQ0 A0A0A0MSQ0 Plastin-3 -0.3449 0.4436 -0.0987 
P14314 GLU2B Glucosidase 2 subunit beta 0.5275 -0.6081 0.0806 
P14543 NID1 Nidogen-1 0.9876 0.0102 -0.9979 
P14618 KPYM Pyruvate kinase PKM -0.0979 -0.6695 0.7674 
P14625 ENPL Endoplasmin 0.8180 -0.0726 -0.7454 
P14770 GPIX Platelet glycoprotein IX 0.6158 0.0031 -0.6189 
B1AH77 B1AH77 Ras-related C3 botulinum toxin substrate 2 0.6435 -0.3765 -0.2671 
Q5R345 Q5R345 P-selectin 0.6565 0.2754 -0.9319 
P16152 CBR1 Carbonyl reductase [NADPH] 1 -0.3123 -0.0601 0.3723 
P16615 AT2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 0.0671 0.2488 -0.3158 
E7EU05 E7EU05 Platelet glycoprotein 4 0.5017 0.1404 -0.6421 
P16930 FAAA Fumarylacetoacetase 0.1283 0.1499 -0.2782 
P17301 ITA2 Integrin alpha-2 0.7801 -0.2604 -0.5197 
P17987 TCPA T-complex protein 1 subunit alpha -0.0089 -0.5276 0.5365 
P18031 PTN1 Tyrosine-protein phosphatase non-receptor type 1 -0.3843 -0.2658 0.6500 
P18054 LOX12 Arachidonate 12-lipoxygenase, 12S-type -0.2973 -0.3082 0.6054 
P18085 ARF4 ADP-ribosylation factor 4 0.9704 -0.1732 -0.7972 
P18206 VINC Vinculin 0.1387 -0.0849 -0.0538 
P18669 PGAM1 Phosphoglycerate mutase 1 1.0374 -0.7292 -0.3083 
P19086 GNAZ Guanine nucleotide-binding protein G (z) subunit alpha 0.8054 -0.4680 -0.3373 
P19367 HXK1 Hexokinase-1 0.6968 0.3524 -1.0493 
Q5T985 Q5T985 Inter-alpha-trypsin inhibitor heavy chain H2 -0.8814 0.1265 0.7549 
P19827 ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1 -0.5873 -0.0094 0.5968 
P19971 TYPH Thymidine phosphorylase 0.3691 -0.1098 -0.2592 
P20042 IF2B Eukaryotic translation initiation factor 2 subunit 2 -0.5102 0.1533 0.3569 
P20073 ANXA7 Annexin A7 -0.4698 -0.4200 0.8898 
P20340 RAB6A Ras-related protein Rab-6A -0.2965 0.6748 -0.3783 
P20674 COX5A Cytochrome c oxidase subunit 5A, mitochondrial 0.4243 -0.2454 -0.1788 
P21291 CSRP1 Cysteine and glycine-rich protein 1 0.8161 -0.6364 -0.1797 
P21333 FLNA Filamin-A 0.7785 -0.1956 -0.5829 
P21796 VDAC1 Voltage-dependent anion-selective channel protein 1 0.8156 -0.2870 -0.5286 
A6NNI4 A6NNI4 Tetraspanin 0.3965 0.5119 -0.9083 
P22061 PIMT Protein-L-isoaspartate 0.2402 -0.0661 -0.1741 
P22314 UBA1 Ubiquitin-like modifier-activating enzyme 1 0.7475 -0.4888 -0.2587 
P22694 KAPCB cAMP-dependent protein kinase catalytic subunit beta 0.8894 -0.6926 -0.1968 
P22695 QCR2 Cytochrome b-c1 complex subunit 2, mitochondrial -0.1795 -0.2117 0.3912 
P23219 PGH1 Prostaglandin G/H synthase 1 0.6503 -0.1735 -0.4768 
P23229 ITA6 Integrin alpha-6 0.6886 0.0186 -0.7072 
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B 0.5992 -0.5759 -0.0233 
A0A1W2PQH3 A0A1W2PQH3 Malic enzyme 1.1079 -0.7047 -0.4032 
P23528 COF1 Cofilin-1 -0.9427 0.1587 0.7841 
P24534 EF1B Elongation factor 1-beta 0.6289 -0.5369 -0.0920 
Q5QNZ2 Q5QNZ2 ATP synthase F 0.6026 -0.3954 -0.2073 
P24557 THAS Thromboxane-A synthase 0.4773 0.2974 -0.7747 
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G5E9R5 G5E9R5 Acid phosphatase 1, soluble, isoform CRA_d -0.4562 0.6854 -0.2292 
P24844 MYL9 Myosin regulatory light polypeptide 9 0.8529 -0.3458 -0.5070 
P25325 THTM 3-mercaptopyruvate sulfurtransferase 0.2912 -0.1820 -0.1092 
P25705 ATPA ATP synthase subunit alpha, mitochondrial 0.3000 0.3282 -0.6281 
P25788 PSA3 Proteasome subunit alpha type-3 0.0320 0.1632 -0.1952 
P25789 PSA4 Proteasome subunit alpha type-4 0.0059 -0.3484 0.3425 
P26038 MOES Moesin 0.8711 -0.4954 -0.3757 
P26447 S10A4 Protein S100-A4 0.4495 -0.5071 0.0575 
A6NLN1 A6NLN1 Polypyrimidine tract binding protein 1, isoform CRA_b -0.5447 0.1670 0.3778 
P26639 SYTC Threonine--tRNA ligase, cytoplasmic -0.5048 0.2534 0.2514 
P26641 EF1G Elongation factor 1-gamma 0.7797 -0.2273 -0.5525 
P27105 STOM Erythrocyte band 7 integral membrane protein 0.5839 -0.1518 -0.4320 
P27169 PON1 Serum paraoxonase/arylesterase 1 -0.9258 0.1241 0.8017 
P27338 AOFB Amine oxidase [flavin-containing] B 0.7860 -0.2196 -0.5665 
P27348 1433T 14-3-3 protein theta 0.4867 0.4613 -0.9480 
P27797 CALR Calreticulin 0.3311 0.2591 -0.5903 
P27824 CALX Calnexin 0.7127 -0.6917 -0.0210 
P29144 TPP2 Tripeptidyl-peptidase 2 0.9334 -0.9834 0.0500 
P29350 PTN6 Tyrosine-protein phosphatase non-receptor type 6 0.9086 0.0927 -1.0013 
P29401 TKT Transketolase 0.8768 -0.7039 -0.1729 
E9PK01 E9PK01 Elongation factor 1-delta 1.1153 -0.4526 -0.6627 
P30040 ERP29 Endoplasmic reticulum resident protein 29 0.1779 0.1136 -0.2915 
P30041 PRDX6 Peroxiredoxin-6 0.4661 -0.0469 -0.4191 
P30044 PRDX5 Peroxiredoxin-5, mitochondrial 0.2217 -0.0278 -0.1939 
P30048 PRDX3 
Thioredoxin-dependent peroxide reductase, 
mitochondrial 
0.3947 -0.0642 -0.3305 
P30085 KCY UMP-CMP kinase 0.4156 0.1526 -0.5682 
P30086 PEBP1 Phosphatidylethanolamine-binding protein 1 0.2594 0.2210 -0.4803 
P30101 PDIA3 Protein disulfide-isomerase A3 0.7007 -0.2069 -0.4938 
P30153 2AAA 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
0.8201 -0.1863 -0.6337 
P30273 FCERG 
High affinity immunoglobulin epsilon receptor subunit 
gamma 
0.4046 0.1318 -0.5364 
P30405 PPIF Peptidyl-prolyl cis-trans isomerase F, mitochondrial 0.3149 -0.4800 0.1651 
P30740 ILEU Leukocyte elastase inhibitor 0.5389 -0.1087 -0.4302 
P31146 COR1A Coronin-1A 0.8047 -0.6710 -0.1337 
P31150 GDIA Rab GDP dissociation inhibitor alpha 0.4181 -0.0790 -0.3391 
P31323 KAP3 
cAMP-dependent protein kinase type II-beta regulatory 
subunit 
0.4322 0.1980 -0.6302 
P31946 1433B 14-3-3 protein beta/alpha 0.7555 -0.4379 -0.3176 
P31948 STIP1 Stress-induced-phosphoprotein 1 0.1429 0.1917 -0.3346 
P32119 PRDX2 Peroxiredoxin-2 -0.1724 0.3916 -0.2193 
P35232 PHB Prohibitin 0.3362 0.6084 -0.9446 
P35237 SPB6 Serpin B6 0.5624 -0.3319 -0.2305 
P35542 SAA4 Serum amyloid A-4 protein -0.9693 0.3400 0.6293 
P35579 MYH9 Myosin-9 0.9123 -0.3532 -0.5592 
P35606 COPB2 Coatomer subunit beta' 0.3649 -0.4408 0.0759 
P35908 K22E Keratin, type II cytoskeletal 2 epidermal -0.3629 -0.2207 0.5835 
P36542 ATPG ATP synthase subunit gamma, mitochondrial 0.7018 -0.4979 -0.2040 
P36871 PGM1 Phosphoglucomutase-1 0.2248 -0.3376 0.1128 
P36957 ODO2 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 
-0.4221 0.6882 -0.2661 
P37802 TAGL2 Transgelin-2 0.6475 -0.2158 -0.4317 
P37837 TALDO Transaldolase 0.4866 0.6037 -1.0903 
E7EPV7 E7EPV7 Alpha-synuclein 0.8015 -0.2627 -0.5388 
P38117 ETFB Electron transfer flavoprotein subunit beta 0.4264 -0.2691 -0.1573 
P38606 VATA V-type proton ATPase catalytic subunit A 0.7755 -0.2578 -0.5178 
P38646 GRP75 Stress-70 protein, mitochondrial 0.7181 0.2657 -0.9838 
A0A0C4DGS1 A0A0C4DGS1 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
0.9212 -0.7944 -0.1268 
P40197 GPV Platelet glycoprotein V 0.2377 -0.3275 0.0898 
P40227 TCPZ T-complex protein 1 subunit zeta 0.5758 -0.0561 -0.5197 
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P40925 MDHC Malate dehydrogenase, cytoplasmic 0.5635 -0.1320 -0.4315 
P40926 MDHM Malate dehydrogenase, mitochondrial 0.8399 -0.1194 -0.7206 
P40939 ECHA Trifunctional enzyme subunit alpha, mitochondrial 0.1592 -0.2909 0.1317 
P41226 UBA7 Ubiquitin-like modifier-activating enzyme 7 -0.0649 0.0251 0.0398 
P41240 CSK Tyrosine-protein kinase CSK 0.2925 -0.5496 0.2571 
B1AUU8 B1AUU8 Epidermal growth factor receptor substrate 15 -0.4881 0.5501 -0.0620 
P43304 GPDM Glycerol-3-phosphate dehydrogenase, mitochondrial 0.8513 -0.0369 -0.8143 
P45880 VDAC2 Voltage-dependent anion-selective channel protein 2 0.8161 0.0249 -0.8411 
P46109 CRKL Crk-like protein -0.1028 0.1981 -0.0952 
I3L0N3 I3L0N3 Vesicle-fusing ATPase -0.8436 0.4108 0.4328 
G5E9W8 G5E9W8 Glycogenin 1, isoform CRA_e -0.7136 0.4215 0.2921 
P46977 STT3A 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 
0.1594 -0.5164 0.3570 
P47755 CAZA2 F-actin-capping protein subunit alpha-2 1.1223 -0.6475 -0.4748 
P48047 ATPO ATP synthase subunit O, mitochondrial 0.5189 -0.4953 -0.0237 
P48059 LIMS1 
LIM and senescent cell antigen-like-containing domain 
protein 1 
0.0498 0.2573 -0.3070 
P48426 PI42A Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 0.3124 -0.0709 -0.2416 
P48444 COPD Coatomer subunit delta 0.4059 0.0201 -0.4260 
P48643 TCPE T-complex protein 1 subunit epsilon 0.7251 -0.0578 -0.6673 
P48735 IDHP Isocitrate dehydrogenase [NADP], mitochondrial 0.6843 0.1374 -0.8217 
A0A0U1RQF0 A0A0U1RQF0 Fatty acid synthase 0.2205 0.3127 -0.5331 
P49368 TCPG T-complex protein 1 subunit gamma 0.8387 -1.0077 0.1690 
P49411 EFTU Elongation factor Tu, mitochondrial 1.2314 -0.3900 -0.8414 
P49748 ACADV 
Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
0.8999 -0.1809 -0.7190 
P49755 TMEDA Transmembrane emp24 domain-containing protein 10 1.2023 -0.5442 -0.6581 
P50148 GNAQ Guanine nucleotide-binding protein G 1.0175 -0.5350 -0.4825 
P50395 GDIB Rab GDP dissociation inhibitor beta 0.2585 0.4745 -0.7329 
P50402 EMD Emerin 0.9401 -0.5890 -0.3511 
P50416 CPT1A Carnitine O-palmitoyltransferase 1, liver isoform -0.1130 -0.2637 0.3767 
P50453 SPB9 Serpin B9 -0.1141 0.7161 -0.6020 
P50502 F10A1 Hsc70-interacting protein 0.9564 -0.7047 -0.2517 
P50552 VASP Vasodilator-stimulated phosphoprotein 0.4689 -0.0237 -0.4451 
P50851 LRBA 
Lipopolysaccharide-responsive and beige-like anchor 
protein 
1.1979 -0.6610 -0.5368 
P50990 TCPQ T-complex protein 1 subunit theta 0.7130 0.1258 -0.8388 
P50991 TCPD T-complex protein 1 subunit delta 0.7980 -0.7660 -0.0320 
P50995 ANX11 Annexin A11 0.9843 -0.5619 -0.4224 
P51148 RAB5C Ras-related protein Rab-5C 0.7185 -0.7172 -0.0013 
P51149 RAB7A Ras-related protein Rab-7a 0.7417 -0.1499 -0.5917 
P51452 DUS3 Dual specificity protein phosphatase 3 0.2737 0.3024 -0.5761 
P51572 BAP31 B-cell receptor-associated protein 31 0.5096 -0.2185 -0.2911 
P51575 P2RX1 P2X purinoceptor 1 -0.5415 -0.0122 0.5537 
A6NKZ2 A6NKZ2 N-acylglucosamine 2-epimerase 0.2141 0.3002 -0.5143 
P51659 DHB4 Peroxisomal multifunctional enzyme type 2 0.8200 0.0450 -0.8650 
P52209 6PGD 6-phosphogluconate dehydrogenase, decarboxylating 0.6421 -0.3272 -0.3150 
J3KTF8 J3KTF8 Rho GDP-dissociation inhibitor 1 0.4492 -0.4133 -0.0359 
P52566 GDIR2 Rho GDP-dissociation inhibitor 2 0.6936 0.2811 -0.9746 
P52907 CAZA1 F-actin-capping protein subunit alpha-1 0.9567 -0.6785 -0.2782 
P53396 ACLY ATP-citrate synthase -0.2361 0.4947 -0.2586 
P53621 COPA Coatomer subunit alpha 0.1348 0.4788 -0.6136 
A8MXQ1 A8MXQ1 
Pituitary tumor-transforming gene 1 protein-interacting 
protein 
0.3226 -0.2373 -0.0854 
P54577 SYYC Tyrosine--tRNA ligase, cytoplasmic 0.4589 0.3402 -0.7991 
F8W1A4 F8W1A4 Adenylate kinase 2, mitochondrial 0.6173 -0.6181 0.0008 
P54920 SNAA Alpha-soluble NSF attachment protein 0.9064 -0.1367 -0.7697 
P55072 TERA Transitional endoplasmic reticulum ATPase 0.5275 -0.3396 -0.1879 
P55084 ECHB Trifunctional enzyme subunit beta, mitochondrial 0.9434 -0.4403 -0.5030 
P55160 NCKPL Nck-associated protein 1-like -0.0364 0.3671 -0.3307 
F8W020 F8W020 Nucleosome assembly protein 1-like 1 0.9221 -0.0376 -0.8845 
E9PLK3 E9PLK3 Aminopeptidase 0.7735 -0.2126 -0.5609 
P58546 MTPN Myotrophin 0.7155 -0.5447 -0.1707 
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P59998 ARPC4 Actin-related protein 2/3 complex subunit 4 0.3763 -0.2492 -0.1271 
P60174 TPIS Triosephosphate isomerase -0.3786 -0.5179 0.8965 
F8W1R7 F8W1R7 Myosin light polypeptide 6 0.4915 -0.3666 -0.1250 
P60709 ACTB Actin, cytoplasmic 1 -0.4308 0.2579 0.1729 
P60842 IF4A1 Eukaryotic initiation factor 4A-I 0.9324 -0.2565 -0.6759 
G3V295 G3V295 Proteasome subunit alpha type -0.4402 0.0476 0.3926 
P60953 CDC42 Cell division control protein 42 homolog -0.1759 -0.0203 0.1963 
P61006 RAB8A Ras-related protein Rab-8A 0.3815 -0.8774 0.4959 
P61026 RAB10 Ras-related protein Rab-10 0.7075 -0.6435 -0.0641 
P61088 UBE2N Ubiquitin-conjugating enzyme E2 N 0.4930 -0.2679 -0.2251 
P61106 RAB14 Ras-related protein Rab-14 0.2035 -0.1185 -0.0850 
P61158 ARP3 Actin-related protein 3 0.4576 -0.0147 -0.4429 
P61160 ARP2 Actin-related protein 2 0.5320 0.1142 -0.6462 
P84077 ARF1 ADP-ribosylation factor 1 0.8529 -0.6342 -0.2188 
P61224 RAP1B Ras-related protein Rap-1b 0.6322 -0.0439 -0.5883 
P61225 RAP2B Ras-related protein Rap-2b 0.3720 -0.5342 0.1622 
P61586 RHOA Transforming protein RhoA 0.9411 -0.4023 -0.5388 
P61604 CH10 10 kDa heat shock protein, mitochondrial 0.6587 0.4455 -1.1042 
P61769 B2MG Beta-2-microglobulin 0.5604 0.0901 -0.6505 
F5GXX5 F5GXX5 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit DAD1 
0.1003 0.1504 -0.2507 
P61970 NTF2 Nuclear transport factor 2 0.2541 -0.0666 -0.1875 
P61981 1433G 14-3-3 protein gamma 0.3664 -0.4411 0.0747 
P62136 PP1A 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit 
0.1223 -0.1303 0.0080 
P62140 PP1B 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit 
0.1224 -0.7427 0.6204 
P62258 1433E 14-3-3 protein epsilon 0.8144 -0.3640 -0.4504 
P62328 TYB4 Thymosin beta-4 0.2400 0.0406 -0.2805 
P62805 H4 Histone H4 0.9348 -0.3412 -0.5937 
P62820 RAB1A Ras-related protein Rab-1A 0.1629 0.1037 -0.2666 
P62826 RAN GTP-binding nuclear protein Ran 0.1532 -0.4079 0.2546 
P62873 GBB1 Guanine nucleotide-binding protein G 0.6624 0.2126 -0.8750 
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 0.5483 -0.6501 0.1018 
P62942 FKB1A Peptidyl-prolyl cis-trans isomerase FKBP1A 0.7793 -0.6904 -0.0889 
P62993 GRB2 Growth factor receptor-bound protein 2 -0.4835 0.1505 0.3330 
P63000 RAC1 Ras-related C3 botulinum toxin substrate 1 0.1795 0.4611 -0.6406 
P63104 1433Z 14-3-3 protein zeta/delta 0.8121 -0.4100 -0.4021 
P63218 GBG5 Guanine nucleotide-binding protein G -0.3256 0.4897 -0.1641 
P67936 TPM4 Tropomyosin alpha-4 chain 0.5637 -0.2579 -0.3057 
P68133 ACTS Actin, alpha skeletal muscle 0.3086 -0.1102 -0.1984 
P68036 UB2L3 Ubiquitin-conjugating enzyme E2 L3 0.8832 -0.1674 -0.7158 
Q5VTE0 EF1A3 Putative elongation factor 1-alpha-like 3 1.1317 -0.4696 -0.6621 
P68363 TBA1B Tubulin alpha-1B chain 0.1248 0.2979 -0.4227 
P68366 TBA4A Tubulin alpha-4A chain 0.4798 -0.1421 -0.3378 
P68371 TBB4B Tubulin beta-4B chain 0.0216 -0.0676 0.0460 
P68871 HBB Hemoglobin subunit beta -0.3656 -0.5690 0.9346 
P69905 HBA Hemoglobin subunit alpha -0.2842 -0.7962 1.0803 
P78371 TCPB T-complex protein 1 subunit beta 1.0300 -0.8718 -0.1582 
P78417 GSTO1 Glutathione S-transferase omega-1 0.9420 -0.4786 -0.4634 
P81605 DCD Dermcidin -0.5421 0.4187 0.1234 
C9JFR7 C9JFR7 Cytochrome c -0.1339 0.0000 0.1339 
Q00013 EM55 55 kDa erythrocyte membrane protein 0.0712 -0.7718 0.7005 
Q00325 MPCP Phosphate carrier protein, mitochondrial 1.0049 -0.6570 -0.3479 
Q00610 CLH1 Clathrin heavy chain 1 0.9941 -0.1188 -0.8753 
Q01082 SPTB2 Spectrin beta chain, non-erythrocytic 1 -0.1400 -0.4078 0.5479 
Q01433 AMPD2 AMP deaminase 2 0.7985 -0.5272 -0.2713 
Q01518 CAP1 Adenylyl cyclase-associated protein 1 0.5478 -0.8651 0.3173 
Q01813 PFKAP ATP-dependent 6-phosphofructokinase, platelet type 0.7681 -0.2801 -0.4880 
I3L1P8 I3L1P8 Mitochondrial 2-oxoglutarate/malate carrier protein 0.4165 -0.3046 -0.1120 
Q04917 1433F 14-3-3 protein eta 0.8251 -0.3659 -0.4591 
A0A0U1RQP1 A0A0U1RQP1 Dynamin-1 -0.1930 0.5224 -0.3295 
Q05209 PTN12 Tyrosine-protein phosphatase non-receptor type 12 0.7431 -0.0402 -0.7029 
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E7EX44 E7EX44 Caldesmon 0.6988 -0.6218 -0.0770 
A0A087WW43 A0A087WW43 Inter-alpha-trypsin inhibitor heavy chain H3 -0.5483 0.1507 0.3977 
Q06187 BTK Tyrosine-protein kinase BTK 0.8373 -0.8979 0.0606 
Q06323 PSME1 Proteasome activator complex subunit 1 -0.1239 -0.0155 0.1395 
Q06830 PRDX1 Peroxiredoxin-1 0.2212 0.2328 -0.4541 
Q07960 RHG01 Rho GTPase-activating protein 1 0.9012 -0.5485 -0.3527 
Q08495 DEMA Dematin 0.4021 -0.3233 -0.0788 
Q08722 CD47 Leukocyte surface antigen CD47 0.5337 -0.1969 -0.3368 
Q0ZGT2 NEXN Nexilin 0.4250 -0.2115 -0.2135 
Q10567 AP1B1 AP-1 complex subunit beta-1 0.6684 -0.7398 0.0714 
Q12913 PTPRJ Receptor-type tyrosine-protein phosphatase eta 0.7203 -0.6173 -0.1030 
Q13011 ECH1 Delta 0.3499 0.4398 -0.7897 
Q13045 FLII Protein flightless-1 homolog 0.2366 -0.4819 0.2453 
A0A0D9SGG1 A0A0D9SGG1 Lymphocyte cytosolic protein 2 0.7009 -0.0619 -0.6390 
Q13162 PRDX4 Peroxiredoxin-4 0.2750 -0.2539 -0.0211 
Q13177 PAK2 Serine/threonine-protein kinase PAK 2 -0.8073 -0.0693 0.8766 
Q13201 MMRN1 Multimerin-1 1.0038 0.1346 -1.1384 
Q13418 ILK Integrin-linked protein kinase 0.2417 -0.1320 -0.1097 
Q13423 NNTM NAD(P) transhydrogenase, mitochondrial 0.9707 -0.1371 -0.8337 
Q13576 IQGA2 Ras GTPase-activating-like protein IQGAP2 0.6244 -0.2652 -0.3593 
Q13586 STIM1 Stromal interaction molecule 1 1.1748 -0.3993 -0.7754 
Q13637 RAB32 Ras-related protein Rab-32 0.9240 -0.3089 -0.6150 
Q14008 CKAP5 Cytoskeleton-associated protein 5 -0.0340 -0.0816 0.1156 
Q14019 COTL1 Coactosin-like protein 0.3017 0.2054 -0.5070 
B1AMS2 B1AMS2 Septin 6 0.5477 -0.5490 0.0013 
Q14165 MLEC Malectin 0.6982 -0.7394 0.0412 
Q14247 SRC8 Src substrate cortactin 0.5952 0.0166 -0.6119 
Q14344 GNA13 Guanine nucleotide-binding protein subunit alpha-13 0.4602 -1.0135 0.5533 
Q14554 PDIA5 Protein disulfide-isomerase A5 0.4490 0.0596 -0.5086 
Q14624 ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 -1.2222 0.3275 0.8947 
Q14644 RASA3 Ras GTPase-activating protein 3 0.3415 -0.4135 0.0720 
Q14677 EPN4 Clathrin interactor 1 0.7505 -0.8329 0.0824 
Q14697 GANAB Neutral alpha-glucosidase AB 1.0518 -0.5139 -0.5378 
Q14766 LTBP1 
Latent-transforming growth factor beta-binding protein 
1 
0.8044 -0.4834 -0.3210 
Q14847 LASP1 LIM and SH3 domain protein 1 0.6850 0.1772 -0.8622 
Q14974 IMB1 Importin subunit beta-1 -0.0105 -0.1282 0.1386 
Q15019 Sep-02 Septin-2 -0.0327 -0.5337 0.5664 
E9PAP1 E9PAP1 Histone-lysine N-methyltransferase SETDB1 0.6858 -0.5260 -0.1597 
Q15084 PDIA6 Protein disulfide-isomerase A6 0.5199 -0.0940 -0.4259 
Q15149 PLEC Plectin 0.6996 -0.3853 -0.3143 
A6PVN5 A6PVN5 Serine/threonine-protein phosphatase 2A activator 0.1750 -0.6348 0.4599 
Q15365 PCBP1 Poly(rC)-binding protein 1 0.8565 -0.1874 -0.6691 
Q15404 RSU1 Ras suppressor protein 1 0.3951 -0.2005 -0.1946 
Q15555 MARE2 Microtubule-associated protein RP/EB family member 2 -0.3329 -0.5762 0.9092 
Q15691 MARE1 Microtubule-associated protein RP/EB family member 1 1.1245 -0.7737 -0.3508 
Q15746 MYLK Myosin light chain kinase, smooth muscle 0.8434 -0.6271 -0.2163 
Q15833 STXB2 Syntaxin-binding protein 2 0.6533 -0.0304 -0.6229 
Q15836 VAMP3 Vesicle-associated membrane protein 3 0.7695 -0.5726 -0.1969 
Q15907 RB11B Ras-related protein Rab-11B 0.5519 0.1375 -0.6894 
Q15942 ZYX Zyxin 0.4441 -0.3928 -0.0513 
E7ES33 E7ES33 Septin 7 0.6866 -0.6956 0.0090 
Q16643 DREB Drebrin 0.8253 -0.7151 -0.1102 
Q16698 DECR 2,4-dienoyl-CoA reductase, mitochondrial 0.6858 -0.3473 -0.3385 
Q16762 THTR Thiosulfate sulfurtransferase -0.5117 0.4601 0.0517 
Q16799 RTN1 Reticulon-1 0.9025 -0.5261 -0.3764 
A0A087WYS1 A0A087WYS1 UTP--glucose-1-phosphate uridylyltransferase -0.2628 -0.0540 0.3167 
Q27J81 INF2 Inverted formin-2 0.9142 -0.0610 -0.8532 
Q3ZCW2 LEGL Galectin-related protein 0.5047 0.4213 -0.9260 
Q4KMQ2 ANO6 Anoctamin-6 0.2674 -0.3633 0.0959 
Q53GQ0 DHB12 Very-long-chain 3-oxoacyl-CoA reductase 0.3932 -0.1859 -0.2073 
Q5JSH3 WDR44 WD repeat-containing protein 44 0.8692 -0.1196 -0.7496 
Q5SQ64 LY66F Lymphocyte antigen 6 complex locus protein G6f 0.4975 -0.5026 0.0051 
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Q6DD88 ATLA3 Atlastin-3 0.5991 -0.3364 -0.2628 
Q6IBS0 TWF2 Twinfilin-2 1.0176 -0.4944 -0.5232 
Q6PJW8 CNST Consortin 0.3642 -0.1280 -0.2361 
Q6ZNJ1 NBEL2 Neurobeachin-like protein 2 0.2821 -0.0618 -0.2202 
Q70J99 UN13D Protein unc-13 homolog D 0.9147 -0.0936 -0.8211 
Q7KZF4 SND1 Staphylococcal nuclease domain-containing protein 1 0.7114 -0.4354 -0.2760 
Q7L576 CYFP1 Cytoplasmic FMR1-interacting protein 1 0.7666 -0.5392 -0.2274 
Q9H8S9 MOB1A MOB kinase activator 1A -0.3353 -0.3098 0.6451 
Q7LDG7 GRP2 RAS guanyl-releasing protein 2 1.0204 -0.2363 -0.7841 
Q7Z406 MYH14 Myosin-14 0.1736 -0.3742 0.2006 
Q7Z434 MAVS Mitochondrial antiviral-signaling protein 0.8244 -0.2740 -0.5504 
Q86UX7 URP2 Fermitin family homolog 3 0.8351 -0.4279 -0.4072 
Q86VP6 CAND1 Cullin-associated NEDD8-dissociated protein 1 0.2460 -0.2649 0.0189 
Q86WI1 PKHL1 Fibrocystin-L -0.9329 0.7943 0.1386 
Q86YW5 TRML1 Trem-like transcript 1 protein 0.1406 0.1581 -0.2988 
Q8IVB4 SL9A9 Sodium/hydrogen exchanger 9 -0.4070 0.2119 0.1952 
Q8N392 RHG18 Rho GTPase-activating protein 18 0.8585 -0.2640 -0.5945 
H0YDV5 H0YDV5 Myc target protein 1 0.1309 -0.3020 0.1712 
Q8NBX0 SCPDL Saccharopine dehydrogenase-like oxidoreductase -0.0327 -0.2580 0.2907 
Q8NG06 TRI58 E3 ubiquitin-protein ligase TRIM58 0.1736 0.1027 -0.2762 
Q8TC12 RDH11 Retinol dehydrogenase 11 0.4747 -0.1561 -0.3186 
Q8TF42 UBS3B 
Ubiquitin-associated and SH3 domain-containing protein 
B 
0.5271 -0.2376 -0.2895 
Q8WUM4 PDC6I Programmed cell death 6-interacting protein 0.6306 -0.2705 -0.3601 
Q8WWA1 TMM40 Transmembrane protein 40 0.9408 -1.0558 0.1150 
Q8WXF7 ATLA1 Atlastin-1 -0.4146 0.2160 0.1986 
Q92619 HMHA1 
Rho GTPase-activating protein 45 [Cleaved into: Minor 
histocompatibility antigen HA-1 
0.2049 -0.0421 -0.1628 
Q92686 NEUG Neurogranin 0.5871 -0.5098 -0.0773 
Q93084 AT2A3 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 0.4496 0.0400 -0.4897 
K7EIJ0 K7EIJ0 WW domain-binding protein 2 -0.1134 -0.1404 0.2538 
Q96AP7 ESAM Endothelial cell-selective adhesion molecule 0.2177 -0.4196 0.2019 
Q96C24 SYTL4 Synaptotagmin-like protein 4 0.7340 -0.3756 -0.3584 
C9JAI6 C9JAI6 
CKLF-like MARVEL transmembrane domain-containing 
protein 5 
1.0520 -0.6655 -0.3865 
Q96G03 PGM2 Phosphoglucomutase-2 0.2172 0.0254 -0.2426 
Q96HC4 PDLI5 PDZ and LIM domain protein 5 0.9747 -0.2098 -0.7649 
Q96KP4 CNDP2 Cytosolic non-specific dipeptidase 0.6967 -0.3372 -0.3595 
Q96QK1 VPS35 Vacuolar protein sorting-associated protein 35 -0.5904 0.4118 0.1786 
C9JJV6 C9JJV6 Myeloid-associated differentiation marker 0.6577 -0.3355 -0.3222 
B4DDF4 B4DDF4 Calponin 0.7415 -0.7612 0.0197 
Q99497 PARK7 Protein/nucleic acid deglycase DJ-1 -0.2924 0.4372 -0.1448 
J3KPX7 J3KPX7 Prohibitin-2 1.0744 -0.6020 -0.4724 
Q99798 ACON Aconitate hydratase, mitochondrial 0.2679 -0.1981 -0.0698 
Q99832 TCPH T-complex protein 1 subunit eta 0.7068 -0.5817 -0.1251 
E7EMB8 E7EMB8 Tyrosine-protein phosphatase non-receptor type 18 0.3481 -0.4600 0.1120 
Q9BR76 COR1B Coronin-1B 0.7586 -0.0842 -0.6744 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 0.6734 -0.2697 -0.4037 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 0.7285 -0.1269 -0.6016 
Q9BUL8 PDC10 Programmed cell death protein 10 0.3967 0.7672 -1.1639 
Q9BV40 VAMP8 Vesicle-associated membrane protein 8 0.1419 -0.4064 0.2645 
Q9BX10 GTPB2 GTP-binding protein 2 0.4647 -0.4744 0.0096 
Q9BX67 JAM3 Junctional adhesion molecule C 0.4212 0.4108 -0.8320 
Q9BXS5 AP1M1 AP-1 complex subunit mu-1 -0.1086 0.3572 -0.2486 
Q9C0C9 UBE2O (E3-independent) E2 ubiquitin-conjugating enzyme -0.5038 -0.3065 0.8103 
Q9H0U4 RAB1B Ras-related protein Rab-1B 0.5962 -0.2820 -0.3142 
Q5T123 Q5T123 SH3 domain-binding glutamic acid-rich-like protein 3 -0.5444 -0.0302 0.5746 
Q9H2K8 TAOK3 Serine/threonine-protein kinase TAO3 0.5807 -0.7124 0.1317 
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 -0.2665 -0.1846 0.4510 
Q9H4B7 TBB1 Tubulin beta-1 chain 0.6461 -0.3353 -0.3108 
Q9H4M9 EHD1 EH domain-containing protein 1 0.7736 -0.3656 -0.4080 
Q9H939 PPIP2 
Proline-serine-threonine phosphatase-interacting 
protein 2 
0.8059 -0.3131 -0.4927 
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Q9HBI1 PARVB Beta-parvin 0.6341 -0.1969 -0.4372 
Q9HCN6 GPVI Platelet glycoprotein VI 0.4634 -0.2183 -0.2452 
Q9NQ75 CASS4 Cas scaffolding protein family member 4 0.0606 -0.8132 0.7526 
Q9NQC3 RTN4 Reticulon-4 0.5636 -0.0380 -0.5256 
Q9NR12 PDLI7 PDZ and LIM domain protein 7 0.2192 -0.3539 0.1347 
Q9NR31 SAR1A GTP-binding protein SAR1a 0.5832 -0.0572 -0.5259 
Q9NRW1 RAB6B Ras-related protein Rab-6B 0.5735 -0.1626 -0.4109 
Q9NTJ5 SAC1 Phosphatidylinositide phosphatase SAC1 0.7642 -0.0388 -0.7253 
D6RGI3 D6RGI3 Septin 11 -0.1914 0.4913 -0.2999 
Q9NX76 CKLF6 
CKLF-like MARVEL transmembrane domain-containing 
protein 6 
-0.6163 0.8677 -0.2514 
Q9NXH8 TOR4A Torsin-4A 0.9091 -0.6770 -0.2321 
Q9NY65 TBA8 Tubulin alpha-8 chain 0.4761 0.2295 -0.7057 
Q9NYL9 TMOD3 Tropomodulin-3 0.9531 -0.5632 -0.3899 
Q9NYU2 UGGG1 UDP-glucose:glycoprotein glucosyltransferase 1 0.1245 0.0921 -0.2166 
Q9NZ08 ERAP1 Endoplasmic reticulum aminopeptidase 1 0.0389 0.2609 -0.2998 
Q9NZN3 EHD3 EH domain-containing protein 3 0.8105 -0.0520 -0.7585 
Q9P0L0 VAPA 
Vesicle-associated membrane protein-associated protein 
A 
0.4442 -0.4815 0.0374 
M0R165 M0R165 Epidermal growth factor receptor substrate 15-like 1 -0.5369 -0.1240 0.6609 
Q9UBW5 BIN2 Bridging integrator 2 -0.0114 -0.5321 0.5435 
Q9UDY2 ZO2 Tight junction protein ZO-2 0.8942 -0.2814 -0.6128 
Q9UFN0 NPS3A Protein NipSnap homolog 3A 0.4206 -0.0095 -0.4111 
Q9UHQ9 NB5R1 NADH-cytochrome b5 reductase 1 -0.2030 0.2071 -0.0041 
Q9UIB8 SLAF5 SLAM family member 5 0.5316 -0.4992 -0.0325 
Q9UJU6 DBNL Drebrin-like protein 0.6805 -0.1940 -0.4865 
Q9ULV4 COR1C Coronin-1C 0.3131 -0.6689 0.3558 
Q9Y251 HPSE Heparanase 0.5297 -0.1456 -0.3841 
Q9Y277 VDAC3 Voltage-dependent anion-selective channel protein 3 0.1362 0.4486 -0.5848 
Q9Y2A7 NCKP1 Nck-associated protein 1 0.0804 -0.2498 0.1694 
Q9Y2Q3 GSTK1 Glutathione S-transferase kappa 1 0.4354 -0.7115 0.2762 
Q9Y2Q5 LTOR2 Ragulator complex protein LAMTOR2 -0.5681 1.1751 -0.6071 
Q9Y490 TLN1 Talin-1 0.2747 -0.0283 -0.2464 
A0A087X054 A0A087X054 Hypoxia up-regulated protein 1 1.0611 -0.7530 -0.3082 
Q9Y613 FHOD1 FH1/FH2 domain-containing protein 1 0.4356 -0.0406 -0.3949 
Q9Y624 JAM1 Junctional adhesion molecule A 0.3475 -0.0757 -0.2717 
Q9Y6C2 EMIL1 EMILIN-1 1.0385 -0.3888 -0.6497 
A0A024R6I7 A0A024R6I7 Alpha-1-antitrypsin 0.7338 -0.5484 -0.1854 
A0A075B738 PECA1 Platelet endothelial cell adhesion molecule 0.4971 -0.5093 0.0122 
S4R460 S4R460 Immunoglobulin heavy variable 3/OR16-9 -0.0282 -0.1225 0.1507 
A0A140T9L8 A0A140T9L8 C6orf25 0.4291 -0.2005 -0.2286 
A6NJA2 A6NJA2 Ubiquitin carboxyl-terminal hydrolase 14 -0.4161 0.2318 0.1843 
B1AK87 B1AK87 F-actin-capping protein subunit beta 0.7187 0.1552 -0.8739 
B4DR80 B4DR80 Serine/threonine-protein kinase 24 0.2516 0.0931 -0.3447 
G3XAH0 G3XAH0 HCG2002594, isoform CRA_c 0.3869 -0.4908 0.1039 
H7BYY1 H7BYY1 Tropomyosin 1 (Alpha), isoform CRA_m 0.4126 0.1657 -0.5783 
J3KN67 J3KN67 Tropomyosin alpha-3 chain 0.6050 -0.3564 -0.2486 
Q32Q12 Q32Q12 Nucleoside diphosphate kinase 0.7783 -0.5312 -0.2472 
Q5HYB6 Q5HYB6 Epididymis luminal protein 189 0.4511 -0.2486 -0.2024 
Q5JXI8 Q5JXI8 Four and a half LIM domains protein 1 0.1467 0.0352 -0.1819 
Q5T0I0 Q5T0I0 Gelsolin 1.0373 -0.5118 -0.5255 
Q6ZN40 Q6ZN40 Tropomyosin 1 (Alpha), isoform CRA_f 0.4406 0.0878 -0.5284 
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Appendix 2: Significantly altered proteins between young, intermediate and old platelets 
 
 
Protein ID 
 
Protein 
 
Protein Name Young  
Z score 
Intermediate  
Z score 
Old  
Z score p value 
M0R009 A1BG Alpha-1B-glycoprotein -0.9429 0.1061 0.8367 0.0197 
Q8N392 ARHGAP18 Rho GTPase-activating protein 18 0.8620 -0.0950 -0.7670 0.0494 
P52566 ARHGDIB Rho GDP-dissociation inhibitor 2 0.6936 0.2811 -0.9746 0.0278 
P06576 ATP5F1B ATP synthase subunit beta, mitochondrial 1.1680 -0.1766 -0.9914 0.0001 
P48047 ATP5PO ATP synthase subunit O, mitochondrial 0.8588 -0.7887 -0.0701 0.0457 
A0A087X232 C1S Complement C1s subcomponent -0.6595 -0.4318 1.0913 0.0079 
P0C0L4 C4A Complement C4-A -1.1248 0.6892 0.4356 0.0043 
P01031 C5 Complement C5 -1.1690 0.4508 0.7182 0.0017 
P07360 C8G Complement component C8 gamma chain -0.9833 0.0274 0.9559 0.0056 
P07384 CAPN1 Calpain-1 catalytic subunit 1.0486 -0.4221 -0.6265 0.0149 
P49368 CCT3 T-complex protein 1 subunit gamma 0.9158 -0.9266 0.0108 0.0133 
P50991 CCT4 T-complex protein 1 subunit delta 0.7858 -1.0102 0.2243 0.0138 
P23528 CFL1 Cofilin-1 -0.9427 0.1587 0.7841 0.0259 
Q00610 CLTC Clathrin heavy chain 1 0.9551 -0.0839 -0.8713 0.0144 
C9JAI6 CMTM5 CKLF-like MARVEL transmembrane domain-containing protein 5 1.0555 -0.4296 -0.6259 0.0137 
P13073 COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 0.0394 0.7994 -0.8388 0.0488 
B4DJV2 CS Citrate synthase 0.9569 -0.1444 -0.8125 0.0200 
A0A0C4DGS1 DDOST Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 0.9496 -0.5912 -0.3584 0.0435 
Q5VTE0 EEF1A1P5 Putative elongation factor 1-alpha-like 3 1.0931 -0.1623 -0.9307 0.0017 
E9PK01 EEF1D Elongation factor 1-delta 0.9422 -0.6864 -0.2558 0.0375 
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 0.8928 -0.1212 -0.7716 0.0397 
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P50402 EMD Emerin 0.9439 -0.4975 -0.4464 0.0499 
Q9Y6C2 EMILIN1 EMILIN-1 1.0280 -0.3463 -0.6817 0.0168 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 0.8537 -0.0542 -0.7995 0.0448 
P12259 F5 Coagulation factor V 1.0488 -0.2452 -0.8036 0.0081 
P02671 FGA Fibrinogen alpha chain -0.6393 -0.4206 1.0598 0.0126 
P11413 G6PD Glucose-6-phosphate 1-dehydrogenase 0.9112 -0.6806 -0.2306 0.0484 
Q14697 GANAB Neutral alpha-glucosidase AB 1.0670 -0.4191 -0.6479 0.0113 
Q14344 GNA13 Guanine nucleotide-binding protein subunit alpha-13 0.8965 -0.8411 -0.0554 0.0273 
P50148 GNAQ Guanine nucleotide-binding protein G 1.0175 -0.5350 -0.4825 0.0236 
P43304 GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial 0.8130 0.0812 -0.8942 0.0323 
P06744 GPI Glucose-6-phosphate isomerase 0.9212 -0.6576 -0.2636 0.0478 
Q5T0I0 GSN Gelsolin 1.1058 -0.7632 -0.3425 0.0045 
P78417 GSTO1 Glutathione S-transferase omega-1 0.9498 -0.4130 -0.5368 0.0463 
Q9BX10 GTPBP2 GTP-binding protein 2 0.4992 -0.9628 0.4636 0.0419 
P55084 HADHB Trifunctional enzyme subunit beta, mitochondrial 0.9566 -0.6524 -0.3042 0.0364 
P69905 HBA1; Hemoglobin subunit alpha -0.2842 -0.7962 1.0803 0.0056 
P19367 HK1 Hexokinase-1 0.6968 0.3524 -1.0493 0.0125 
P0DMV9 HSPA1B Heat shock 70 kDa protein 1B 0.5691 0.4524 -1.0215 0.0220 
P38646 HSPA9 Stress-70 protein, mitochondrial 0.7189 0.2886 -1.0075 0.0186 
P61604 HSPE1 10 kDa heat shock protein, mitochondrial 0.6560 0.4488 -1.1047 0.0065 
A0A087X054 HYOU1 Hypoxia up-regulated protein 1 0.8908 -0.7725 -0.1183 0.0401 
P01859 IGHG2 Immunoglobulin heavy constant gamma 2 0.7569 -1.0082 0.2513 0.0160 
B9A064 IGLL5 Immunoglobulin lambda-like polypeptide 5 -0.9803 -0.0275 1.0077 0.0033 
Q27J81 INF2 Inverted formin-2 0.9248 -0.1883 -0.7365 0.0364 
P08514 ITGA2B Integrin alpha-IIb 0.8581 -0.0641 -0.7940 0.0448 
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P05106 ITGB3 Integrin beta-3 1.1148 -0.5295 -0.5853 0.0061 
Q5T985 ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 -0.8814 0.1265 0.7549 0.0460 
Q14624 ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 -1.2222 0.3275 0.8947 0.0001 
P00338 LDHA L-lactate dehydrogenase A chain 1.1609 -0.7740 -0.3868 0.0016 
Q3ZCW2 LGALSL Galectin-related protein 0.6028 0.4044 -1.0071 0.0248 
P50851 LRBA Lipopolysaccharide-responsive and beige-like anchor protein 1.1215 -0.9221 -0.1994 0.0011 
P07948 LYN Tyrosine-protein kinase Lyn 0.4737 -1.0078 0.5341 0.0263 
Q15691 MAPRE1 Microtubule-associated protein RP/EB family member 1 1.1064 -0.7125 -0.3939 0.0054 
A0A1W2PQH3 ME2 Malic enzyme 1.1021 -0.5683 -0.5338 0.0075 
Q13201 MMRN1 Multimerin-1 1.0038 0.1346 -1.1384 0.0002 
P00403 MT-CO2 Cytochrome c oxidase subunit 2 1.2085 -0.8838 -0.3247 0.0002 
P19105 MYL12A Myosin regulatory light chain 12A 0.5900 0.4342 -1.0242 0.0209 
P14543 NID1 Nidogen-1 1.0075 0.1286 -1.1361 0.0002 
Q13423 NNT NAD(P) transhydrogenase, mitochondrial 0.9269 -0.0713 -0.8556 0.0201 
P18669 PGAM1 Phosphoglycerate mutase 1 1.0077 -0.6126 -0.3951 0.0242 
J3KPX7 PHB2 Prohibitin-2 1.1294 -1.0367 -0.0927 0.0002 
Q86WI1 PKHD1L1 Fibrocystin-L -1.0000 0.2339 0.7661 0.0168 
P27169 PON1 Serum paraoxonase/arylesterase 1 -0.9258 0.1241 0.8017 0.0272 
P02775 PPBP Platelet basic protein 0.9185 -0.1984 -0.7201 0.0405 
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha 
isoform 
0.8129 0.1300 -0.9429 0.0225 
P05771 PRKCB Protein kinase C beta type 1.0061 -0.2489 -0.7572 0.0164 
A6NLN1 PTBP1 Polypyrimidine tract binding protein 1, isoform CRA_b -0.7988 -0.1566 0.9554 0.0218 
P29350 PTPN6 Tyrosine-protein phosphatase non-receptor type 6 1.0043 -0.2040 -0.8003 0.0137 
Q7LDG7 RASGRP2 RAS guanyl-releasing protein 2 0.9852 -0.3341 -0.6511 0.0281 
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P61586 RHOA Transforming protein RhoA 0.9411 -0.4023 -0.5388 0.0498 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 1.0420 -0.7063 -0.3357 0.0133 
P04844 RPN2 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 0.8292 0.1204 -0.9496 0.0195 
Q16799 RTN1 Reticulon-1 1.1585 -0.6249 -0.5336 0.0026 
Q8NBX0 SCCPDH Saccharopine dehydrogenase-like oxidoreductase 0.6500 -1.0046 0.3546 0.0233 
Q5R345 SELP P-selectin 0.7351 0.2861 -1.0212 0.0152 
O75368 SH3BGRL SH3 domain-binding glutamic acid-rich-like protein 0.8471 0.2033 -1.0504 0.0062 
Q00325 SLC25A3 Phosphate carrier protein, mitochondrial 0.9957 -0.5474 -0.4484 0.0296 
P05141 SLC25A5 ADP/ATP translocase 2 0.8051 0.0528 -0.8579 0.0425 
O00161 SNAP23 Synaptosomal-associated protein 23 1.0689 -0.9345 -0.1345 0.0023 
Q7KZF4 SND1 Staphylococcal nuclease domain-containing protein 1 0.8334 0.1226 -0.9559 0.0180 
P12931 SRC Proto-oncogene tyrosine-protein kinase Src 0.7118 0.1840 -0.8958 0.0490 
P50502 ST13 Hsc70-interacting protein 1.0891 -0.8654 -0.2238 0.0032 
Q13586 STIM1 Stromal interaction molecule 1 1.1641 -0.4928 -0.6713 0.0021 
P37837 TALDO1 Transaldolase 0.4604 0.5746 -1.0350 0.0188 
P01137 TGFB1 Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated 
peptide 
0.6628 0.3600 -1.0228 0.0186 
P49755 TMED10 Transmembrane emp24 domain-containing protein 10 1.2180 -0.5790 -0.6390 0.0006 
O94886 TMEM63A CSC1-like protein 1 0.8545 -0.8713 0.0168 0.0299 
Q9NYL9 TMOD3 Tropomodulin-3 0.9454 -0.4448 -0.5006 0.0492 
P49411 TUFM Elongation factor Tu, mitochondrial 1.1144 -0.2063 -0.9081 0.0014 
Q6IBS0 TWF2 Twinfilin-2 1.1051 -0.4982 -0.6069 0.0070 
P68036 UBE2L3 Ubiquitin-conjugating enzyme E2 L3 0.9614 0.0037 -0.9651 0.0064 
Q70J99 UNC13D Protein unc-13 homolog D 0.9046 -0.0879 -0.8167 0.0295 
Q15836 VAMP3 Vesicle-associated membrane protein 3 0.8917 -0.9159 0.0242 0.0172 
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Appendix 3: Significantly altered proteins between young and old platelets 
 
 
Protein ID 
 
Protein 
 
Protein Name 
Young  
Z score 
Old 
 Z score 
p value T test  
difference 
M0R009 A1BG Alpha-1B-glycoprotein -0.9429 0.8367 0.0193 -1.7796 
Q8N392 ARHGAP18 Rho GTPase-activating protein 18 0.8620 -0.7670 0.0127 1.6290 
P52566 ARHGDIB Rho GDP-dissociation inhibitor 2 0.6936 -0.9746 0.0031 1.6682 
P06576 ATP5F1B ATP synthase subunit beta, mitochondrial 1.1680 -0.9914 0.0001 2.1594 
A0A087X232 C1S Complement C1s subcomponent -0.6595 1.0913 0.0063 -1.7509 
P0C0L4 C4A Complement C4-A -1.1248 0.4356 0.0153 -1.5604 
P07360 C8G Complement component C8 gamma chain -0.9833 0.9559 0.0065 -1.9392 
P07384 CAPN1 Calpain-1 catalytic subunit 1.0486 -0.6265 0.0104 1.6751 
P23528 CFL1 Cofilin-1 -0.9427 0.7841 0.0149 -1.7268 
Q00610 CLTCL1 Clathrin heavy chain 1 0.9551 -0.8713 0.0138 1.8264 
C9JAI6 CMTM5 CKLF-like MARVEL transmembrane domain-containing protein 5 1.0555 -0.6259 0.0144 1.6814 
P01031 CO5 Complement C5 -1.1690 0.7182 0.0042 -1.8873 
B4DJV2 CS Citrate synthase 0.9569 -0.8125 0.0063 1.7694 
Q5VTE0 EEF1A1P5 Putative elongation factor 1-alpha-like 3 1.0931 -0.9307 0.0019 2.0238 
P60842 EIF4A1 Eukaryotic initiation factor 4A-I 0.8928 -0.7716 0.0255 1.6644 
P50402 EMD Emerin 0.9439 -0.4464 0.0123 1.3903 
Q9Y6C2 EMILIN1 EMILIN-1 1.0280 -0.6817 0.0104 1.7097 
Q9BSJ8 ESYT1 Extended synaptotagmin-1 0.8537 -0.7995 0.0247 1.6532 
P12259 F5 Coagulation factor V 1.0488 -0.8036 0.0033 1.8523 
P02671 FGA Fibrinogen alpha chain -0.6393 1.0598 0.0218 -1.6991 
Q14697 GANAB Neutral alpha-glucosidase AB 1.0670 -0.6479 0.0085 1.7149 
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P50148 GNAQ Guanine nucleotide-binding protein G 1.0175 -0.4825 0.0249 1.5000 
P43304 GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial 0.8130 -0.8942 0.0147 1.7072 
P06744 GPI Glucose-6-phosphate isomerase 0.9212 -0.2636 0.0096 1.1848 
Q5T0I0 GSN Gelsolin 1.1058 -0.3425 0.0270 1.4483 
P78417 GSTO1 Glutathione S-transferase omega-1 0.9498 -0.5368 0.0048 1.4866 
P55084 HADHB Trifunctional enzyme subunit beta, mitochondrial 0.9566 -0.3042 0.0224 1.2607 
P69905 HBA Hemoglobin subunit alpha -0.2842 1.0803 0.0309 -1.3645 
P19367 HK1 Hexokinase-1 0.6968 -1.0493 0.0234 1.7461 
P61604 HSP70-10 10 kDa heat shock protein, mitochondrial 0.6560 -1.1047 0.0074 1.7607 
P0DMV9 HSPA1B Heat shock 70 kDa protein 1B 0.5691 -1.0215 0.0082 1.5906 
P38646 HSPA9 Stress-70 protein, mitochondrial 0.7189 -1.0075 0.0107 1.7265 
B9A064 IGLL5 Immunoglobulin lambda-like polypeptide 5 -0.9803 1.0077 0.0008 -1.9880 
Q27J81 INF2 Inverted formin-2 0.9248 -0.7365 0.0003 1.6613 
P08514 ITGA2B Integrin alpha-IIb 0.8581 -0.7940 0.0242 1.6520 
P05106 ITGB3 Integrin beta-3 1.1148 -0.5853 0.0086 1.7001 
Q5T985 ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 -0.8814 0.7549 0.0160 -1.6362 
Q14624 ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 -1.2222 0.8947 0.0002 -2.1170 
P00338 LDHA L-lactate dehydrogenase A chain 1.1609 -0.3868 0.0053 1.5477 
Q3ZCW2 LGALSL Galectin-related protein 0.6028 -1.0071 0.0199 1.6099 
P50851 LRBA Lipopolysaccharide-responsive and beige-like anchor protein 1.1215 -0.1994 0.0113 1.3209 
Q15691 MAPRE1 Microtubule-associated protein RP/EB family member 1 1.1064 -0.3939 0.0243 1.5002 
A0A1W2PQH3 ME2 Malic enzyme 1.1021 -0.5338 0.0014 1.6359 
Q13201 MMRN1 Multimerin-1 1.0038 -1.1384 0.0010 2.1423 
P00403 MT-CO2 Cytochrome c oxidase subunit 2 1.2085 -0.3247 0.0039 1.5332 
P19105 MYL12A Myosin regulatory light chain 12A 0.5900 -1.0242 0.0406 1.6141 
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P14543 NID1 Nidogen-1 1.0075 -1.1361 0.0008 2.1436 
Q13423 NNT NAD (P) transhydrogenase, mitochondrial 0.9269 -0.8556 0.0096 1.7825 
J3KPX7 PHB2 Prohibitin-2 1.1294 -0.0927 0.0096 1.2222 
Q86WI1 PKHD1L1 Fibrocystin-L -1.0000 0.7661 0.0023 -1.7660 
P27169 PON1 Serum paraoxonase/arylesterase 1 -0.9258 0.8017 0.0248 -1.7274 
P02775 PPBP Platelet basic protein 0.9185 -0.7201 0.0220 1.6386 
P30153 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 0.8129 -0.9429 0.0042 1.7558 
P05771 PRKCB Protein kinase C beta type 1.0061 -0.7572 0.0139 1.7633 
A6NLN1 PTBP1 Polypyrimidine tract binding protein 1, isoform CRA_b -0.7988 0.9554 0.0207 -1.7542 
P29350 PTPN6 Tyrosine-protein phosphatase non-receptor type 6 1.0043 -0.8003 0.0188 1.8046 
Q7LDG7 RASGRP2 RAS guanyl-releasing protein 2 0.9852 -0.6511 0.0292 1.6363 
P61586 RHOA Transforming protein RhoA 0.9411 -0.5388 0.0481 1.4799 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 1.0420 -0.3357 0.0382 1.3777 
P04844 RPN2 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 0.8292 -0.9496 0.0237 1.7788 
Q16799 RTN1 Reticulon-1 1.1585 -0.5336 0.0032 1.6921 
Q5R345 SELPLG P-selectin 0.7351 -1.0212 0.0188 1.7563 
O75368 SH3BGRL SH3 domain-binding glutamic acid-rich-like protein 0.8471 -1.0504 0.0003 1.8976 
Q00325 SLC25A3 Phosphate carrier protein, mitochondrial 0.9957 -0.4484 0.0127 1.4441 
P05141 SLC25A5 ADP/ATP translocase 2 0.8051 -0.8579 0.0305 1.6630 
O00161 SNAP23 Synaptosomal-associated protein 23 1.0689 -0.1345 0.0388 1.2034 
Q7KZF4 SND1 Staphylococcal nuclease domain-containing protein 1 0.8334 -0.9559 0.0107 1.7893 
P12931 SRC Proto-oncogene tyrosine-protein kinase Src 0.7118 -0.8958 0.0449 1.6076 
P50502 ST13 Hsc70-interacting protein 1.0891 -0.2238 0.0053 1.3129 
Q13586 STIM1 Stromal interaction molecule 1 1.1641 -0.6713 0.0038 1.8354 
P37837 TALDO1 Transaldolase 0.4604 -1.0350 0.0488 1.4954 
 240 
P01137 TGFB1 Transforming growth factor beta-1 proprotein 0.6628 -1.0228 0.0153 1.6856 
P49755 TMED10 Transmembrane emp24 domain-containing protein 10 1.2180 -0.6390 0.0020 1.8570 
Q9NYL9 TMOD3 Tropomodulin-3 0.9454 -0.5006 0.0405 1.4460 
P49411 TUFM Elongation factor Tu, mitochondrial 1.1144 -0.9081 0.0001 2.0225 
Q6IBS0 TWF2 Twinfilin-2 1.1051 -0.6069 0.0171 1.7121 
P68036 UBE2L3 Ubiquitin-conjugating enzyme E2 L3 0.9614 -0.9651 0.0011 1.9264 
Q70J99 UNC13D Protein unc-13 homolog D 0.9046 -0.8167 0.0062 1.7213 
 
 
 
